var title_f12_26_12704="En coup de sabre - two examples";
var content_f12_26_12704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two examples of en coup de sabre",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depressed linear plaques are present on the foreheads of these patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12704=[""].join("\n");
var outline_f12_26_12704=null;
var title_f12_26_12705="Pholcodine: International drug information";
var content_f12_26_12705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pholcodine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actuss (AU);",
"     </li>",
"     <li>",
"      Codisol (DK);",
"     </li>",
"     <li>",
"      Codotussyl toux seche (FR);",
"     </li>",
"     <li>",
"      Duro-Tuss (AU);",
"     </li>",
"     <li>",
"      Galenphol (GB);",
"     </li>",
"     <li>",
"      Homocodeina (ES);",
"     </li>",
"     <li>",
"      Humex Fournier (FR);",
"     </li>",
"     <li>",
"      Linctus Tussinol (AU);",
"     </li>",
"     <li>",
"      Pavacol-D (GB);",
"     </li>",
"     <li>",
"      Pectolin (AU);",
"     </li>",
"     <li>",
"      Pholcodin (HR);",
"     </li>",
"     <li>",
"      Pholcodine Linctus (GB);",
"     </li>",
"     <li>",
"      Pholcolin (IE);",
"     </li>",
"     <li>",
"      Pholtrate (AU);",
"     </li>",
"     <li>",
"      Respilene (FR);",
"     </li>",
"     <li>",
"      Sedlingtus (AU);",
"     </li>",
"     <li>",
"      Sirop des Vosges (FR);",
"     </li>",
"     <li>",
"      Trophires (ES);",
"     </li>",
"     <li>",
"      Tuxi (NO);",
"     </li>",
"     <li>",
"      Weifacodine (NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cough",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Children 5-12 years: 2.5-5 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: 5-10 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup: 2 mg/5 mL (90 mL); 5 mg/5 mL (100 mL); 10 mg/5 mL (100 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10427 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12705=[""].join("\n");
var outline_f12_26_12705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979987\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979982\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979985\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979981\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821135\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979984\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10427|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12706="Bullous myringitis 2";
var content_f12_26_12706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous myringitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bullous myringitis is characterized by painful vesicles that appear on the tympanic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12706=[""].join("\n");
var outline_f12_26_12706=null;
var title_f12_26_12707="Ultrasound early periventricular leukomalacia";
var content_f12_26_12707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal ultrasound image of early periventricular leukomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal ultrasound image showing increased echogenicity with punctate areas of low sonolucency above the posterior portion of the ventricle, typical of early periventricular leukomalacia. The echogenic mass in the ventricle is normal choroid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12707=[""].join("\n");
var outline_f12_26_12707=null;
var title_f12_26_12708="Mecasermin (recombinant human insulin-like growth factor I): Pediatric drug information";
var content_f12_26_12708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mecasermin (recombinant human insulin-like growth factor I): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/55/22388?source=see_link\">",
"    see \"Mecasermin (recombinant human insulin-like growth factor I): Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1618073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Increlex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F16159984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Growth Hormone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F16159991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/55/22388?source=see_link\">",
"      see \"Mecasermin (recombinant human insulin-like growth factor I): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary IGFD:",
"     </b>",
"     Increlex&reg;: Children &ge;2 years and Adolescents: SubQ: Initial: 0.04-0.08 mg/kg/dose twice daily; if tolerated for 7 days, may increase by 0.04 mg/kg/dose; maximum dose: 0.12 mg/kg given twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Must be administered within 20 minutes of a meal or snack; omit dose if patient is unable to eat. Reduce dose if hypoglycemia occurs despite adequate food intake; dose should not be increased to make up for &ge;1 omitted dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children &ge;2 years and Adolescents: No dosage adjustments are provided in the manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children &ge;2 years and Adolescents: No dosage adjustments are provided in the manufacturer&rsquo;s labeling; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1618332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Increlex&reg;: 10 mg/mL (4 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1618075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16159992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Must be administered within 20 minutes of a meal or snack. May cause hypoglycemic effects; patients should avoid high-risk activities within 2-3 hours of dosing until a tolerated dose is established. If patient is unable to eat, omit dose and do not make up for omitted dose. Rotate injection site.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F16159988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Increlex&reg;: Store intact vial at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Protect from direct light. After initial entry into vial, store at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F), protect from direct light and use within 30 days; discard any remaining drug.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16159985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGF-1 deficiency; primary IGFD), or with growth hormone (GH) gene deletions who have developed neutralizing antibodies to GH (FDA approved in children &ge;2 years)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F1618312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cardiac murmur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hyper-/hypoglycemia, iron-deficiency anemia, ovarian cysts, thymus hypertrophy, thyromegaly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reactions: Bruising, erythema, hair growth, lipohypertrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, bone pain, extremity pain, muscular atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Papilledema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Ear pain, hypoacusis, middle ear fluid, otitis media, serous otitis media, tympanometry abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Snoring, tonsillar hypertrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Alopecia, anaphylaxis, cardiomegaly, hypercholesterolemia, hypersensitivity, hypertriglyceridemia, hypoglycemic seizure, intracranial hypertension, obstructive sleep apnea, valvulopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16159986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mecasermin or any component; patients with closed epiphyses; active or suspected neoplasia; intravenous use",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F16160022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes or family history of diabetes; insulin dosage may require adjustment when growth hormone therapy is instituted. Progression of scoliosis and slipped capital femoral epiphyses may occur in children experiencing rapid growth; monitor and evaluate if symptoms present. Correct thyroid or nutritional deficiencies prior to therapy. Not intended for use in patients with secondary forms of IGF-1 deficiency (GH deficiency, malnutrition, hypothyroidism, chronic anti-inflammatory steroid therapy).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16159987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Mecasermin may cause insulin-like hypoglycemic effects, especially in small children (due to inconsistent oral intake); patients should avoid high-risk activities (eg, driving) within 2-3 hours after dosing until a tolerated dose is established. Do not administer on days a patient cannot or will not eat. Increlex&reg; should be administered with a meal or a snack.  Intracranial hypertension with papilledema, visual changes, headache, nausea, and/or vomiting has been reported with growth hormone products and reverses after interruption of dosing; fundoscopic examinations are recommended. Lymphoid hypertrophy has been reported and may lead to complications, such as snoring, sleep apnea, and chronic middle ear infections; periodic examinations are recommended. Hypersensitivity and allergic reactions including anaphylaxis have been reported; if a reaction occurs discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Increlex&reg; contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of benzyl alcohol containing diluents in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1618077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1618078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16159993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preprandial glucose during treatment initiation and dose adjustment; hypersensitivity reactions; facial features; lymphoid tissue; funduscopic examination; growth; new onset of a limp or complaints of hip or knee pain; progression of scoliosis. Monitor small children closely due to potentially erratic food intake.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F16159994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe primary IGFD is defined as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Height standard deviation score &le; -3.0",
"     <b>",
"      and",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Basal IGF-1 standard deviation score &le; -3.0",
"     <b>",
"      and",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Growth hormone: Normal or increased",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16159989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mecasermin is an insulin-like growth factor (IGF-1) produced using recombinant DNA technology to replace endogenous IGF-1. Endogenous IGF-1 circulates predominately bound to insulin-like growth factor-binding protein-3 (IGFBP-3) and a growth hormone-dependent acid-labile subunit (ALS). Acting at receptors in the liver and other tissues, endogenous growth hormone (GH) stimulates the synthesis and secretion of IGF-1. In patients with primary severe IGF-1 deficiency, growth hormone receptors in the liver are unresponsive to GH, leading to reduced endogenous IGF-1 concentrations and decreased growth (skeletal, cell, and organ). Endogenous IGF-1 also suppresses liver glucose production, stimulates peripheral glucose utilization, and has an inhibitory effect on insulin secretion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16159990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Severe primary IGFD: 0.184-0.33 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;80% bound to IGFBP-3 and an acid-labile subunit (IGFBP-3 reduced with severe primary IGFD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic and renal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 100% (healthy subjects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Severe primary IGFD: 5.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F16159995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For subcutaneous injection only; rotate injection sites. Must be administered shortly before or after a meal or snack; may cause hypoglycemia. Do not administer if unable to eat. May cause enlarged tonsils. Report increased snoring, difficulty breathing or swallowing, or severe headaches.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F16160023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     If using syringes that measure dose in units, doses in mg/kg must be converted to units using the following formula:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weight (kg) &times; Dose (mg/kg) &times; 1 mL/10 mg &times; 100 units/1 mL = units/injection",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Backeljauw PF, Underwood LE, and GHIS Collaborative Group, \"Therapy for 6.5-7.5 Years With Recombinant Insulin-Like Growth Factor I in Children With Growth Hormone Insensitivity Syndrome: A Clinical Research Center Study Syndrome,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2001,  86(4):1504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12708/abstract-text/11297575/pubmed\" id=\"11297575\" target=\"_blank\">",
"        11297575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Metz KA, Assa'ad A, Lierl MB, et al, &ldquo;Allergic Reaction to Mecasermin,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2009, 103(1):82-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12708/abstract-text/19663134/pubmed\" id=\"19663134\" target=\"_blank\">",
"        19663134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torjusen E, Calderon J, and Rivkees SA, &ldquo;Anaphylactic Reaction to Recombinant Insulin-Like Growth Factor-I,&rdquo;",
"      <i>",
"       J Pediatr Endocrinol Metab",
"      </i>",
"      , 2008, 21(4):381-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12708/abstract-text/18556970/pubmed\" id=\"18556970\" target=\"_blank\">",
"        18556970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88323 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12708=[""].join("\n");
var outline_f12_26_12708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1618073\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159984\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159991\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1618332\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1618075\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159992\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159988\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159985\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1618312\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160022\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159987\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299652\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221491\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1618077\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1618078\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159993\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159994\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159989\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159990\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16159995\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160023\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/88323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/88323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/55/22388?source=related_link\">",
"      Mecasermin (recombinant human insulin-like growth factor I): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12709="Dimercaptosuccinic acid (succimer): Drug information";
var content_f12_26_12709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimercaptosuccinic acid (succimer): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/31/10740?source=see_link\">",
"    see \"Dimercaptosuccinic acid (succimer): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"    see \"Dimercaptosuccinic acid (succimer): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chemet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chemet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For the treatment of high blood lead levels in adults, the CDC guidelines recommend chelation therapy with blood lead levels &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated with blood lead levels &ge;100 mcg/dL and/or symptoms. (Kosnett,  2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild symptoms or blood lead levels 70-100 mg/dL; unlabeled use: 10 mg/kg/dose (or 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) every 8 hours for 5 days, followed by 10 mg/kg/dose (or 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) every 12 hours for 14 days; Maximum: 500 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment courses may be repeated, but 2-week intervals between courses is generally recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"      see \"Dimercaptosuccinic acid (succimer): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (CDC, 2002). Children with blood lead levels &gt;70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (AAP, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: 10 mg/kg/dose (or 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) every 8 hours for 5 days followed by 10 mg/kg/dose (or 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) every 12 hours for 14 days. Maximum: 500 mg/dose. For children &lt;5 years of age, dose should be based on mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; dosing by mg/kg may be suboptimal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment courses may be repeated, but 2-week intervals between courses is generally recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F223376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with caution and monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F223377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with caution and monitor closely",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chemet&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5168980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule can be separated and contents sprinkled on a small amount of soft food, or the contents placed on a spoon and administered followed by fruit drink.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of lead poisoning in children with serum lead levels &gt;45 mcg/dL",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5168740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of lead poisoning in symptomatic adults",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages as reported in pediatric patients unless otherwise noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Appetite decreased, diarrhea, hemorrhoid symptoms, metallic taste, loose stools, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, drowsiness, fatigue, fever, headache, sleepiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (including papular rash, herpetic rash and mucocutaneous eruptions); pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, mucosal irritation, sore throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Proteinuria (adults), urine output decreased (adults), voiding difficulty (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, flank pain, leg pain (adults), neuropathy, paresthesia, rib pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cloudy film in eye, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media, plugged ears",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, nasal congestion, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions (especially with retreatment), eosinophilia, neutropenia (causal relationship not established)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to succimer or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lead poisoning: Investigate, identify, and remove sources of lead 	exposure prior to treatment. Succimer is not used to prevent lead poisoning. Primary care providers should consult experts in chemotherapy of lead toxicity before using chelation drug therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Encephalopathy:  Succimer does not cross blood-brain barrier and should not be used to treat encephalopathy associated with lead toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor serum transaminase levels closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Succimer is dialyzable, however, the lead chelates are not.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hydration: Adequate hydration should be maintained during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rebounding serum lead levels: May occur after treatment as lead is released from storage sites into blood. Severity of rebound may guide intensity of future monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6165840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Following maternal occupational exposure, lead crosses the placenta in amounts related to maternal plasma levels. Possible outcomes of maternal lead exposure &gt;10 mcg/dL includes spontaneous abortion, postnatal developmental delay, and reduced birth weight. Chelation therapy during pregnancy is for maternal benefit only and should be limited to the treatment of severe, symptomatic lead poisoning.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5170808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6165842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if succimer is found in breast milk. The amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Calcium supplementation may reduce the amount of lead in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Chemet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $989.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F223354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood lead levels (baseline and 7-21 days after completing chelation therapy); serum aminotransferase, CBC with differential, platelets (baseline, and weekly during treatment); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chemet (AT);",
"     </li>",
"     <li>",
"      Succicaptal (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Succimer is an analog of dimercaprol. It forms water soluble chelates with heavy metals which are subsequently excreted renally. Succimer binds heavy metals; however, the chemical form of these chelates is not known.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid but incomplete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Highly bound to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly and extensively to mixed succimer cysteine disulfides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~25%) with peak urinary excretion between 2-4 hours (90% as mixed succimer-cysteine disulfide conjugates, 10% as unchanged drug); feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),",
"      <i>",
"       Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention",
"      </i>",
"      , Atlanta: CDC; 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-8):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/17975528/pubmed\" id=\"17975528\" target=\"_blank\">",
"        17975528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC, Hurlburt KM, Maiorino RM, et al, &ldquo;Pharmacokinetics of Meso-2,3-Dimercaptosuccinic Acid in Patients With Lead Poisoning and in Healthy Adults,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(2):309-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/8040783/pubmed\" id=\"8040783\" target=\"_blank\">",
"        8040783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fournier L, Thomas G, Garnier R, et al, &ldquo;2,3-Dimercaptosuccinic Acid Treatment of Heavy Metal Poisoning in Humans,&rdquo;",
"      <i>",
"       Med Toxicol Adverse Drug Exp",
"      </i>",
"      , 1988, 3(6):499-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/2851085/pubmed\" id=\"2851085\" target=\"_blank\">",
"        2851085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardella C, &ldquo;Lead Exposure in Pregnancy: A Review of the Literature and Argument for Routine Prenatal Screening,&rdquo;",
"      <i>",
"       Obstet Gynecol Surv",
"      </i>",
"      , 2001,  56(4):231-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/11285436/pubmed\" id=\"11285436\" target=\"_blank\">",
"        11285436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glotzer DE, &ldquo;The Current Role of 2,3 Dimercaptosuccinic Acid (DMSA) in Management of Childhood Lead Poisoning,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1993, 9(2):85-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/8397892/pubmed\" id=\"8397892\" target=\"_blank\">",
"        8397892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia RC and Snodgrass WR, &ldquo;Lead Toxicity and Chelation Therapy,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64(1):45-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/17189579/pubmed\" id=\"17189579\" target=\"_blank\">",
"        17189579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graziano JH, Lolacono NJ, Moulton T, et al, &ldquo;Controlled Study of Meso-2,3-Dimercaptosuccinic Acid for the Management of Childhood Lead Intoxication,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(1):133-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/1309865/pubmed\" id=\"1309865\" target=\"_blank\">",
"        1309865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kosnett MJ, Wedeen RP, Rothenberg SJ, et al, &ldquo;Recommendations for Medical Management of Adult Lead Exposure,&rdquo;",
"      <i>",
"       Environ Health Perspect",
"      </i>",
"      , 2007, 115(3):463-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/17431500/pubmed\" id=\"17431500\" target=\"_blank\">",
"        17431500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Lead Exposure in Children: Prevention, Detection, and Management. American Academy of Pediatrics Committee on Environmental Health,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(4):1036-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/16199720/pubmed\" id=\"16199720\" target=\"_blank\">",
"        16199720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mann KV and Travers JD, &ldquo;Succimer, An Oral Lead Chelator,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1991, 10(12):914-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/1663439/pubmed\" id=\"1663439\" target=\"_blank\">",
"        1663439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcus S, Okose P, Jennis T, et al, &ldquo;Untoward Effects of Oral Dimercaptosuccinic Acid in the Treatment for Lead Poisoning,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1991, 33:376.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon M, &ldquo;Severe Lead Poisoning in Pregnancy,&rdquo;",
"      <i>",
"       Ambul Pediatr",
"      </i>",
"      , 2003, 3(1):37-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/12540252/pubmed\" id=\"12540252\" target=\"_blank\">",
"        12540252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Staudinger KC and Roth VS, &ldquo;Occupational Lead Poisoning,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1998, 57(4):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12709/abstract-text/9490995/pubmed\" id=\"9490995\" target=\"_blank\">",
"        9490995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9102 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12709=[""].join("\n");
var outline_f12_26_12709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223371\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223372\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223387\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223374\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223383\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223375\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223376\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223377\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223356\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5168980\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223357\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5168740\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223385\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223361\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223346\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300085\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223110\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223352\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6165840\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5170808\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6165842\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323897\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223354\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038833\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223345\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223360\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/31/10740?source=related_link\">",
"      Dimercaptosuccinic acid (succimer): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=related_link\">",
"      Dimercaptosuccinic acid (succimer): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12710="Colestipol: Drug information";
var content_f12_26_12710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colestipol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/17/1301?source=see_link\">",
"    see \"Colestipol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/38/36453?source=see_link\">",
"    see \"Colestipol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colestid&reg;;",
"     </li>",
"     <li>",
"      Colestid&reg; Flavored",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Colestid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Bile Acid Sequestrant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules: Initial: 5 g 1-2 times/day; maintenance: 5-30 g/day given once or in divided doses; increase by 5 g/day at 1- to 2-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Initial: 2 g 1-2 times/day; maintenance: 2-16 g/day given once or in divided doses; increase by 2 g once or twice daily at 1- to 2-month intervals",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13389599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; not absorbed from the gastrointestinal tract.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13389598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; not absorbed from the gastrointestinal tract.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral, as hydrochloride: 5 g/scoop (500 g); 5 g/packet (30s, 90s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg;: 5 g/scoop (300 g, 500 g); 5 g/packet (30s, 90s) [unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg; Flavored: 5 g/scoop (450 g) [contains phenylalanine 18.2 mg/scoop; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg; Flavored: 5 g/packet (60s) [contains phenylalanine 18.2 mg/packet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride [micronized]: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg;: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other  drugs should be administered at least 1 hour before or 4 hours after colestipol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules: Do not administer in dry form (to avoid GI distress). After administration, rinse glass with a small amount of liquid to ensure all medication is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Administer tablets 1 at a time, swallowed whole, with plenty of liquid. Do not cut, crush, or chew tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in management of primary hypercholesterolemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13389564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diarrhea associated with excess fecal bile acids (Westergaard, 2007); relief of pruritus associated with elevated levels of bile acids (Datta, 1963; Scaldaferri, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7297703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Colestipol may be confused with calcitriol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, chest pain, edema of hands or feet, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache (including migraine and sinus), lightheadedness, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain and cramping, anorexia, bloating, constipation, cholecystitis, cholelithiasis, diarrhea, dysphagia, esophageal obstruction, flatulence, indigestion, heartburn, hemorrhoids (bleeding), nausea, peptic ulceration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, backache, joint/muscle pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bile acid sequestering resins or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Chronic use may be associated with bleeding problems; may be prevented with use of oral vitamin K therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation: May produce or exacerbate constipation problems; fecal impaction may occur; initiate therapy at a reduced dose in patients with a history of constipation. Hemorrhoids may be worsened.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased absorption (orally administered drugs): Not to be taken simultaneously with many other medicines (decreased absorption).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients susceptible to fat-soluble vitamin and folic acid deficiencies: Use with caution in patients susceptible to fat-soluble vitamin deficiencies. Absorption of fat soluble vitamins A, D, E, and K and folic acid may be decreased; patients should take vitamins &ge;4 hours before colestipol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens).  Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins).  Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: Colestipol may decrease the absorption of Diltiazem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: Colestipol may decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bile Acid Sequestrants may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Colestipol is not absorbed systemically (&lt;0.17%), but may interfere with vitamin absorption; therefore, regular prenatal supplementation may not be adequate. There are no studies in pregnant women; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not enter breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13277389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to lack of systemic absorption (&lt;0.17%), colestipol is not expected to be excreted into breast milk; however, the tendency of colestipol to interfere with vitamin absorption may have an effect on the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F154478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F154477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granules",
"     </b>",
"     (Colestid Flavored Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (450 g): $165.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granules",
"     </b>",
"     (Colestid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (300 g): $128.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granules",
"     </b>",
"     (Colestipol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (500 g): $149.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Colestid Flavored Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (60): $236.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Colestid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (30): $107.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Colestipol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (30): $75.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Colestid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (120): $135.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Colestipol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (120): $78.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13389617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum cholesterol, LDL, and triglyceride levels should be obtained before initiating treatment and periodically thereafter (in accordance with NCEP guidelines)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F154479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cholestabyl (DE);",
"     </li>",
"     <li>",
"      Colestid (AT, AU, BB, BE, BG, BM, BS, BZ, CH, CZ, ES, GB, GY, HN, HR, HU, IE, IL, IT, JM, LU, NL, NZ, PL, PT, SR, TT);",
"     </li>",
"     <li>",
"      Lestid (DK, FI, GR, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with bile acids to form an insoluble complex that is eliminated in feces; it thereby increases the fecal loss of bile acid-bound low density lipoprotein cholesterol",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Datta DV and Sherlock S, &ldquo;Treatment of Pruritus of Obstructive Jaundice With Cholestyramine,&rdquo;",
"      <i>",
"       B Med J",
"      </i>",
"      , 1963, 1(5325):216-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/14025214/pubmed\" id=\"14025214\" target=\"_blank\">",
"        14025214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scaldaferri F, Pizzoferrato M, Ponziani FR, et al, &ldquo;Use and Indications of Cholestyramine and Bile Acid Sequestrants,&rdquo;",
"      <i>",
"       Intern Emerg Med",
"      </i>",
"      , 2011 [pub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/21739227/pubmed\" id=\"21739227\" target=\"_blank\">",
"        21739227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westergaard H, &ldquo;Bile Acid Malabsorption,&rdquo;",
"      <i>",
"       Curr Treat Options Gastroenterol",
"      </i>",
"      , 2007, 10(1):28-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12710/abstract-text/17298762/pubmed\" id=\"17298762\" target=\"_blank\">",
"        17298762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9294 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12710=[""].join("\n");
var outline_f12_26_12710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154486\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154520\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154488\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154489\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389599\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389598\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154468\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154454\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154472\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154471\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389564\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7297703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154518\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154475\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154458\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299082\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154463\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277388\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154492\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277389\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154478\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154477\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389617\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154479\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154457\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154474\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9294\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9294|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/17/1301?source=related_link\">",
"      Colestipol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/38/36453?source=related_link\">",
"      Colestipol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12711="Amlodipine and olmesartan: Drug information";
var content_f12_26_12711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amlodipine and olmesartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/36/3653?source=see_link\">",
"    see \"Amlodipine and olmesartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5528405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5528409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5528465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose is individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within the same antihypertensive class). May also be used as initial therapy in patients who are likely to need &gt;1 antihypertensive to control blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Initial therapy (antihypertensive naive):",
"     </i>",
"     Amlodipine 5 mg/olmesartan 20 mg once daily; dose may be increased after 1-2 weeks of therapy. Maximum recommended dose: Amlodipine 10 mg/day; olmesartan 40 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Add-on/replacement therapy:",
"     </i>",
"     Amlodipine 5-10 mg and olmesartan 20-40 mg once daily depending upon previous doses, current control, and goals of therapy; dose may be titrated after 2 weeks of therapy. Maximum recommended dose: Amlodipine 10 mg/day; olmesartan 40 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5528466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial therapy is not recommended in patients &ge;75 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5528467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific guidelines for dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5528468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial therapy is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5528475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Azor&trade; 5/20: Amlodipine 5 mg and olmesartan medoxomil 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Azor&trade; 5/40: Amlodipine 5 mg and olmesartan medoxomil 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Azor&trade; 10/20: Amlodipine 10 mg and olmesartan medoxomil 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Azor&trade; 10/40: Amlodipine 10 mg and olmesartan medoxomil 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5528407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5528470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5528411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, including initial treatment in patients who will require multiple antihypertensives for adequate control",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5528447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Cardiovascular: Peripheral edema (dose related: 18% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined (limited to important or life-threatening): Anaphylaxis, hypotension, nocturia,  orthostatic hypotension, palpitation, pruritus, rash, urinary frequency",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5528417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5528418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur with olmesartan use; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with amlodipine/olmesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; use caution during initiation of therapy, particularly in patients with heart failure, severe aortic stenosis, post-MI patients, volume- or salt-depleted patients, or those undergoing surgery or dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal function deterioration: Olmesartan may be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; amlodipine and olmesartan exposure increased in hepatic dysfunction. Initial therapy is not recommended; the appropriate combination dosage form is not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal artery stenosis: Use olmesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Initial therapy is not recommended in patients &ge;75 years of age; the appropriate combination dosage form is not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Titration: Dosage titration may occur after 1-2 weeks in antihypertensive na&iuml;ve patients and 2-4 weeks in add-on or replacement therapy if blood pressure control inadequate.  This may be done by increasing one component at a time or by increasing both components to achieve more rapid control of blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5528453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5528452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Olmesartan. Management: Administer olmesartan at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5528456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice). Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, garlic, goldenseal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5528412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5528413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5528415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5528416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5528469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes which contain potassium. May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6179932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Azor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-20 mg (30): $149.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-40 mg (30): $189.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 mg (30): $149.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40 mg (30): $189.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5528472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic electrolyte panels, renal and liver function, urinalysis; BP, heart rate, peripheral edema; in CHF, serum potassium during dose escalation and periodically thereafter",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alzor CCB (PH);",
"     </li>",
"     <li>",
"      Axeler (FR);",
"     </li>",
"     <li>",
"      Azoren (HK, SG);",
"     </li>",
"     <li>",
"      Cardioplus AM (CN);",
"     </li>",
"     <li>",
"      Forzaten (BE);",
"     </li>",
"     <li>",
"      Konverge (IE);",
"     </li>",
"     <li>",
"      Normetec (PH, TH);",
"     </li>",
"     <li>",
"      Sanoral (EE);",
"     </li>",
"     <li>",
"      Sevikar (AU, BE, CH, DE, DK, FI, GB, GR, KP, NL, PT, TW);",
"     </li>",
"     <li>",
"      Tespadan (BG);",
"     </li>",
"     <li>",
"      Vascord (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5528459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Amlodipine inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     As a selective and competitive, nonpeptide angiotensin II receptor antagonist, olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; olmesartan interacts reversibly at the AT1 and AT2 receptors of many tissues and has slow dissociation kinetics; its affinity for the AT1 receptor is 12,500 times greater than the AT2 receptor. Angiotensin II receptor antagonists may induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, they do not affect the response to bradykinin, and are less likely to be associated with nonrenin-angiotensin effects (eg, cough and angioedema). Olmesartan increases urinary flow rate and, in addition to being natriuretic and kaliuretic, increases excretion of chloride, magnesium, uric acid, calcium, and phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5528461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/26/12711/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8845 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12711=[""].join("\n");
var outline_f12_26_12711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708611\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528405\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528409\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528465\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528466\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528467\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528468\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528475\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528407\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528470\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528411\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528447\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528417\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528418\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528453\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528452\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528456\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528412\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528413\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528415\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528416\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528469\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179932\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528472\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390214\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528459\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528461\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8845|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/36/3653?source=related_link\">",
"      Amlodipine and olmesartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12712="Tuberculosis in solid organ transplant candidates and recipients";
var content_f12_26_12712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tuberculosis in solid organ transplant candidates and recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/26/12712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/26/12712/contributors\">",
"     Aruna Subramanian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/26/12712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/26/12712/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/26/12712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/26/12712/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/26/12712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of tuberculosis (TB) among solid organ transplant recipients is higher compared with the general population, but varies by geographic location [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The diagnosis of TB in solid organ transplant recipients presents challenges that may lead to treatment delay. These include atypical clinical presentations, increased likelihood of negative tuberculin skin tests (TSTs), and negative sputum smear results despite active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The treatment of tuberculosis in transplant recipients also has its own challenges, which include pharmacokinetic interactions between immunosuppressive and antituberculous medications, allograft-related drug toxicities, and inadequate immune responses to Mycobacterium tuberculosis due to exogenous immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews Mycobacterium tuberculosis infections in solid organ transplant recipients. Nontuberculous mycobacterial infections in solid organ transplant recipients; bacterial, viral, and fungal infections in lung transplant recipients; as well as the evaluation, treatment, and prophylaxis of infection in solid organ transplant recipients are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of active TB among transplant recipients in developed countries has ranged from 1.2 to 6.4 percent, but has been reported to be as high as 10 to 15 percent in endemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4-6,8\">",
"     4-6,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of TB in solid organ transplant recipients is not well established and varies by geographic location, but the incidence has been shown to be significantly higher among transplant recipients compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a prospective study of 4388 solid organ transplant recipients at 16 transplant centers in Spain, the incidence of TB was 512 cases per 100,000 patients per year compared with 19 cases per 100,000 inhabitants per year in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/1\">",
"     1",
"    </a>",
"    ]. Among solid organ transplant recipients, lung transplant recipients had the highest incidence of TB (2072 cases per 100,000 patients per year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB occurs most commonly in lung transplant recipients as a result of reactivation of latent infection in the recipient, but also may arise from unrecognized infection in the allograft, or acquisition of new infection after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4,6,9\">",
"     4,6,9",
"    </a>",
"    ]. There are several reports of TB transmission from the donor allograft to the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Timing following transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of TB in solid organ transplant recipients, TB occurred a median of 183 days after transplantation (range 28 to 499 days), with 95 percent of cases occurring within the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/1\">",
"     1",
"    </a>",
"    ]. Among lung transplant recipients, the median time to onset was 3.5 months following transplantation compared with 11.5 months among renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/1\">",
"     1",
"    </a>",
"    ]. Donor-derived TB typically occurs earlier than reactivation of latent TB that originated in the recipient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Presenting manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-third to one-half of all cases of active TB after transplant are disseminated or occur at extrapulmonary sites, a much higher rate than that seen in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Lung transplant recipients are most likely to develop pulmonary manifestations of TB, although disseminated disease also occurs in a substantial proportion of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, TB may have an atypical presentation in this population (eg, pyomyositis, cutaneous ulcers or abscess, tenosynovitis).",
"   </p>",
"   <p>",
"    Fever occurred in 91 percent of solid organ transplant recipients with disseminated TB and 64 percent of those with localized TB; night sweats and weight loss were also common [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small minority of transplant patients has classic cavitary changes on chest radiograph. Radiographic findings of pulmonary TB in solid organ transplant recipients have included a focal infiltrate (40 percent), a miliary pattern (22 percent), nodules (15 percent), pleural effusions (13 percent), diffuse interstitial infiltrates (5 percent), and cavities (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of active TB in transplant recipients requires a high index of suspicion and often requires an invasive procedure, such as bronchoscopy with bronchoalveolar lavage or lung biopsy. TB should be considered in all transplant recipients with unexplained fevers, night sweats, and weight loss, and in all lung transplant recipients with evidence of pulmonary infection. Staining and culture for acid fast bacilli should be performed on all induced sputum and bronchoscopy specimens in such patients. In addition, mycobacterial infections should be considered in transplant recipients with atypical skin lesions or soft tissue infections. Skin biopsy specimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abscess fluid should be sent for acid fast bacilli staining and culture, and histopathology. It should be noted that neither tuberculin skin testing (TST) nor interferon-gamma release assays (IGRA) distinguish between active and latent TB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACTIVE TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations in the following section reflect the 2009 guidelines of the American Society of Transplantation (AST) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5\">",
"     5",
"    </a>",
"    ], and the 2009 guidelines of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for the treatment of active TB in transplant recipients are based largely on randomized trials in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/12\">",
"     12",
"    </a>",
"    ]. Data regarding the safety and efficacy of TB therapy in solid organ transplant recipients come from retrospective studies, case reports, and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4,13-19\">",
"     4,13-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the AST and GESITRA have recommended that the approach to the treatment of TB in solid organ transplant recipients be similar to immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. However, the following important issues specific to solid organ transplant recipients should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AST states that a rifamycin-containing regimen is strongly preferred for both severe and localized nonsevere TB due to the potent sterilizing activity of such regimens, and the importance of preventing the emergence of resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,12\">",
"       5,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to the AST, GESITRA recommends that rifamycins be avoided in cases of localized (eg, pulmonary) non-severe TB when there is no suspicion or evidence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH) resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"       8",
"      </a>",
"      ]. In patients not receiving a rifamycin, treatment options include a two-drug regimen of INH plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      , or a three-drug regimen of INH plus ethambutol plus either pyrazinamide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      . In those receiving a two-drug regimen, treatment should be continued for 12 to 18 months. In those receiving a three-drug regimen, the duration of treatment can be shortened to 12 months.",
"     </li>",
"     <li>",
"      Experts agree that rifamycins are indicated in patients with severe (eg, cavitary or multilobar disease) or disseminated TB or when there is suspicion or documentation of INH resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"       5,8",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      should be used with caution due to significant interactions between this class of drug and the calcineurin inhibitors and rapamycin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      ). The rifamycins (especially rifampin) reduce serum concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , rapamycin (sirolimus), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      via induction of the cytochrome p450 isoenzyme CYP3A4, and the combination of a rifamycin with these drugs has been associated with the development of rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8,13,20\">",
"       5,8,13,20",
"      </a>",
"      ]. Rifamycins also reduce levels of glucocorticoids, although this has been less well characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      is used, the dose of the calcineurin inhibitor or rapamycin should be increased approximately three- to fivefold and serum concentrations should be monitored [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"       8",
"      </a>",
"      ]. CYP3A4 induction by rifampin takes several days to occur, usually peaks within a week, and lasts for days to weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       Rifabutin",
"      </a>",
"      is an attractive alternative to rifampin because it has similar activity against M. tuberculosis but is a weaker inducer of cytochrome p450 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8,23-25\">",
"       5,8,23-25",
"      </a>",
"      ]. While there is less experience with rifabutin in the treatment of TB in transplant recipients, it appears effective in HIV-infected individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"       5,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"       \"Rifampin and other rifamycins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients receiving a rifamycin-containing regimen should be treated for a minimum of six months. However, duration should be extended in patients with severe disseminated disease, cavitary disease with sputum that remains culture positive after two months of treatment, bone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      joint disease, or central nervous system disease. Some experts recommend that treatment should be continued for at least nine months in all solid organ transplant recipients, since a shorter duration may be associated with increased mortality in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      is often used as part of the initial treatment regimen in non-transplant patients with a contraindication to the rifamycins, this agent is generally avoided in solid organ transplant recipients because of the risk of nephrotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The TB treatment regimen will depend on local resistance patterns and epidemiologic and susceptibility data from the individual patient's isolate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality of TB is higher among solid organ transplant recipients compared with immunocompetent individuals. In a literature review of TB in solid organ transplant recipients, 146 of 499 patients (29 percent) died [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4\">",
"     4",
"    </a>",
"    ]. Only 12 lung transplant recipients were included, two of whom died. Predictors of mortality included disseminated disease, prior rejection, and receipt of OKT3 or anti-T cell antibodies. However, in another study, disseminated disease was not associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of TB among solid organ transplant recipients, crude mortality was 19 percent, but mortality attributable to TB was only 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of rejection caused by the interaction between the rifamycins and the calcineurin inhibitors also contributes to the morbidity of TB in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/6\">",
"     6",
"    </a>",
"    ]. If immunosuppression is reduced upon starting TB treatment, there is also the theoretical possibility of immune reconstitution inflammatory syndrome, as is seen in HIV patients who receive antiretroviral therapy along with anti-tuberculous medicines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H9#H9\">",
"     \"Immune reconstitution inflammatory syndrome\", section on 'IRIS associated with mycobacterial infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculin skin testing (TST) should be performed in all transplant candidates to screen for latent TB, and should be performed two weeks later in those with a negative initial test in order to detect the booster effect [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. Induration &ge;5 mm is considered to be a positive result. The interferon-gamma release assay (IGRA) is a useful alternative to TST, and may be helpful for detecting latent TB in some solid organ transplant candidates and recipients with a negative TST, especially in patients with end-stage renal disease or advanced liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. IGRA can also be helpful in patients who received the Bacille Calmette-Gu&eacute;rin (BCG) vaccine since its results are not affected by receipt of BCG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with evidence of latent TB by TST",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IGRA, an evaluation for evidence of active TB is indicated. If the sputum is positive for TB by staining or culture, transplantation is contraindicated until the patient has been treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of latent TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have proven the efficacy of treating latent TB in immunocompetent individuals, but only case reports and case series have suggested benefit in solid organ transplant candidates and recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the increased risk of reactivation and severe disease among solid organ transplant recipients argues for initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) prophylaxis, particularly in regions in which TB is endemic. It is optimal to treat latent TB prior to transplantation, although it is also acceptable to treat following transplantation when necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. Treating prior to transplantation is especially challenging in liver transplant candidates who may not tolerate the potential hepatoxicity of isoniazid. Treatment prior to transplantation can be attempted with very close monitoring of liver function tests. However, in such cases, it may be safer to begin therapy after transplantation, once liver function has normalized. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link&amp;anchor=H11#H11\">",
"     \"Infectious complications in liver transplantation\", section on 'Tuberculosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Practices for the management of latent TB among transplant candidates and recipients vary in different countries, largely due to differences in the regional prevalence of TB.",
"   </p>",
"   <p>",
"    Transplant candidates and recipients should be treated for latent TB if any of the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial or boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      (TST) with induration &ge;5 mm or a positive interferon-gamma release assay",
"     </li>",
"     <li>",
"      History of untreated latent TB",
"     </li>",
"     <li>",
"      Those who have received an organ from a donor known to have untreated latent TB",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts would also treat transplant candidates who are at high risk for primary TB (eg, recent history of contact with an individual with active TB), even if the TST and interferon-gamma release assay are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Risk of new infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transplant candidates with chest radiographic evidence suggestive of previous TB (apical fibronodular lesions, calcified solitary nodule, calcified lymph nodes, or pleural thickening) that has not been treated should undergo aggressive evaluation, including a thorough epidemiologic history, to determine whether the abnormalities are most likely to represent TB or another granulomatous infection (eg, histoplasmosis). In regions in which endemic mycoses are common and TB is uncommon (eg, parts of the United States), such an evaluation is important to ensure that individuals are not treated unnecessarily for latent TB.",
"   </p>",
"   <p>",
"    For treatment of latent TB, we recommend oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose 300 mg) daily for adults and 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose 300 mg) daily for children for a duration of nine months; oral pyridoxine 25 to 50 mg daily should also be administered (",
"    <a class=\"graphic graphic_table graphicRef65944 \" href=\"UTD.htm?16/61/17373\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. Alternative regimens for latent TB treatment include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    for 16 weeks or INH plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/28\">",
"     28",
"    </a>",
"    ]. The latter combination has been studied in healthy individuals over 12 years of age as weekly directly observed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/29\">",
"     29",
"    </a>",
"    ]. Both of these regimens are limited by the drug-drug interactions between rifamycins and both calcineurin inhibitors and rapamycin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ); rifamycin-containing regimens can be used prior to transplant, but are not recommended after transplant. Patients may proceed to transplant before the full course of therapy for latent TB has been given. In these cases, therapy is typically continued post-transplant, but the regimen sometimes needs to be modified to minimize toxicities and drug-drug interactions.",
"   </p>",
"   <p>",
"    Treatment of latent TB is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    The risk of severe hepatotoxicity from INH is significant even in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/30\">",
"     30",
"    </a>",
"    ]. In solid organ transplant candidates and recipients receiving INH, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin should be monitored at baseline and at least monthly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"     8",
"    </a>",
"    ]; some experts favor testing for hepatotoxicity by monitoring ALT levels every two weeks for six weeks, then monthly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12712/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Active TB",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of tuberculosis (TB) in solid organ transplant recipients is not well established, and varies by geographic location. The prevalence of active TB among transplant recipients in developed countries has ranged from 1.2 to 6.4 percent, but has been reported to be as high as 10 to 15 percent in endemic regions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One-third to one-half of cases of tuberculosis after transplant are disseminated or extrapulmonary. Lung transplant recipients are most likely to develop pulmonary manifestations of TB. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TB should be considered in all transplant recipients with evidence of pulmonary or cutaneous lesions. Depending on the site(s) of involvement, appropriate clinical specimens should be sent (eg, staining and culture for acid fast bacilli [AFB] on bronchoalveolar lavage fluid or abscess fluid; AFB staining and culture and histopathology on biopsy specimens). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In solid organ transplant patients with localized non-severe TB without suspicion or evidence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH) resistance, we suggest using the rifamycin-containing regimens used in immunocompetent hosts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, due to drug interactions, some advocate the avoidance of rifamycins in this scenario. When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      is not used, a longer than usual duration of treatment is required. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of active TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe or disseminated TB or when there is suspicion or evidence of INH resistance, we suggest a regimen that includes a rifamycin; such a regimen is identical to that recommended for immunocompetent hosts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of active TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rifamycins, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , reduce serum concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , rapamycin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      via induction of the cytochrome p450 isoenzyme CYP3A4. The combination of rifampin with members of this class of drugs can lead to the development of rejection unless dose adjustments and therapeutic drug monitoring are performed carefully. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of active TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       Rifabutin",
"      </a>",
"      is an attractive alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      because it is a weaker inducer of cytochrome p450. However, there is less experience with rifabutin in the treatment of TB. Treatment should be continued for at least six months, and some experts recommend routine extension to nine months in transplant recipients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of active TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The TB treatment regimen will depend on local resistance patterns and epidemiologic and susceptibility data from the individual patient's isolate. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of active TB'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Latent TB",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculin skin testing (TST) should be performed in all solid organ transplant candidates to screen for latent tuberculosis, and should be repeated two weeks later in those with a negative initial test in order to detect the booster effect. Interferon-gamma release assay (IGRA) testing may be useful in individuals with a negative TST and in those who have received the Bacille Calmette-Gu&eacute;rin (BCG) vaccine. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that solid organ transplant candidates and recipients be treated for latent TB if they meet any of the following criteria (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TST (initial or boosted) with induration &ge;5 mm or a positive interferon-gamma release assay",
"     </li>",
"     <li>",
"      History of untreated latent TB",
"     </li>",
"     <li>",
"      History of contact with an individual with active TB",
"     </li>",
"     <li>",
"      Receipt of an organ from a donor known to be TST positive if the donor has no history of treatment for latent TB. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of latent TB'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that solid organ transplant candidates who are at high risk for primary TB be treated for latent TB even if screening tests are negative (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of latent TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of latent TB, the drug of choice is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH) 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 300 mg) daily for adults and 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 300 mg) daily for children for a duration of nine months; oral pyridoxine 25 to 50 mg daily should also be administered (",
"      <a class=\"graphic graphic_table graphicRef65944 \" href=\"UTD.htm?16/61/17373\">",
"       table 1",
"      </a>",
"      ). Alternative regimens for latent TB treatment include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for 16 weeks or INH plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"       rifapentine",
"      </a>",
"      for 12 weeks; rifamycin-containing regimens can be used prior to transplant, but are not recommended after transplant due to drug-drug interactions. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of latent TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In solid organ transplant candidates and recipients receiving INH, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin should be monitored at baseline and at least monthly thereafter; some experts favor testing for hepatotoxicity by monitoring ALT levels every two weeks for six weeks, then monthly thereafter. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of latent TB'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/1\">",
"      Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/2\">",
"      Morales P, Briones A, Torres JJ, et al. Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain. Transplant Proc 2005; 37:4050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/3\">",
"      Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010; 12:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/4\">",
"      Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/5\">",
"      Subramanian A, Dorman S, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/6\">",
"      Mu&ntilde;oz P, Rodr&iacute;guez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/7\">",
"      Subramanian AK, Nuermberger EL. Tuberculosis in transplant recipients: diagnostic and therapeutic dilemmas. Transpl Infect Dis 2008; 10:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/8\">",
"      Aguado JM, Torre-Cisneros J, Fort&uacute;n J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/9\">",
"      Winthrop KL, Kubak BM, Pegues DA, et al. Transmission of mycobacterium tuberculosis via lung transplantation. Am J Transplant 2004; 4:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/10\">",
"      Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation 1984; 38:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/11\">",
"      Fiske CT, Griffin MR, Erin H, et al. Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis 2010; 10:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/12\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/13\">",
"      Aguado JM, Herrero JA, Gavald&aacute; J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/14\">",
"      Zhang XF, Lv Y, Xue WJ, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single center in China. Transplant Proc 2008; 40:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/15\">",
"      Schulman LL, Scully B, McGregor CC, Austin JH. Pulmonary tuberculosis after lung transplantation. Chest 1997; 111:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/16\">",
"      Chan AC, Lo CM, Ng KK, et al. Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation. Liver Int 2007; 27:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/17\">",
"      Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 2002; 34:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/18\">",
"      Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation 1999; 68:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/19\">",
"      al-Sulaiman MH, Dhar JM, al-Khader AA. Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine. Transplantation 1990; 50:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/20\">",
"      Offermann G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/21\">",
"      Escalante P. Mycobacterial infections in solid organ transplantation. Curr Opin Organ Transplant 2007; 12:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/22\">",
"      Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003; 42:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/23\">",
"      L&oacute;pez-Montes A, Gallego E, L&oacute;pez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004; 44:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/24\">",
"      Lee J, Yew WW, Wong CF, et al. Multidrug-resistant tuberculosis in a lung transplant recipient. J Heart Lung Transplant 2003; 22:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/25\">",
"      Vandevelde C, Chang A, Andrews D, et al. Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991; 11:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/26\">",
"      Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011; 11:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/27\">",
"      Casas S, Mu&ntilde;oz L, Moure R, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl 2011; 17:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/29\">",
"      Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12712/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010; 59:224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1407 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12712=[""].join("\n");
var outline_f12_26_12712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Timing following transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Presenting manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT OF ACTIVE TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of latent TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Active TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Latent TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/61/17373\" title=\"table 1\">",
"      Dosing regimens for treatment of latent TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12713="Primary care of the adult with intellectual disability (mental retardation)";
var content_f12_26_12713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary care of the adult with intellectual disability (mental retardation)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/26/12713/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/26/12713/contributors\">",
"     Robert Baldor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/26/12713/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/26/12713/contributors\">",
"     Thomas L Schwenk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/26/12713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/26/12713/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/26/12713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental disabilities refer to a number of different conditions with onset in childhood; intellectual disability (ID) is a non-specific term that refers to a mental capacity below normal, due to any condition that impairs development of the brain before birth, during birth, or in the childhood years. ID (also referred to as cognitive impairment or cognitive adaptive disability) is replacing the older terminology &ldquo;mental retardation.&rdquo;",
"   </p>",
"   <p>",
"    Intellectual disability affects 0.6 to 2.5 percent of people in the UK and the US [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. People with intellectual disability are living longer than in the past and most are living in the community rather than in institutional settings. The average age of older adults with intellectual disability is 66 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with Down's syndrome live, on average, twice as long as they did 25 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the adult primary care clinician will be providing healthcare for increasing numbers of patients with intellectual disability and cognitive impairment.",
"   </p>",
"   <p>",
"    Unfortunately, disparity exists in health services provided to those with intellectual disability, when compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Patients with ID are less likely to receive adequate medical care than the general population, despite their increased burden of chronic health problems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with ID have shortened life expectancy, increased numbers of medical problems, and decreased rates of recommended preventive health interventions. These issues can be attributed to multiple factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic factors that result in both ID and a greater burden of somatic health problems.",
"     </li>",
"     <li>",
"      Communication difficulties involving the patient, caregivers, and health providers.",
"     </li>",
"     <li>",
"      Deficiencies in the structure and funding of health services for this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss the approach to an adult patient with intellectual disability who is being seen for primary care. A discussion of intellectual disability in pediatrics is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with ID are often characterized by their Intelligence Quotient (IQ). The IQ, a term first coined in the 1900s, is assessed by a variety of standardized tests including the Simon-Binet scale or the Wechsler Adult Intelligence scale.",
"   </p>",
"   <p>",
"    The normal range for IQ falls between 90 and 120. An IQ two standard deviations below the mean (ie, IQ &lt;70) is consistent with intellectual disability. Intellectual disability is further classified as mild (IQ 50 to 69); moderate (IQ 35 to 49); severe (IQ 20 to 34); or profound (IQ &lt;20).",
"   </p>",
"   <p>",
"    The diagnosis of intellectual disability involves an assessment of the individual's cognitive and functional abilities that goes beyond simply determining the IQ. The American Association of Intellectual and Developmental Disabilities (AAIDD) advocates a three step evaluation process [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measure the intelligence quotient.",
"     </li>",
"     <li>",
"      Assess behavior and emotional skills.",
"     </li>",
"     <li>",
"      Assess the impact of the individual's limitations on his or her ability to manage activities of daily living (ADLs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The DSM IV-diagnostic criteria for intellectual disability are consistent with this assessment (",
"    <a class=\"graphic graphic_table graphicRef81641 \" href=\"UTD.htm?25/16/25867\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/6\">",
"     6",
"    </a>",
"    ]. Utilizing DSM IV criteria, ID is coded on Axis II. Associated general medical conditions that have caused ID are coded on Axis III.",
"   </p>",
"   <p>",
"    The majority of individuals with intellectual disability are able to function well in childhood; limitations might not be apparent until they are challenged with learning upon entering school.",
"   </p>",
"   <p>",
"    Many adults with mild ID are able to live independently in the community. However, those with IQ's below 50, accounting for approximately 10 to 12 percent of those with ID, will require significant support to perform ADL's (",
"    <a class=\"graphic graphic_table graphicRef64507 \" href=\"UTD.htm?3/16/3339\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 2.5 percent of the United States (US) population has an IQ below 70. The degree of disability within this group is considerably variable, as IQ is just one component for determining intellectual disability.",
"   </p>",
"   <p>",
"    The US population prevalence of ID is 11.4 per 1000 in children and 6.6 per 1000 in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/7\">",
"     7",
"    </a>",
"    ]. There is up to a ninefold variation from state to state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that impair intellectual development may be related to a genetic abnormality or to a brain injury occurring prenatally, perinatally, or in early childhood. Injuries resulting in impaired brain development may be related to trauma, metabolic abnormalities (eg, hypothyroidism), toxin exposure (eg, alcohol), or infections (eg, meningitis or encephalitis). The fetal alcohol syndrome is one of the three most common congenital causes of ID. In about one-third of cases, no cause can be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of brain injury in childhood have declined due to several initiatives: use of car seats and bicycle helmets, prenatal immunization for rubella, childhood HIB immunization to protect against H flu meningitis, and newborn blood screening to detect disorders such as hypothyroidism and PKU [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 500 different genetic defects have been associated with ID [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/9\">",
"     9",
"    </a>",
"    ]. Genetic disorders are responsible for the majority of those with severe ID (IQ &lt;50), while mild ID is more likely to be associated with nongenetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two most common genetic etiologies of ID are Down syndrome and Fragile X Syndrome.",
"   </p>",
"   <p>",
"    Down syndrome, the most common, is caused by a sporadic chromosomal disorder resulting in a third chromosome at the 21st position (Trisomy 21). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=see_link\">",
"     \"Management of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    X-linked disorders primarily affect males, with females being carriers and transmission through the maternal line. Fragile X Syndrome is caused by a single gene defect on the X chromosome. Other examples of X-linked inheritance associated with ID include Hunter syndrome, Lesch Nyhan syndrome, and Duchenne muscular dystrophy.",
"   </p>",
"   <p>",
"    Many genetic defects do not cause mentation difficulties directly, but lead to metabolic disorders which then result in developmental impairment. Over 350 inborn errors of metabolism have been identified and affect 1 in 5000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/11\">",
"     11",
"    </a>",
"    ]. Phenylketonuria (PKU) is an example of a single gene disorder. PKU results in the production of a defective enzyme (phenylalanine hydroxylase) involved in protein metabolism, catalyzing the conversion of the amino acid phenylalanine to tyrosine. The resulting build up of phenylalanine causes developmental disability. However, if such individuals are placed on a phenylalanine free diet they can lead perfectly normal lives [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early identification of genetic metabolic disorders through state newborn screening programs has led to improved survival and health status of individuals diagnosed with these conditions. Newborn screening programs in the US vary by state but always include PKU and congenital hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef76630 \" href=\"UTD.htm?2/26/2476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple challenges to providing primary care for patients with intellectual disability. Patients are often not able to directly communicate their needs or concerns; caregivers who accompany them to an appointment may be unable to provide essential information; frequent relocations between group homes impedes the development of a trusting",
"    <span class=\"nowrap\">",
"     patient/provider",
"    </span>",
"    relationship; and patients may be unusually fearful about components of the physical examination or diagnostic testing. Combining these barriers with an increased number of health issues among the intellectually disabled, and the extra clinician time needed to provide even routine care, can further compromise the ability to provide quality care. Nonetheless, the basic premise that must always be in the forefront is that these patients deserve the same intensity of preventive health services and medical intervention as all others.",
"   </p>",
"   <p>",
"    Several aspects of providing care, including attention to specific social issues, are especially pertinent for the mentally retarded population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important to determine the nature of the living situation. Individuals with ID live in a variety of community settings, dependent on their ability to care for themselves. Many live with their parents throughout their life course. Disruptions in care occur as parents age, require care themselves, or die.",
"     </li>",
"     <li>",
"      Non-family settings range from living independently or in shared-living situations with friends to more structured residences such as supervised group homes to traditional nursing homes, or other intermediate care facilities. Individuals living in non-family licensed settings may have facility-related access to healthcare. Frequent changes in residential settings for insurance, age, or jurisdictional reasons often lead to fragmentation of care.",
"     </li>",
"     <li>",
"      It is important not to make assumptions about the degree of communication skills that an individual with ID possesses. Even when communication skills are limited, the patient should be addressed directly and treated in a respectful and caring manner. Acknowledge the patient's right to consent to examinations or tests, even if verbal communication is limited.",
"     </li>",
"     <li>",
"      Individuals who are non-verbal or have limited verbal communication skills are at greater risk for poor nutrition, overmedication, injury, and abuse. Abuse may be either physical or sexual, and may involve other patients or facility staff [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with limited communication, the medical history will come from the caregiver who is accompanying the patient. Physical complaints may be vague and the history limited. Contacting the caregiver who is closest to the patient is helpful in understanding what prompted the medical office visit. Two-way written communication between healthcare provider and caregiver is essential.",
"     </li>",
"     <li>",
"      It is best to approach frightened individuals slowly and perform a limited exam until they have become comfortable with the provider. For some patients, the white coat is problematic, while others may find it a reassuring sign that it is safe to be touched by this individual.",
"     </li>",
"     <li>",
"      In very difficult situations, pre-sedation with an anxiolytic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ) may be required to obtain testing, such as an EKG, or to perform a pelvic exam. Home visits can provide the opportunity to pursue an exam in a more comfortable and safe environment for the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Routine healthcare",
"    </span>",
"    &nbsp;&mdash;&nbsp;General screening and immunization guidelines for routine health maintenance should be followed for individuals with ID [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/15\">",
"     15",
"    </a>",
"    ]. Routine preventive services should include periodic dental exam, age appropriate cancer screening and immunizations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to care routinely provided to the general population, particular interventions should be considered for patients with ID. The Massachusetts Department of Developmental Services has published guidelines specific to these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suggestions for routine healthcare in this population include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate for early stages of mental illness, which is more common in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/17\">",
"       17",
"      </a>",
"      ]. Early intervention may prevent more serious impairments and secondary disability.",
"     </li>",
"     <li>",
"      Screening laboratory studies (blood chemistries, complete blood count, TSH) should be considered at regular health maintenance visits to supplement the limited available information for patients with impaired communication [",
"      <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/16,18\">",
"       16,18",
"      </a>",
"      ]. Decisions to order laboratory studies should be balanced against the difficulty of obtaining a blood specimen, and the lower predictive value of positive test results in an asymptomatic population.",
"     </li>",
"     <li>",
"      People in institutional care should be periodically evaluated for evidence of infectious diseases such as tuberculosis and hepatitis C. Patients who do not have documentation of hepatitis B vaccination should be tested for hepatitis B and vaccinated if negative. Patients should be offered appropriate testing for sexually transmitted diseases, including HIV testing; legal guardians may need to be contacted for their decision and consent regarding HIV testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common sense approach to routine health guidelines should be taken. As an example, a combative individual may need anesthesia to obtain an adequate pap smear. Risks of anesthesia need to be weighed against the risk of cervical cancer in the individual, especially if the patient is unlikely to have had consensual sexual activity and is considered low risk for sexual abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Scheduling visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the periodic health examination in the general population may not be the most efficient way to provide primary care, and many advocate providing preventive health services in the context of sick visits, scheduled routine visits may have greater impact and be more important for patients with ID. A system of providing medical visits only on-demand is less effective for a population with limited ability to communicate who may not be able to express need. Additionally, these patients often require extra time for a visit because of the complexity of the",
"    <span class=\"nowrap\">",
"     patient/caregiver/clinician",
"    </span>",
"    interaction and multiple underlying social, behavioral, and emotional difficulties.",
"   </p>",
"   <p>",
"    In a study in the UK, for example, in which structured health checks were provided by 40 general practices for 180 patients with ID, 51 percent had new health problems identified; serious treatable health problems, including breast cancer, dementia, diabetes, and hypothyroidism were identified in sixteen patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Issues of special concern",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues of guardianship should be clarified early on in the medical relationship. While many individuals with ID are their own guardian, often there is a need for a legal or medical guardian to be appointed. This may be a relative, designated representative, or social service agency as a \"ward of the court\". A successor guardian for an aging parent should be identified.",
"   </p>",
"   <p>",
"    Understanding who has the ability to sign consent for medical interventions is important. Nevertheless, the medical provider can play an important role as a patient advocate when there is controversy over the approach to care.",
"   </p>",
"   <p>",
"    End-of-life issues should be discussed prior to the development of a life-threatening event. Family concerns and preferences are important to solicit. ID itself is not a reason for a routine DNR status; such decisions should include the nature of the individual's terminal illness, likelihood of resuscitation success, and the family's religious and cultural beliefs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sexuality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexuality is an area often overlooked, as it is often assumed that individuals with ID are not sexually active. Issues related to birth control and the possibility of sexually transmitted diseases should be considered and addressed with family and caregivers. Additionally, many individuals are living independently in the community and counseling regarding sexual abuse, alcohol, and substance abuse is important [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9227245\">",
"    <span class=\"h3\">",
"     Victims of violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with intellectual disability are at increased risk of experiencing interpersonal violence, including physical, sexual, and caregiver violence. In a systematic review and meta-analysis of three studies, there was a 60 percent increased risk for experiencing violence among persons with intellectual disability compared to the general population (OR 1.60, 95% CI 1.05-2.45) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/20\">",
"     20",
"    </a>",
"    ]. Another two studies cited in the systematic review but not included in the meta-analysis found that individuals with intellectual impairment had the highest rates of violence compared to individuals with other types of disability, including mental illness and physical or sensory impairments. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMMON PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with ID are at risk for a variety of social problems, and many also suffer from underlying congenital or metabolic abnormalities which may cause unique medical and physical problems. Common comorbid conditions include seizure disorders, cerebral palsy (CP), gastrointestinal motility problems, thyroid disease and behavioral disorders. Appropriate screening should be performed for cardiovascular risk. Unfortunately, this population is also participating in the obesity epidemic, with its resulting increase in diabetes. A table highlights conditions that are more common in this population (",
"    <a class=\"graphic graphic_table graphicRef76615 \" href=\"UTD.htm?33/45/34524\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mental illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and treatment of mental illnesses and other serious disorders in this population are often delayed, inadequate, or not provided at all. While behavioral issues are often the presenting complaint when patients with ID are brought in for psychologic evaluation, depression, anxiety and psychotic disorders often play a role. Psychiatric co-morbidities are common, affecting 31 percent of subjects with intellectual disability (mean age 22.6 years) who were followed over a course of 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/21\">",
"     21",
"    </a>",
"    ]. In this Australian cohort, only 10 percent of those with psychopathology had received mental health intervention during the 14 year study period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Seizure disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizure disorders are more prevalent in patients with ID than the general population. The incidence of seizures is highest in those with the lowest IQ and affect upwards of 50 percent of patients with ID and concurrent cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/22\">",
"     22",
"    </a>",
"    ]. A comorbid seizure disorder is associated with a death rate three times higher than for those without epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/23\">",
"     23",
"    </a>",
"    ]. It is important to discuss seizure safety with those that care for the patient.",
"   </p>",
"   <p>",
"    It is not unusual for more than one anticonvulsive agent to be required in order to control seizures in a patient with severe ID. Periodic measurement of serum levels for anticonvulsants will help maintain therapeutic ranges, avoid breakthrough seizures, and avoid medication toxicity. A trial taper of anticonvulsants if the patient has not had a seizure in over a year has been advocated by some [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/24\">",
"     24",
"    </a>",
"    ], although intellectual disability is a risk factor for seizure recurrence off medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cerebral palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) refers to the presence of a nonprogressive motor impairment and, like ID, is a nonspecific term. While not all individuals with CP suffer from intellectual disability, up to one-third of all mentally retarded individuals are affected by CP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/25\">",
"     25",
"    </a>",
"    ]. CP presents a variety of challenges to the patient and their caregivers, including spasticity and immobility, high rates of strabismus and cerebral visual impairment, bowel and bladder dysfunction, and altered growth and nutrition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic treatment for spasticity includes the use of benzodiazepines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , which is less sedating [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/26\">",
"     26",
"    </a>",
"    ]. Nerve blocks and botulinum toxin injections can be used for those with specific muscle group involvement or if medications have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/27\">",
"     27",
"    </a>",
"    ]. Such therapies need to be repeated three to four times a year. Orthopedic surgeries may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link\">",
"     \"Management and prognosis of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful skin hygiene is important for patients with CP or other significant movement limitations to prevent problems with pressure ulcers. Bone demineralization with consequent fractures, and decubitus ulcers, may occur secondary to long-standing immobility and nutritional deficiencies. A good relationship with a rehabilitation center can be important for assuring the proper fitting of wheelchairs and other supportive devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal dysmotility can cause dysphagia, esophageal reflux, and gastric emptying disorders. This may lead to dental erosion, esophagitis, anemia, feeding problems, aspiration, and pneumonia.",
"   </p>",
"   <p>",
"    Dysphagia can be seen in up to 5 percent of patients with ID. The use of a modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow can be helpful to determine the degree of swallowing dysfunction and guide the use of specialized diets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consultation with a speech or language pathologist can provide insight into feeding strategies and eating behaviors. Methods to minimize aspiration risk include modifying the consistency of foods to include pureed foods and compounds to thicken liquids to a honey-like consistency. Other important steps include feeding meals in a quiet non-stressful setting and feeding slowly in an upright position.",
"   </p>",
"   <p>",
"    The use of gastrostomy tubes (G-tubes) or jejunostomy tubes (J-tubes) to decrease aspiration risk and provide adequate nutrition for those who are incapable of taking in enough calories to maintain weight may be considered. The use of such feeding tubes to prevent aspiration pneumonia is controversial. G-tube feeds can be given slowly while the individual sleeps to avoid the use of this disruptive technology during the day. It is important to instruct caregivers to keep the head of the bed elevated at a 30 degree angle to avoid reflux of stomach contents. J-tubes may be a better choice than G-tubes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation has been reported in up to 40 percent of individuals with ID, usually secondary to immobility and lack of exercise. However, specific gastrointestinal dysfunction may play a role and medical conditions such as hypothyroidism should be considered. Psychotropic and other medications with anticholinergic effects may also be contributing factors. Inadequately treated constipation may cause fecal impaction, intestinal obstruction, and even death. Since history of bowel function may be difficult to obtain, constipation may be missed as a cause of patient distress [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies for dealing with this common condition include increasing fluids and stool softeners. Daily laxatives may be required. Tolerance to stimulant laxatives is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/28\">",
"     28",
"    </a>",
"    ]. For more significant problems stimulant suppositories or enemas given every three to four days may be necessary to avoid obstipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Behavioral disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral disorders are frequent among people with ID and range from self-injurious actions to other aggressive activities which may be directed at other individuals and caregivers. Behavioral disruptions may be a normal reaction to minor changes in the patient's surroundings, appropriate for the developmental age of the patient. Patience and redirecting behavioral treatments should be tried before starting psychotropic medications.",
"   </p>",
"   <p>",
"    Communication difficulties can significantly impede the evaluation of behavioral disorders. Any change in baseline behavior should prompt an investigation for an underlying source of pain, or other contributing medical factor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/29\">",
"     29",
"    </a>",
"    ]. In one report of secondary medical causes of behavioral change, constipation was the number one ranked problem [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/30\">",
"     30",
"    </a>",
"    ]. Others have noted an association with menstrual discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/31\">",
"     31",
"    </a>",
"    ]. Potential for unreported traumatic injuries should be considered. Unusual diagnoses such as porphyria can be contributing.",
"   </p>",
"   <p>",
"    A careful physical exam should be completed to look for sources of discomfort related to infection (respiratory, skin, urine), pain from minor annoyances such as skin irritation, or more serious conditions such as a fracture or testicular torsion.",
"   </p>",
"   <p>",
"    A multidisciplinary approach is helpful in treating behavioral disorders. The most common forms of these behaviors include head-banging, hand-biting, and excessive self-rubbing and scratching. Potential causes for specific behavioral abnormalities should be evaluated (",
"    <a class=\"graphic graphic_table graphicRef52451 \" href=\"UTD.htm?3/6/3179\">",
"     table 5",
"    </a>",
"    ). Behavioral modification therapies should be attempted, before medications are initiated. Behavioral techniques include providing alternative options for the individual to choose, and providing follow through with appropriate rewards or consequences.",
"   </p>",
"   <p>",
"    Antipsychotics are commonly used to treat aggressive behavior for non-psychotic individuals with ID. Rates of antipsychotic use reported in up to 45 percent of individuals in institutions and 20 percent in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/32\">",
"     32",
"    </a>",
"    ]. A randomized trial compared treatment with a first generation antipsychotic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), an atypical antipsychotic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ), and placebo for 86 non-psychotic patients with ID and aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/32\">",
"     32",
"    </a>",
"    ]. At four weeks, all three groups showed a marked decrease in aggression, determined by a quantitative score, with the greatest decrease in the group receiving placebo; this decline persisted at 12 week follow-up.",
"   </p>",
"   <p>",
"    The use of antipsychotics for behavioral control should be questioned, and, if used at all, reserved for resistant behaviors that result in significant self injury or potential harm to others. Medications should be weaned to the lowest effective doses once behaviors are stabilized. Newer atypical antipsychotics agents minimize the risk of extrapyramidal side effects but carry an increased risk for inducing the metabolic syndrome, weight gain, and diabetes. Patients who are treated with psychotropic medications need frequent monitoring for potential side effects (",
"    <a class=\"graphic graphic_table graphicRef64446 \" href=\"UTD.htm?20/28/20940\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, attention-deficit hyperactivity disorder (ADHD) is more prevalent in people with intellectual disability, compared to the general population. There is no evidence from randomized trials that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    is effective for management of ADHD in patients with intellectual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/33\">",
"     33",
"    </a>",
"    ], although it has been prescribed for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Oral hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral hygiene is often overlooked [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/34\">",
"     34",
"    </a>",
"    ]. Periodontal disease is common. Mild sedation may be needed for outpatient dental visits; deeper sedation requiring monitoring is occasionally indicated for patients intolerant of outpatient care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SYNDROME SPECIFIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When caring for an individual with ID, a search for the underlying cause is helpful, however in many instances the cause of the individual's disability is not discernible. Genetic testing can be helpful and may be useful for advising families to the possibilities of an inherited disorder.",
"   </p>",
"   <p>",
"    Various conditions are associated with specific medical risks that may require special screening. The three major congenital etiologies of ID are Down syndrome, fetal alcohol syndrome, and fragile X syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Down syndrome, resulting from an extra chromosome at the 21st position, is seen with increasing frequency with advancing maternal age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/35\">",
"     35",
"    </a>",
"    ]. Characteristic features of Down syndrome include oval shaped eyes with small medial intracanthal skin folds; slightly depressed, flat, nasal bridge; macroglossia; small ears; single crease across the palm (simian crease); and decreased muscle tone with ligamentous laxity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Down syndrome is associated with cardiac abnormalities, particularly septal defects such as endocardial cushion defects, and tetralogy of Fallot. All patients with Down syndrome should have an echocardiogram once to rule out underlying cardiac defects. Although there is no reason to repeat an echocardiogram in adulthood in the absence of a change in cardiac function, for many adult patients an echocardiogram was never previously obtained or the results cannot be located. The need for antibiotic prophylaxis prior to dental and other procedures is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visual impairments, including amblyopia, refractory errors, cataracts, and glaucoma, are common. Hearing impairments are also common. Annual ophthalmologic and auditory exams are recommended, and should be re-assessed in the workup of a newly developing behavioral problem.",
"   </p>",
"   <p>",
"    Ligamentous laxity is associated with Down syndrome and may cause problems if there is atlantoaxial instability with increased mobility at C1-2. This is seen in about 7 percent of Down syndrome patients; the majority are asymptomatic. Symptoms are due to cord compression and should be considered if there is torticollis, neck or shoulder pain, a gait change, or new incontinence. Preoperative neck Xrays (lateral cervical spine films: neutral, flexed, and extended views) should be obtained if general intubation is planned or if the individual plans to engage in contact sports or participate in the Special Olympics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of Down syndrome\", section on 'Atlantoaxial instability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other common medical problems include decreased cell-mediated immunity and thyroid dysfunction. The reduction in cell-mediated immunity results in a slightly higher rate of leukemia than in the general population, which is typically manifested in childhood. Additionally, these individuals are at increased risk for infection. Individuals with Down syndrome have a 30 percent lifetime risk of developing hypothyroidism and should be screened on an annual basis with a TSH.",
"   </p>",
"   <p>",
"    Patients with Down syndrome have a significantly increased risk for Alzheimer dementia which should be considered for the individual whose function begins to deteriorate. The occurrence of Alzheimer dementia occurs at a younger age in people with Down syndrome than the general population; it is not unusual to be seen in the 40s [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/36\">",
"     36",
"    </a>",
"    ]. Almost 20 percent of patients with Down syndrome over age 45 have dementia, which is correlated with increased mortality risk in these individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alzheimer dementia is associated with neurofibrillary tangles and beta-amyloid plaques. The gene for beta-amyloid precursor protein (APP) is located on chromosome 21. It is thought that over expression of this gene, due to the extra chromosome, results in excess APP production. Additionally chromosome 21 codes for superoxide dismutase (SOD-1); increased activity of this enzyme may enhance the production of hydroxyl radicals and further contribute to neural damage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessing dementia in the intellectually disabled patient is challenging. Evaluation instruments, such as the Dementia Questionnaire for Persons with Mental Retardation and the IBR Mental Status Examination, may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fragile X syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragile X syndrome is the most common form of inherited ID in males. A defect of the FMR1 (fragile X mental retardation) gene on the X chromosome leads to problems with the production of the FMR protein, assumed to be essential for normal brain functioning. Females, with two X chromosomes, are carriers, though may have some minor symptoms. This syndrome is seen in 1 of every 2000 male births.",
"   </p>",
"   <p>",
"    Characteristic features include macrocephaly, large ears, strabismus, high palate, and hyperextensible fingers. Speech delays and behavioral problems, including attention deficit, are common with autistic-type behaviors seen in about a quarter of affected individuals. Physical symptoms, such as large testes, are more apparent after puberty. Hand biting or flapping and speech disturbances are also common. Cardiac valve defects may be present, particularly mitral valve prolapse.",
"   </p>",
"   <p>",
"    Diagnosis is established by molecular testing for the FMR1 gene rather than routine chromosome analysis. No specific treatment other than genetic counseling is currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fetal alcohol syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal alcohol syndrome (FAS) is the leading cause of preventable intellectual disability. While not a genetic condition, fetal alcohol syndrome (FAS) is a common disorder, seen in about one to three per 1000 births in the US; incidence is likely higher in countries with higher rates of alcohol abuse. FAS is the extreme expression of prenatal alcohol consumption causing the abnormalities seen in fetal alcohol spectrum disorders (FASDs). In the US a 2002 survey revealed that approximately 10 percent of pregnant women used alcohol and 2 percent engaged in frequent use or binge drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethanol acts as a toxin on newly forming embryonic cells, particularly during the first trimester when a woman may not yet realize she is pregnant. The history of alcoholism may be associated with multiparity, older maternal age at time of pregnancy, or maternal mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristic facial features include a long philtrum, a wide and narrow upper lip, wide nasal bridge, and a small upturned nose. The \"Lip-Philtrum Guide\" is a useful tool [",
"    <a class=\"abstract\" href=\"UTD.htm?12/26/12713/abstract/42\">",
"     42",
"    </a>",
"    ] and is available through the",
"    <a class=\"external\" href=\"file://depts.washington.edu/fasdpn/\">",
"     University of Washington website",
"    </a>",
"    . Central nervous system damage can include microcephaly, seizures, learning disabilities, and developmental delay. Growth deficiency, visual problems, hearing loss, heart defects, and genital urinary tract abnormalities are also seen.",
"   </p>",
"   <p>",
"    Early identification of FAS can lead to intervention programs to prevent secondary complications. These secondary complications include educational difficulties, mental health problems including attention deficit, substance abuse, and trouble with the law. A stable and nurturing home, educational support services, and consistent supportive environment are helpful in preventing these outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prader-Willi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;This most common form of obesity caused by a genetic disorder results from an abnormality of the long arm of chromosome 15. The Prader-Willi syndrome is characterized by infantile hypotonia and failure to thrive. Later in life hypogonadism, mental impairment, and short stature are seen and despite early trouble with maintaining weight, such patients experience hyperphagia, with resulting morbid obesity, which may lead to diabetes mellitus or premature congestive heart failure.",
"   </p>",
"   <p>",
"    Strict food supervision, physical activity, and a special education program are the only treatments. Genetic testing is helpful with predicting the risk of recurrence so that appropriate counseling may be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intellectual disability (ID) affects up to 2.5 percent of the population. Adult primary care services are becoming more important for this population as people with intellectual disability are living longer and living in the community. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of intellectual disability (ID, formerly referred to as mental retardation or MR) is based on assessment of the IQ (&lt;70), an individual's behavioral and emotional skills, and their ability to manage activities of daily living (ADLs). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common genetic etiologies of ID are Down syndrome and Fragile X Syndrome. Fetal alcohol syndrome is the major non-genetic cause of ID. However, a specific etiology cannot be determined for many patients with ID. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In providing care for patients with ID, it is important to understand the living situation, communicate with people who can provide medical historical information when the patient is unable to do so, recognize the potential for injury and abuse, and try to accommodate patient's fears while providing quality healthcare. Screening for infectious disease in institutionalized patients (TB, hepatitis B, C) and screening laboratory studies to supplement a limited patient history may be indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12200?source=see_link\">",
"       \"Approach to the patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical problems common to this population include mental illness and behavioral disorders, seizure disorder, cerebral palsy, dysphagia, and constipation. Constipation may affect up to 40 percent of patients with ID and can be an unsuspected cause of behavioral change.",
"     </li>",
"     <li>",
"      Patients with Down syndrome should be evaluated for cardiac abnormalities, visual and hearing impairments, hypothyroidism, and early dementia. Atlantoaxial instability should be consideration when suggested by symptoms of neck pain or possible cord compression. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Down syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Fragile X syndrome is a sex-linked disorder causing macrocephaly and autistic-type behaviors. Fetal alcohol syndrome causes characteristic changes in facial configuration, developmental delay, and often behavioral difficulties. Prader-Willi syndrome can cause morbid obesity. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Syndrome specific issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705284216\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. John O&rsquo;Brien, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/1\">",
"      van Schrojenstein Lantman-De Valk HM, Metsemakers JF, Haveman MJ, Crebolder HF. Health problems in people with intellectual disability in general practice: a comparative study. Fam Pract 2000; 17:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/2\">",
"      Baxter H, Lowe K, Houston H, et al. Previously unidentified morbidity in patients with intellectual disability. Br J Gen Pract 2006; 56:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/3\">",
"      Fisher K, Kettl P. Aging with mental retardation: increasing population of older adults with MR require health interventions and prevention strategies. Geriatrics 2005; 60:26.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Closing the Gap: A National Blueprint to Improve the Health of Persons with Mental Retardation. Office of the Surgeon General. Rockville, MD 2002. Available at: www.nichd.nih.gov/publications/pubs/closingthegap/index.cfm (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     American Association of Intellectual and Developmental Disabilities (AAIDD, formerly AAMR). Available at: www.aaidd.org (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). State-specific rates of mental retardation--United States, 1993. MMWR Morb Mortal Wkly Rep 1996; 45:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/8\">",
"      Alexander D. Prevention of mental retardation: Four decades of research. Ment Retard Dev Disabil Res Rev 1998; 4:50.",
"     </a>",
"    </li>",
"    <li>",
"     The National Human Genome Research Institute. Available at: www.genome.gov (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/10\">",
"      Moser HG. A role for gene therapy in mental retardation. Mental Retardation and Developmental Disabilities Research Reviews. Gene Therapy 1995; 1:4.",
"     </a>",
"    </li>",
"    <li>",
"     Scriver CR. The metabolic and molecular bases of inherited disease, 7th ed, McGraw Hill, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/12\">",
"      Ding Z, Harding CO, Th&ouml;ny B. State-of-the-art 2003 on PKU gene therapy. Mol Genet Metab 2004; 81:3.",
"     </a>",
"    </li>",
"    <li>",
"     National Newborn Screening and Genetics Center. Available at: genes-r-us.uthscsa.edu (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/14\">",
"      Lennox N, Eastgate G. Adults with intellectual disability and the GP. Aust Fam Physician 2004; 33:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/15\">",
"      Down Syndrome Medical Interest Group (DSMIG), Cohen WI. Health care guidelines for individuals with Down syndrome. Down Syndrome Quart 1996; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     Massachusetts Health Quality Partners: Preventive health recommendations for adults with mental retardation. Available at: file://www.guidelines.gov/content.aspx?id=37906 (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/17\">",
"      Chen CY, Lawlor JP, Duggan AK, et al. Mild cognitive impairment in early life and mental health problems in adulthood. Am J Public Health 2006; 96:1772.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Healthy Ageing: Adults with Intellectual Disabilities, Physical Health Issues. Available at: file://who.int/mental_health/media/en/21.pdf (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/19\">",
"      Cocco KM, Harper DC. Substance use in people with mental retardation: assessing potential problem areas. Ment Health Aspects Dev Disabil 2002; 5:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/20\">",
"      Hughes K, Bellis MA, Jones L, et al. Prevalence and risk of violence against adults with disabilities: a systematic review and meta-analysis of observational studies. Lancet 2012; 379:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/21\">",
"      Einfeld SL, Piccinin AM, Mackinnon A, et al. Psychopathology in young people with intellectual disability. JAMA 2006; 296:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/22\">",
"      Coulter DL. Epilepsy and mental retardation: an overview. Am J Ment Retard 1993; 98 Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/23\">",
"      McKee JR, Bodfish JW. Sudden unexpected death in epilepsy in adults with mental retardation. Am J Ment Retard 2000; 105:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/24\">",
"      Tyler CV Jr, Bourguet C. Primary care of adults with mental retardation. J Fam Pract 1997; 44:487.",
"     </a>",
"    </li>",
"    <li>",
"     Tilton AH, Butterbaugh G. Mental retardation and cerebral palsy. In: Neurological Therapeutics Principles and Practice, Noseworthy JH (Ed), Martin Dunitz, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/26\">",
"      Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 1996; 11 Suppl 1:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/27\">",
"      Katz RT. Management of spasticity. Am J Phys Med Rehabil 1988; 67:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/28\">",
"      M&uuml;ller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/29\">",
"      Ryan R, Sunada K. Medical evaluation of persons with mental retardation referred for psychiatric assessment. Gen Hosp Psychiatry 1997; 19:274.",
"     </a>",
"    </li>",
"    <li>",
"     Charlot LR, Abend S, Silka V, et al.. A short stay inpatient unit for adults with development disabilities. In: Contemporary Dual Diagnosis MH/MR Service Models Volume 1: Residential and Day Services, NADD Press, Kingston, NY 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/31\">",
"      Carr EG, Smith CE, Giacin TA, et al. Menstrual discomfort as a biological setting event for severe problem behavior: assessment and intervention. Am J Ment Retard 2003; 108:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/32\">",
"      Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/33\">",
"      Thomson A, Maltezos S, Paliokosta E, Xenitidis K. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Cochrane Database Syst Rev 2009; :CD007011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/34\">",
"      Prater CD, Zylstra RG. Medical care of adults with mental retardation. Am Fam Physician 2006; 73:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/35\">",
"      Hult&eacute;n MA, Patel S, Jonasson J, Iwarsson E. On the origin of the maternal age effect in trisomy 21 Down syndrome: the Oocyte Mosaicism Selection model. Reproduction 2010; 139:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/36\">",
"      Bush A, Beail N. Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis. Am J Ment Retard 2004; 109:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/37\">",
"      Coppus AM, Evenhuis HM, Verberne GJ, et al. Survival in elderly persons with Down syndrome. J Am Geriatr Soc 2008; 56:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/38\">",
"      Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/39\">",
"      Silverman W, Schupf N, Zigman W, et al. Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard 2004; 109:111.",
"     </a>",
"    </li>",
"    <li>",
"     National Down Syndrome Society. Available at: www.ndss.org (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/41\">",
"      Centers for Disease Control and Prevention (CDC). Alcohol consumption among women who are pregnant or who might become pregnant--United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 53:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/26/12713/abstract/42\">",
"      Astley SJ, Clarren SK. Diagnosing the full spectrum of fetal alcohol-exposed individuals: introducing the 4-digit diagnostic code. Alcohol Alcohol 2000; 35:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2779 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12713=[""].join("\n");
var outline_f12_26_12713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Routine healthcare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Scheduling visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Issues of special concern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Legal issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sexuality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9227245\">",
"      - Victims of violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMMON PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mental illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Seizure disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Behavioral disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oral hygiene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SYNDROME SPECIFIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fetal alcohol syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H705284216\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/16/25867\" title=\"table 1\">",
"      DSM-IV criteria for MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/16/3339\" title=\"table 2\">",
"      Associated disability of MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/26/2476\" title=\"table 3\">",
"      Components newborn scrn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/45/34524\" title=\"table 4\">",
"      Commonly missed conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/6/3179\" title=\"table 5\">",
"      Rx self-injurious behaviors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/28/20940\" title=\"table 6\">",
"      Monitoring atyp antipsych",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12200?source=related_link\">",
"      Approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=related_link\">",
"      Management of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_26_12714="Staphylococcal folliculitis on leg";
var content_f12_26_12714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50187%7EDERM%2F62930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50187%7EDERM%2F62930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Staphylococcal folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple follicularly-based inflammatory papules and pustules are present on the leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDjPJdUAIDgjKAD7v5UQs6GNrxB5Y4CEk7B9P61JHAZJH8+UYBDFw3TPoB1GOtXI085GcLE7lQowCCUHYDoTjvXBc9chjaM7nRWe0B+VgOfr/8AWqzbqksjxL5cU2SUBPBA5+U+p9Kjb5GRGZgpOdmN2B6//rqURKr+XMxXcdyOSNg/+ufTtUljmmKKQ8glzxKr/K2fY0y5MG5UDPFg5VlHGO4z1qawZbicmX91KgKq3AVz3B49Kc0bLEJRuVN2Vicghvr3wRQMS1kEtuERS8iNtkJ5HthatWwDttQItym5m3crIB/X2qsDktPbKUkj+Z/3nTnHHrU0DL5HmScMkm/d0dDnru7027gICkocKm5EIYwjOTnuv09KnC43mCRVMg2ncdolGM7fr71Fcyq5W4Erx3KPvTA+WQeoHr69qL1yZIpZEkWJ8MYmPDN6g9gSfwqlLoFhvkhoPOUBuSioDhojnhW9c+tRxS3dkxSMffYZjl+YE+qn0q9NHIYysCuzbeUwMhM5ZW9MeveonkDrDE4JtEz5DEn92PT1x2x2NWyCeRVKxiCVhIRkRsRjHofaonj2OPKUGV3+aDBwCBwy/wCNV3ja33SSJuR8pJGwyUPXP9cVbQieOF4JXfqRMhIK8cDmk9R7CW/7wIhjjcAl22tsyPXP8JH6ikWeFpB9rKL5i7VdFGDg8Z7Z9x2pjyNLaofIijKjdIQMFlz94HuPUdqaltwzs6yWyufKkUbueOCOw96GG5NdLPaXOLhZBKQVeIj+Dvz39cVXdprZPLtJZZ7GZsHOASo5BOP4h2qW6uWluPJ1CUELgJIh4b0DH2pIGZJZo5ThJSpaMDAb0x6H0o9RFadUFwm1Q6MMox43rk5DejVYupDbqssETfZJSQowdgKj7oPXcKhuS6AttfyWby3RsZTngn3962ZC1lpvDq1ncLkjeGB9x3Rx/wDWoHcx9yxWrSO48iQ/NgfdPapdO/0d4zbEQ3IY5O7cCh/h+hpMgKTu8wSgiJhwSO+R0Jx2qT7FFHbJL5zGELiNuhkOcEf7OO2etIZFOod3lVmihQnAUAmJj1z/ALB9utVWLXDNEUjjCZYMCV38D5R/QVZiYxziWKKO5giAJjk6Ov8AdP8ASmyTrPCrW+YixEbRt0HcEnrmi9xMjuI2kjKquZIlwT93cMdCOzVSBlNsGceYkY+Xeudo7lfXFWkgzK8kwlDIN7+WQec8N9KWeWKa7jjMiQzfeeTd8snpx29x3pMExIJLZ7ZoHZvtJbMb4+8D29vrUMilJY1uJJBGG+fv5fuAOoxilk3i6iFqdshVjuYjAP07d+DUVvMUmt4Z2REkJBmZeR25HcA80yRUYszQ3GxnCkRu2VyvpnrnuKpSKE2m0eWGaNi7kruBHqD39xV24dfMlt0ljuJVOI5Y8FTj37D37VSkjEK4kVkZhlMPkFu4Pp1yD0o8wJrhDE4jSJcgAuQ2d4/vYPQe5qvqtrDBDbmM5iYblkjctgjqGz0PSpbW0PmOjAx3I4AEgIxjkMT1/OmRpHBIyzRJHDN8nmyKSM9iB39KTVxakM0Dg5jYbXG4Fv73Tb+dU5Ns4LNbFZFI3lCcqMdMVqLayruhdOBlwrZO31H5c5pNQBS6AeKKKZQDgsSSp6jPcdwfeo2GZjxQsgaLLrwACMFW/wAKs2o2r+/jdYHyrBR09CCaSOO4ZttuVAmBwryfe79en4VNZyFIy0kyYK4aPO78vShvQaM+5hO4Qs25eoAOQP8A69UpMRs0bHp3K4ro2RPL3zqSmCCoGcds57fjWNfQiIEnHAGWUZOKhDsVluCkZjiwp91z+VT27PFcCWSNZSw6HlT7Gqhi3yK2Aqrge/tmrPEaAxksQfmQ54NNtit3LkMgabCIODjymGT9KcwCsY5ohEQflUkkZrOR8blAYyPgAyAkir6FwqjIkXkYdM4/+tT8wGuqtGw8ks45YjHKnr+FMiuWihRI8lVHCscnP9KllUIdz264JwjlWXt61Arfui0nmFiDxkfgeaVwJUBRwV+WQ/MiM/GamkQMFd5BFhgpjzuGMcn61QGyaTKB45BjChv1z2qzbn7wmLFnB3Ovr68+tFwJAfLXynuCYn9B1x7U1JJI4fNYGSPfxhSVJHb8qRlaQ7XUnoAGTHX19KklkZBHEUMKtkNtkJBI43e1MTHmaGWN5VZ0fjKkdOfvCpJJEnAEqpMY2y23K+Z7D/Gq0krIQxgXeq4wrZyPX/8AXTpJ4WYeU3ksBk+Yp+X/AIFSuVceggeULaTSxcHCMNwB9M9/rVpZfOieUboxt8t0bJUZ7g1XgRzGrliCrDKLzkkcEYqCSU28ySh0aTHyEggEHr170x3Lc00i24jeVZCM9CG49QOxoMcQEwE6LK+0s23cTz2PUe+OaiDsqvLEGAH3sAKVJ6Dn+lErrLhtquJCuCo+dfxPf9KG30E2SRurQvHcybl3bggPvnPuamlZg4mthB5Z/wBUWXaGP4/ljNMWQGPzBG6YA6oMk96hD7MxSsWg2ll9Y8nII9s9RTu7WBaFmFpI2PlofNYYxuxt9wB3GP1pisJmEcwVSOAQ2zBJ+8R6VCI/LwEkcgHcCoxz6g0lurzKyqqPIVBHy7lIGeD707Bcv+cZ5/KkkAb+F3G0kj0Hrj86XznYSMdsxPXdnseAT61C8cykB03B0BGD83HOfXjpzSwuGbzWnCt1YN0x2OB1JFCv1Bk8LJexM2/96PmIIIwPUkenbNT3CK7SNMCreUGj2oAWI4wR+pPWoma4CMsci7SNrbflMuBkj8QKjONsU5LGIj5Hz2HBPqOad9RXHSR+QrCUsy4+Z427kZUt7+wopiMs8ZjeQom7OQuMfU+nNFO6E0SXP7m5j2BQ4XAaJjnkc/XNNs5CylESRJ1J4LAZHpj2qq+LWSRgNhZfmwD+GPanI8ShwyHzAQWeNj931NT6DNGKcIwYvJGW5d2XOSDwAP8AGlkgJgeSVWO8+ZhB8vPcD+dPSWMffSNnkyMnhiOxA9evNCtLCEHlurBtw5+VlPX8aXqWSKkN2FSERiTHIc4WQjt7Hr9abbO13IFnBLj7nzElivb8O1XBapfPM6usDrGXlhUgqAOhXHf69Kr3KsbePdIoLALE4I+cDuR2PvQBLcxSRDzFXE0fzySdOOm7b+hqxCm7bcRRxxBTjDsGVSR90+zckGoo7qRbY2V3OwkQ4Uyt8gXqy57E+3WozIjTo8AtxHn505xj+6T2OOQaALF4IBbPLFCTapjevV4SegPY59RgGqZVEskZLxJoY2UqHBVhk8gjuM9fTireoRpaXtu0ULwrgoqOS25uPlf29D+VJIUdvPgjRoX3fuT87xjoc+p9M9qBjCGt5JoPMuEumBUgMBvz6n0FW8wSWwDRNM4VWaRT0TpvwO/GOKp6aZorYqh3w7vNQpw6t2PTj+RqaF47iO3ktkkjuNxWXGOT7Drz3FPmJSCKITQqzOwYEqjMSUlX+6fRvQ/nSM7WSTWowjbwzDHKHsx/UEdOlTwqcXEMcmyRB86HkcdSo9PanT3CtZW8M5DQIWPmAEshx8ynH3h/KquDRTubmSbeiwpFMh+4oyFGOSP8KsxW3lxz/ZoTH8od1PPkjA+YHv8A4GlW2t5kgktBOsSghnGcKw6HPfjqarETCQSxBDNHhmXfhGBPHHccdKYbDW2vGsc6BEQM2P4W7jg/nVpH3Is8pVo+MzAbgn+I/lWbK0P2cS3D7JGcsSx27D6Ad1q3azMBG0ZSa3XAmiU43jsQPfpQSOMcj3kUgRHz8pUHHngjOSPQio4IbWyeQW8ZbzGDxZbd5Ldww/iHb9avW/MrCJC9rIxWOST5TGep6dMGqkIV7mV5FBG8qwU/Ke24n8M+9ADWVYLRlEglt5GyzAkbJc8EDrntxxTC5V2ZkCqpyw253kfwle/1qSSOO2llkOWk4KOuMZ/3euDnFQxhlidZDsuYySI1zkZx0zzt9KB3FuWHnxyuFhduVjjUYHHYdx7VWt3jmPnQoFcklUOSxHp7rn8qvvGPPYOSyjG5o/vpxzt989aqXAcWbyJ5rB2xGV6AD265PHtRygzKeSa2mJYO0TEiSInaCe6npxTLmdAM4XcPuKVxgf8A6qjntp5ZSkjB2ByzZLEn0/xql5c9rPvboOSe2KOUm5q2srKCjuwtJsNJJEMkccA57iqN4jhZWcsYshFXGSSBxg/manslYW8zKCLdiSyFuScdceg/WtW1PkRwy6hDN9kX5baRfuRljkjJ7HuO1OK7kyXUzdPjjW0MgcSQsMgEchgOjEeueh61oG2UQlJHMlswEsb7cqpxgq3cDGeOxqxcEaXfOI4wDzHL5GHty3VW9DkcH68VTg/0m3uHEEcEITLR9BI2eiE9SOuPQU5JBFkJCeWGAKrGwbEZwy+xB+9Q3nTQeWj+fatwkRHKDPK47ZPoc1t3Vg1vbiaaTE2B5JBJB4+7n1HbPWsy5jjRik6nZGpEpjYbVc8g7h/nPFZa3KsVRL5jGaWWRZEJUnljntu7kdiaWXzCm5j+7L5R2+YYHVfcfyp80kt2f37vtiQOd6YcjHGAOgP4+tNd48GSIEQOBsRvvDBySf5e9DKRVuYkDtLA0ciNg+Uy4K89Bnv/AEqKRSru7WzckPwMcE52kVdKxIxKxSGBzuZSSXXIyOOgA6g1UinltZCWjimX5iU37d4xn9DzU2DqTKgSMS7xGHO3DIcsM8qewIqO5tgQysq+Yw3x5OAV789Kmt5J5PmSZZLaRgZA5+fjqT6jt60+8gC/6homONygZII+p6fSpsNGLJZqyjJaMkEL8/f3zVXMkRK7juQbWKjPH1rUuoyuNib0k4+Y9/TNU1RjIqOkaqD97JyCfWkhSGJHiBiJ48khxG2VY/TNSx7VAIMmG4+ds4PfkVKbZbktG7JG38M2dygDqp+tZ6mOMurIFQjaB3U/0qtloL1LltIvmyebuiReVyCyt2Io2xsg8wqrc5cqeR71LFiRMfvNoPyndwR6YqKONkLRrIwUHdw/K+xFSA4WTZErGJ8rtyCRn/aFRmaQPtjkDI2Fwx+b6g98UkksgiKGQlB/Aew7/SpITbvGVRjlVByVzQA6OZzGy72IBycM35kHsaSymlaSSAvuYlvvMPlyOmKqyxuY8E7iowASRx6H+lFvNJDJmWN1KrtwxyDznGarZCLTyiNlkBJmXkgpjOeoP0qlLdTyzkQNhH4HmPuKk+/61LNd/aXLyLGjE/eIwB65qORA8QZwy8/OUxg/1pIGEd80MkcM5idl6uo+Yc9z3qyZmMbxoP3JJC7iBtPqapQxtFhnjjfjh1OQtSIFQNI3mFCeSF7+9WwRb3bkZoISycbwSTsPtToZGK/u4iZj8rjd169QaarxnO4zADhGC53fWlN024I7sMnDYAPToc+vtSAVIy/KM4iUEhSSdmOx96twSRqsarbt52GYA8BcjPBPUd+aoh3Kt5bpnPzDaFY/X1pzTM5BXzioIBJPQ96adth3uT/8smBX5wcqMdPYetMjkMmDEyoCfusMYI54xTHkMruZDv2HnGcntkVLGqb2MCiWNl2yK2Bt9h70hEsNxNcHBuFiJyuV4De2PU1C8MoWMmPbGO/U89cH2xQrEBlMjeWOhPBb6YHb3qdH84lnd1mK5d9uePp9aewyQs0mw2wD5GXwfvH2/ChWXYJGUhZMgsRwG6L7/Wq6MizBVlEJA445Uj1HvU0c8PmmS7yC6jcGBIYg54Hv6U13AfCjxIvnjKAD5ecgf4HqM0VGX+Znjk+Q/MoTPy59RRVgbhtIp0RVLGOM7WiLbnQdQFUDJGOvarE7W81xAURTldrKsezZ/tDJwTj86miiXypnVJftq8Yj+Qxc8MB1bNLFd7YGcwISOZWA4H+0w7c0ovoymitJFEZvsz/ZGtFYHzYTgPxwVzxx3FTrH5irF56NZpJtjuEO3y+fukH/AD6VHGZNOh2Tu5EuGyIg+3IBDg9CMdqnmtZRcNFI6KZEB3eWUjlHUnA7989qGAtvbyg/aIrdVmhcH7RHnJbsR7H1xzTEEd48s0qbH3HzYthKSgZLN7ZPUD61HAsts8d1bvHNZlsKkz5AA6g9m78VDMUtnjPmb7d2MkDISAATjn+79D2qBlnUFtfsvm2zmS03BXjbDPGOv0z6H0pLdXtVVcK+m3CcbBkqM8MR1yDU4USSC6eOG3ljHzwxrkFSPvD+8uevpmo2jtpIDIsjeW4xtDZMUnfB7+44zTQE8NsTI8kuCZFKqshOJB6hvyx+VNRftNuRCginLBDDn/WEnggdyMZqs0EohltZB9oS3O5GHJk4zjcD2HOO9LZuJ4EgKKEbcsUyn5mGcbW9Dnoe1SMsW0REhgMipdW7ElwNrMvUnJ44Paq9qw/eyKUhmddrrziRT3B9T19jVi7SaKSCK72mdBjB5Ljpnd69uOKdf2sTwieJsxykktjiIgZIOeh/nTEVWVoHAScKrAMZAcurEnr+XPpWjIIRbg3H7sS8ScfICBwcdQf5g1XtHM1i0NzMVeL502r1XuQe5xzj8aQJJHHDdxxO6ABpCXD7xnC/4YpoBbeaW0s54CoaI/M8anaIwRkSL/nGDUYaI4jk/fJkMhiUkpnoSO4FTXcrpEElWKdgC8fl5+VM5x/u5zx60un2byxpJaS+ZO+WVUGXLd0I7DFO9gZI1ol1M8d2sEshBAmiUY6cMpP+etZjQpbu0ib0KKA4U/NnuMdMdw1akZCROxJaCc/OgPzA+3fj27U1hA1q5nkzIikBo/lBP91z1A9KpO6IaISEWVRb7n3YB3jCj+6c9M9qE2LL5WSbRG+Y4y8IPBHv9KW+sPIsYWF020qPNjKEiIEjDfQmlWOdtSt47VvJmmOIpJUwknYtk9Qex7UARiEx3Nul7uFqULRux3Dn+Iexx9QaNUQNaR3VmrTGxb5/MySVP8wvf68VoNbtbecs25pfN8uSHOSrA5BQ+/XPfmqaGZYltYmWUvzCYzjPHKE+npSuUkLcK1/awzxL9nAO5gD/AKoNxkn0z3pVsLrMT29uZJGUqqZGRx98Y6ccgn60yW4eeWQNmGNAyhIxkoD97PbZ61M9z9mmlFnczpHMphklCj94uBhQvVR2zVKQpK5kaXFaGaaO44ZIywdwzJvHVmK9AP5mpdQ0lZrEypKk38LSEbYwfTNaWqwwx3y/Z4LdUVRE8PmErI+Mkkd8np9OaraiHv7g2Nm+Ipkj+aQkBODz6ZA+XFapoysznLS2cOkKSKbiZgibzgLjqD/jV2dVmV7aVlHlgyQiQElXJ5iHc59far8ellLSQ53XUThChIG/5sKqLgljnr+tReVJLb3ErlMMcTu6Y8l3Pb/a4IArN2H0EtVs4spKJI4kYj7OnzJGmMBgQc/e5x6c1CImbz2Zg88bbGGCQ5IwGX9DmpjqC3kUc1vAYUs4xFIJOTKc+39c+lFlIs8e5HIuYIwy7lALKR9wAdcDv75pPYaGRO37yMyTPcIzEK5GCuMZAPfv602O1ZomlkkjAjyiqQQHbP3PxzyT3qxIkc0BZOUV1jcSnJiJPBHfd156UWl1D9ouYrhTMFjOyRW2qwHRl7AnvmpKKrwG2nEgXaoG0OzHKEDlSP0Pt0qvcTQPJJI0MASSMr5THp2yB3I6irswe8lS6vHDeYnnuq871HG4jr7fTtQRBLeSqY4zbxKCxYncR2x34PT2osBnWsLLIDAWBddwjZssyjkD6nsTUXPlyBpD97dtcZViOoB78H860NmzEDPJK4P7vHXdnpj+99euKrzxBoomDGaNAQscjDKYOcMPrzx9KAMiPyncCJVUAHAdjwSfve5HrV9sRjyXlfYPutjg56Y/rTjE12GacvDNnbzHhZVA4GP7w74oW2eHyUgRpZFBZhEo2tGBljn+9jrSaC9iuYg5ccp823nlQf8AZNVry22HcG+7ncVJP6VqQNE1uyox+zs/3XYBl7jJqK4ic7miibGcED76jPGR3x6isrO5e6MlfKiibaIwFH3XxnH9arSq8qgkr5R7IoGfrV8whSPtCRs6/M244JqUxwxRnMSbGAILA8nuDzTWjJa0KVqm1HTzG3rk4xkdOtTS+VLa7goMnTewPzD1p8iKfnTKsnysAufxz6UkamWQNF8qpyp28E/3T/8AXotqIqos42t8pkHOScgimeeJopGEZVhyxCggVoSw5wuAnJ+UA7gfftVZ4Ek3SFCGBw3JBPuRSYEKyBosgKJNoLFuN4qNkUgBQoTorKRkj0I9alwFZgQEfqC/QA9aaY/IR8jDjD7QSQaYEUYbJG9Ihsw21PvDP6mpA7GZHBxIq/eGRk9hg8ZqZFW4QOjojHko0hG2oGyu7IDkn5SOQD70CHT+Y8jRb5I5WX51I4Pr0oYgbSgjXPB+YgHioVlCAo0QxnqBjH0olkeRQXYFePu469iQKYEhaORlDp5Sl8nbkBD6+wpImCzfvGQnOcEcEd856ihZWdwHePgZyN3zfh60XMakxsuVBORnkkf0oAklAiYTxKfKPYAf17VIk4ikJZCwcdFOdw/+tVVGZRkiaNgOwB3VYRoGgJuFPPQ9MeuMUASSAqokEXlgcBuePwpjhYzGYnUxknCAAYPofWq1xcP9zfIIs5+Zfu+4J96mtn2jLorITgFiCVNC0AtwG2mwkYKJy3zkkIff1BqJy3mttyFDZLA4z7UyLBmDKcHGCrdCMVE5ZW2su6Ej5R/EPrQ2BaEx2kTqhbOY2ZcHPbp0FPLRPGRKJUkUbTt5qsszSQ7tgcLw2PvCnzSgrGp+Yr3Oc/X60XYF8yxz+W0YjWXGGCLtQ46H9O9FZuDsBUhXz+DD3oq0wO9khJmiEzm2nAylxK+Qgx0yOc1YWGZikroiz5IEqpvEw6cY7j0PXrSRRNNazMqmNI/luLdlyVk7MO4BqH948hfz2yFCxyI2wNjkA47j1oNBlpc+U7NIvmWzAja7kFWP909s44q2xU2aNaymS1HIMqAmFs8gjsPpVaO8ARppbQzzxKfOHI+QdSB39eORSSN8guoVc20jIUZ1AUnd8wdR29u9NK4EcsBBSO4t5I4C26aOMffA6OoPT6ioIgtv5/lObpehXYMBT/H/AI+laTAXN+oike0eNSwhlPG7rhR3TvVd5nmM1zGUtrgN5iQMcKykcnJ/hPpUtMCxZJFPbRvYSXAvYs78jdg/3go7dj7UslzFcxgOkf2rHl3NvH0lA5Ei+hHpUQYQj7bbLcQyKdjhAC0P+9j9D0I4psm26WSKZVa7yStwnyh1b9B0OPqab2AfAZLWHyZRHCm5WE4GHhY8DP8Asn07VHJbCUzxxxNbogBIU5bn/loB6eo/Gp7cKqyRPGJZ4vl2Sjl0Gcbfb1znnmluVMCxTISjRygDdyYvRXH93+lQOxHbSrJbubucmeJSIp+SGweEPp/Wo7eSdYrlMqBNGS8ckfGwnjn+9joafHHHd3U235N64QLgguD6/wAs09iyWGwxGZ4kA3s20ohPDH/YHIIPIouFhqwmCGGGG48wkl4TjB3j+E/7X6darxTytAJ1UvKColhf7uT1P0PHPtVi3tz9pcW5WRtv3O2AM5X6HPNOtH+02kUtvGsc8YdJEJz5p64x2z27dqBDZU8kwzQXW5yDIA6gZI4Ye39am0+8FnNK5JjhkjKy+Vy0JHRs9F/qDVS2CCdop13q+Q7YB2sejAe3QilskktBOUVh5hKoB9yT1Vh/ED1B7Yqr3AntFKwG5khXMmQhcHY6eo9OKHh/diTd5qSsQFD8vGoHb19PpUcEkZ2W7XXzBiEUZKxtydv0J6U5oyszOrLGXfbnoVYcsR6DtRsBatVa0eA6Wxlaf92Q/wAysSeN2fukdKiSRZzcR3VuZJEBCoJD/o5zlmA/u7u/YmrNt5EMTTRuR5jeVLAuAcdivrzzmoL+2jnnlXcQkwytyWYEt/cc9845FO90FgSUSPDLI5mWNUVpDwE9Bx27c1G0UdysxeRo0c4m8rG1CT8hX0BIwR2q4t5d3lmttew7rq3UKYlQIWTH3z/eGO9UrO0a7ZIodqy8lYwM71wfvH9CaVmMlnlE1rFbwiUSRqWmxjIz3yOq4x17024mWCG0tLcC4ikbzC7kBzz91nHTp+Aq7Y2S3WI7W6hFwI2eN2U/Ie8We5bPesTxLBHFa2k1ihhlREjaCQj5pMfMc9s/0prciSJbm8uYyZkjgie2co2VAYE8555f6+wq7cBrPTZJrb99YXcggknCjdG/3uOepHas03E2rwSXNyVe/WWJBDjBk2jC4HfkZyOvQ1eQwG6uzGzxWF2jfu1G3Y5AJAXkE9QB71bIRajiMEumLdM1lLFlo1SMmQbjlZFI/izwR6VTNvBGj213CrXP2kCWNZCoMXUhVx1Zj948g5qazQsIrDUdyQQMZJPLx5rIFySrE8kf0qu8D36GRJZXv0Ln96eZIxjq3Y7ep/Klux2GXu2TTRe3TgsXaEBVyxUHHOPlBUevJqtMf3FusdrFE7SsInUnyySBwCecDv29K0pI3mmi1CG2hawtlUTW4+VYiCQAV6seO/t61UI+x3FzJdLmyVTFH12xq3OD3UHPGOc1bRF7MhtITOrNGzLLb/vNspAXjlk9Tk4wadLJDebrm2RIIWJJgySyjqQCeuDk44xVfdIksE0LpG5ykgXJIYYwSDwQcjFaEszeQotNiQzErLblsuZSMM2OoBHfpUmiQy8df7OSeK8TyLvcxQH5o3BIBbuB16cdKowRMVdZvknRlJcn7pwcBvc498ULBDdXHkL+4Y58s8EfKOFJ75GMDtirFqY4J/8ASY8XETGORyciQHJPPqAD9c0AVPJYzbbcOZsbllbgsex/2TzzzUVwCVikEhFyGK7Spbd7g+uen51YG2e6ZLZEiCNuhDkjavUAg9c5z9MUsrPc7poVSV14ZmJHlueAQM8nqc9qTQISSAW620imd5kYsQwD7fxB4J9O1UFKxK8pZQBIBLEhIGT3VvxPy9MVoQ21226OZxtkwqtjhn9Ofrye1VkRIgkZUPcSDaqxjfuBODj/AGgRwe9AbmfNHJvJWMJvYNkJw3/6+OKnYyxPE16ro6rtVchTz6e1WVgMpW3kliSAEsGfjyyc8N6HilmZtyLLJksv7wZ8xVxkDPp9KhrqO/Qz72VpUVHVgzD5Wdeo/u5qCWAk7DkxMwVXzuVOOhPqM9auXDLKcTkM64ywyWz2Pp+VV5IWjlBaaRtuVEm3afqf5UrXBsbYmWNGYRkQ7CrhcAr789qoxo7tvQKYmydx+YL6ZA6E1cdYpmdS8nmLkkZwOB+tQsJGtt9tJGWLFZYyudnYMPX0x2oitSWLJOHO+VApHBOOVI71FIjBnLbm4ycHJ+nP50yVpLtlBRWkUhWUDBOO596dOiiQC48zOdpyN31we9S46lKVw8hZ14AZiOSTyp9PxqtLFLExIAOD8yk/pV4bDESg3PH8oBO3K+mPWrKIsiB0lAkRcjeMkj6YpNBe5ll3IJ/eKf7uAQKiJzGduDJnJAP9KvlVMRKyHceVIXv9KqsJC/muqhlxkjjn1oewWKzgSAN5ZC7cj0Jp0KhVPLfMMDnAzUskiOM7Wjzzgk4J9famspYiIhMgZ68nnpTJIQzIHLRpk4zu6hvamkx7xswQ3fninp8khZhIo5DIRyDRKrsMpJGivxgDH50wGupQkOp4OQ4yePapHkLBgVUIw3Egnj0JpJIpIGCCWNpF4Gwg5NLCZA5jfO/njHI9vekBFvAQI+JGz8u7OMfWkjeIZZ4XKkHCjkA+tS/umfHzIo/u8YP41E8Xysdx39cjPPt+VMBRIWysi53cjHIB9KWO4KM4dAyHhkJxkjuPemfMY/LaQRoRwcd6SUbG2uuD3YHhqQE7zRspeMlpfUnAAojbJV1RhE3AY8jPpVVdqgeWFKjg1JDJLC+ITtRiSQRlR+H9aYFuN45Pv5AxkHqN1FQRSOifu9j+Z1wOlFWK56k1u8f2SYTIGZThXYIzqOqMw4I4xniknshNYF/JeK0UgSw7vmV+pOfTHT1qC3to7WIMxMmVDIzfMQO6EdCDmnXDyQXdt5AV3jiyESM/vBnOwkcHqRupqzNdSeSXzktVeSIpa8rcxvlo0PAU92X8MioJAGudo3RW5/eGWNfMA7FQMcg98896lAthbvLaJKhJDksgcxuf4T3Ve2e9V7u4ktyqxR7ULhZLXdlQ3Zge3sadhEsTsJYxPBAILR9y4+ZlXPIUg5ZfYdP0qC+dftjm+cSRKQ0Vxb/Ko7ggeg6emTVuzDrbiOCVZrQOTEjnDJJ6EdQevPQ1SjaATTGaAiFV/eoQCImJx8n+cUDHZW0uo5VDMi/6+FjguvqDznrT7y2mYKIVRbWTmF4yF3DPQr9e3rS20CQSQowBSIiWMBc+ehOMhj0A9DT4RD5jtBeT/wBmSSEy22eY2PVgv+c0mgIWuPLjjlD7XTISbO1o2OQVZepHYH061Va6WGVGdS4IKtERkgkcEe3pWjdQ3EhhluLgfxSo+ARgAD5/Q7QKJZXuBHBMPNmJU2b8AgMcspPb29KnQepAYd1sg3JvYCR5Qfvc5DfWrUUjgGZpolulUK8rchwejY9DnBHSqWnxz294+IUBVy/lu33Dn/IxTLt3MSTpl41JUwnqg7qR/XpS3C5LHCTEHjbZNBLhYBklDjnHqpPNOe7LAzKixC4/dyhDgLnqCP7p6j3psuYhDLDKySBPMglxjPPMbfTH61Ks/wC5nMQUThdkkYAClSRtHPbvntilYQxF8qwayu8IYy3kSbCWfdyqk+lAka4tYhJ+5KpsEWCdsecnB9zzjtUdzDI4YXkkxjY7Fm252E9F/E/lTbx5IIizIHuIgVlbGHUdiO2RVICR3il2OEiaeIYZ14WX+6cetSvcQm6t5JNjQuvlhSvMeeob1x2pqKyyRXNsCZV+coqDldvX2XH+earfatjSSArKZosSKUzsPZgR2HHNK4F8W7RuwhDG5VQwzwsqZ5x7ioY7oWshMjhrfI6nPXo/++vPtU6RK9hFexSO67fmCqQsUvQKOfu5yal0p5YNSimtY8Xe8qUJGAxHOAem4cc8U0x20KZUXN0uL0+aF3RyDkMD/DjtxyfapHWGFmuUbyLhZ1dSrEiPsR6bcjOacJYoJJYQxW0vHWVVGDJHt4yuOByf5ip5/NgaPfGBctg/N/H7HPbH60riEhnaN2uUjwgOJoe8igZJP58GnTGN3trlEguLSQgyQkE7UXjaxPX19aJdkriaAsgyvnKSN3mHOHwRwvY9s1Xa4uNNt7i3GY5yxa4gHV8n+EcgYP6UD8ird6e9teF7FZjCipLHJ5fywljwD/snt3NPsIGltpIGkSF7eVpDDIQpVs5Lg9iPStg5isR5MsdzBeKf3aNuwoP3Seg9vpxWGIzLdIUkaRrZjKplTA25A6deemOelWmRbsW9QkXULITLbssf+pkCg5jl5KtzzkDJwOCOKdpdu1/q0aTSubhMIDDgMwAO1kB4HuPU0uoXizSwXxuDGqIYnCoA5I+7kAdBnr1x9Kb5cKm3Nu5e9tivlOCIzgclRjgjqQRzzQhN6D4RdrrF1qt5aCdo7jMkEjY8yQLlXKj7xUc7cY/Km6nqkstpdXKWiTWd1M5jb7yJNgZTJHK9Gwe/FJDexpcLcja91vMqS5B+XHzKydNxyefaolwi3BMKfZpgAqtIf9HkY/K+O/I59MmmpCcNRLODzSI/IxaBPJj81gJd5xnPGBn5gM9uKq3gWKdZoTI0qOySMFADov3SvOQeCCOnFTA4sJGklkN0ibiRHuSVCxyxY4xjnHUmr9xeTW9nbW81iiXbW4EUqkOstuw4QIBw38RbOc02GxmC2gSKGZGjmgdRK7KhZUyc4XPVgOxo1CUKHZQrLMBl1IZSjcgfXr79azo5msbiWOD7S1ocGJxtHlzYxkjoeCfzrSkuLe2kVrO3RY2ULiIsVQcAsp/iz347nFAGdPcxJbxxzeZ+7JaLZ13ZxvY9cLjgelXLCdYJMyQGUbstIww6uRwxB459+1VGt3W4trkFJUkJKj0G7qR1wQM464rWlaS8jaK0AbKGRpnwrNGh5jPYnoAOuDmqS0Ie9jNLbFUyyO0USASK4yXBzkYPYnr9KYPlgLkHIKmOQDjB+Urge3QdhVpTYTTRxTQyiNVfyt4LFWz91h25yM96hMBVo3j8tZAQpjDbWWTHf0z61Ny0rDJVE1u0UqJJKPvRrKD1+6y468dR2FRrbsbbz5Wh2hfKHOW+X+I/XI571aQRpp8cESCUvIGi2ACTHQ5xyD6e1OuZ0t5n85YJVfh1jUgSL/dOBwe9DG9GZ1uTHGJUbYEH0YHruGfQ00l57kQ+eHBUlnUgBh1+YnitiZXaFJ7qRpI1CtHvx8y4wFbHcgcemKqy2kcvlx7UzO4CBTgbj0JPT04qbBdGNtikZ2H7txhwRgKV7YA5zmo7+1UufPKxyAYkIBUKT6jvVq+SVnkSFA00Mnzvs5wOM/TtUti0sTM00CvbuPmmPJUkdNx6YNNKwjOWEx28Rh8t/lZXJBHl/wB3Ppnt+tNeErFgRgqGxIp6gn3qe+tH8wQAFTtG9c58wZ9emKQSSoArIkcMa5wfboCPrQ0K9iG5jV4o41dThd+5TnFWN6wRQEyqyuQShAG1gOhxziiEhpmWNU6DIDZD1HJbpBKuyHGWzIWOVPsD2qLlD5ZA375SPMBxtQ/KRVaO3LMrosbhydwHVfrSh4S7oMAKeJFOR9Pf61N5TBPMV1kLcEJ1H1qWNMp+WJVkWRQ4Xhs8EelRYXbhyuBwWXr7VqEOiAKQ3Hykj+tU7pIRF8nBYZdAQefaktgaKtt5kDHcEYvlTu/i/GkkQlWZo1YA4wpxipxGzQqiZbaM43dc1AzbF2Lnex5Eg6fjTERuFBUE7lxwxXFLn5A8ZUP0bac7galDDyQu/IPBAwQKj+zKrLKmdo4YkY/SgCJ3LFlVwrf7IFEkY2RFQVkI+Ylhj8BTo3VP3fyhh6rnNNcKZ8hwGHUEcCgREiPLvMj4IGW4poVWjGTtK8ghetOmh2sGYbx0yvekkkLFEZflXoKAGLEWG7aGPUmkkG8AchMchegNSYZcmJjtx0NJISOFJI9QKBakKP5AG4M6jsx60U75ZQoQlWxg7ulFF2Fj2FIVWwKW7S3NuhwdwAaM9c47EfjmlmtUEMLwMTaSvtSZSX2HHOB7ddp71Xtrq4trlmgmVoSQl0siZxg+noB0Papple1ebyJQg2nDKNySofQeoH41drGtyO3VAjtbH7Q67iJDGU81M87s8MPYcjNUp/JikF4jPbbjhldAwiB6+5q06C4thcqxEEG1vsRJA3N1P5d6hML312x08SyzhNzRBs7lHXLHsO1aJXJbsTfZ7UXZns4YzIIgGhkYncD3z/Ep9eo4qsZUtY45LKQmQnIRh/y0B5Vgf5d8VBKId6wedcLEp/0eZwVIOOYmJ4GOoFLa3CXfmTXEqwvDhfLK8Sjnnd/C3cD2oatuJSuW3nlXzCYkggVlkljj5dSe6DnGc9OlSoWt41jhjjM5+7c4BBjb15w307GoE3rcIwuoZZP4WVcGQE5w47mqsMm65nIUeXz2z5bE849Pr+FKyK5i1YpBNAVglLXCy7fLlIOG/vA9gemTVdFfDwbFMAG/azbdpzgqD2Y44pLh4pJUa04Yg+bEgyHGRgD2Pp2NPRFl3Q75H3ktCsjDcp7Lz3xxn1FS4gmPcRPBNPEjq1r8k6kjc0ROAw7lgTjIp9m80AvLhZ/LnMexvNG5ZEbhc+uR1FVJClzCruzfb48kgHmXHB47MMYIPWrHnR3NtmO32mBWSS33ZBQnJwPQHn2pSQ4tDZY42MkhidY0wksZ5aFwBl/QIe9QzSG4kKTZSSE7ZDkMrKBxj1/wNSWskkTtJEyAMgZJC5xjsjDvnkVWhXz7pxGVilXhU/5557Y7dcD60uUC0JWjtHedd8YVY5EHQNn5Wz3Hv+FOlZpFLSwAJsYrJnBKZwef4jzj8qbFGgmY4byH+Zo93zKB95VPTORwPpUEdxNbWazRZkWE7ooz1RDwxUdMevvSsBZgHlsI0ml86PiP+8yY5jHuM5GaltpRhYnRcSMMN5Z555/E8ZX6YpkxWQ/aLbzDI5Eil+HQdCSfTPHrTBLu/eXXm72fzJUJGwtyPNHqOB0xgUASi52xyrboVd12tADnYTxz7Ht6GrEUo8qSazTeFCpJlfmcYwQR/U9+e9Z7THYGkLxzhf3krHO4k/eB7g9/zq2kyLpiSxxFL8DkBvkdOcj+WPek9WBHcQRtE0bXEsVoZDNAxAyzY9P881YllPkwGf8A1qsDLOSMpgYAx3U8H3NRQgmNFjLPDMcBmbedx+8fbnt602dpI5t3S5JxJEBt2hTlsg9ScA+lMCa2bzr6SCU7otu5GRtpkT+6SemTzg1avWYpa2Txwl0dyJl6Tg8E5PXH/wBeoZ0MoeFPLFtMRMspXaeMfcX8+KLiUmSWMhxdbA8G0ZMrE/fBJ+UY6ilcCtosh0mC/SF5Lm2uEIkTlSnuMdxgH3Aqe0spLoPcT3ipdOR9mYjd5/y9sdMjHHai8STyfs6xbbvhmVcL5jDj5T0KnPPcYNJZmDTGT7PIs1vdAK8RTHluOuT6fTtVN3EkXZ7UC0jv4op5LkNsuomIXyk4VQT+Qz3zUFlZLeX91b5MTgkQqZMeS+SzIAQSRxjjrVq7uIjqM1zOzeVOCu1WDY4wGI6bSfy61DZWl2jTDy5V1BYjPFJGwG5FPzHdnoBkZHepuxvVFGyFs+pSx6hC0FtN/q41bEKSOcAsxGfL4z65GKNQgdb4QPNbzXEOSkjKUSRAO+ccnHf1FWbmWC7tEidfMtEG2MRghi3VVx/snms9rqSe7SfUA9x5oBSZsOSwGCWJ6qO/riqXclqzGWrT+bDdRM7rHt8uBhkrwRnHsMkD2zVnWLyO3nENk0kmno4nWYZzbO4++B0yRkBeg5NQpM8i3FxbRyAxsFZVPyiIjPJ6gnPHtxVW7cQxW0Mlx5tvuM1zHtIVZCAAx/vAA/pWqsQyJmgnhSwkQpGZTsRjgl+oIP48+uBUkMrJDCsjA7AqrIAVKFWyFY9vQfWqdgoa9bzleO3A8qOaVfmZhyCB+mas31rs1D7PnZFdKCFlfKrjrn3I6Gr5TPm11EhKRhrh0y7KSrOxG1zncQP4s5wPoasrb3L2dq1tCvmSt++CncSy9OB0G3j8KryXV0bWO0hSDZFuePIG7YSMjPfp/OnWski+WwkMTE4hfPA5yzsPbnBHbNQzRFy52yzmUR20FuwAaGIkbQPunnk7jzVa4i850iumIn2eUkw+6CD94eoHIqSQLaTXHmgyFCdzMuDhj2z0BHOe2amt44biO5tYHYxqjMGOMq2fkwTyRxjjvSSGQwRy29wZLWSB7i3P77yQR8o4yMj5uuecUhWPzAXSVtkJMa7wN4J5Bx0yefXiopppI5WVyFljjKnIJZucbfcjnr0NT21mZmjbEKrKGcFTxE4HCkerY7dM0xplW0VY5JoyfNWaPd50ROQOrcHqOMZqSWZhKJLgRGFm6RnHUdF9gO44yaRF+0OkMkZVFj2FXlKrEe8jY7dttPidMW8tvbJb3SE42ncGAGNwDdO5x0p9CblS7jmkRvIm+WLKoCCSvcqD9O9Vrb7E0qi9imUZBeGFsZwOnsD19a1bdI/tCp5rCObp/sd+fX14qK/K4DhNpjJj2BeVHr9T71LQzOuGNxa/fkBkYiAu+cqP4W+g6VUs/tE7bptqxBsDAyT747nFbZhEdjcyCTy5wRiMqG3xn0PTOe3tVUX0cVtDaPGIV3q4nVAXJ7YJ7U1ETZHbGWJZY45G+6QjeWPmXr161HcO3lfLlX2htrDnB7En+lWLxJVuED3DeSGzIRn5M/xj14qcQnUr6ee7uJJ44kwJkX74HCMc/dHFPlQkzG+yEkyW5WMYxwOAR6etPjgkW4cySDfyrHOCeK1seYI1DBGCgoVJCu3cfWqN/G88W4R/vATkDnce/NS0rFIookjxkBXJf7uDwKQWUTqisSkoP8VXbBU8vasn8BOz0PvSRrJIo81RlRtVjzz1xWfKXuZxhCyFm4ZTzkYxT5Y4xL57tliO3IFX5dtxt3KQ4GG/2h/jWc8EcZPl7wjHkP1FSJqxBLGDE0kOAoOfc1IkbKm5VGGAY5PWrKEKZGb5BtAyBw4+lMdHAGx12rgqc9M0CKk2XVjJGuR02nB/Kq/ljbvHHqD6VeeNZJQQCsv8OB1qG4YK4VWywOAabXcRWMMjNhW/d9cFc0yKLzJjt4z68VbkjVyCz7JAfu5+9VaaBt+9XZT7dKQEk0Twn/Vj5uCD0/A1WZ1XiJGVW67ucVMQflWR3JPPXoaEbcw8wblY4445psSIsAOu7gHt60VKqb2dciNl+7uoosxnqdupErpMkS30iFHErDY4/hYeh4OfWoH08Sqk5R4ooypcBizkk8uo9PpVuOFbS1m+1xwNuUlEXkxt/CyjuD6dRVhpB9miiuy9vfAB0fBCtnqeOhwM+9I3M6EmUGQADYu0SRtw65xkj0z2FWdLaCOUC6U2sUylwzjaFf8AhYPjoc8ioC1wb1JbB18y3PJcZyvcAY9Oven3TwiBoYUlELDc8Mi5VDzh4znlTnGD0rWLM5K+hU8ZO18ZbiWFhdFgkyR/cZsAK4X8OaqabF5ywW91FGYIwQbmNT8/pn1A9cZFaUfnNC8WohZLhEVo5WbORjldw9vXNRRQmCWaMBjAqgtGT84Q9HB6E+vrV8yIUbFE2/8AZ4d9jzr5YcAkMVGcc47A+vtUnkNJIbrzw9xgZeIcA4+6V6n8etXJbOX7WPs7s0NzARFOeWKggFWXt06Gsv7LNbyOttM01xs8wjbgSxZ6n1xik/IB5h81pLmBipRhI7xAkrxj5QOxOfpVXUbmOZI2uMxyqcs8QBDY/UNW1HHBqFrLdhPsr25HmtGcLbep2g5Kn+da+maPZ6tCux4zcxxh22p8jqBksucZx1bvzVpEydjijereose921WHJ8wDbvUfxbuzAdRyD2q3bSp5yzWymGaQ7ZOMeU6j/WEdwRnjp2rC8RbotedrVxmMgwvF0x7fTmtazaS4jW+JUTQk/aIEGAyjjevr15FRNDiyd5WnkSe0VVYho3RTiOU/xEDHCnjgdKc0qpi7jJiUgc4O5c8MM9yOtJbPG1rZwu4FqZD5exMmN88+/I7U6XCXk5lRmXfsniK7WBGPXocc/jWZrccuby7lhuJEheCMuroeJWGMMB69OKkvA5jgmWZPMUsCoXIye49jzx60zyWiltGicROZC1rKgGHVSTtye4I61KXnQNeqkKM4LBGOeM/MmO/Wo6gNdIYoEN0jJbFsSYIaRG7MPTqOKZp6SQzRByJnjBKKfmDgjO3247d6UgsiSoQYbhXDFjlsA56eq8/UVKwjhs51aNkwP3QUcSMy/Lu549Qe3IpgM0+aLVX+yxNCs0bEospPEZH3ce1MmRLJBLBcsrLuA2/MTGeD9BUARo9QN5GqJLEscZTHAIGAT7GrOpBZ4Ypll2Rq+1Y3AzG56rgdRx39aAJLIQ8SLCY4HG2QEY8o/wADL6n1q0PMS5f7UuZFQNKZXyGTHDH2J6VmwP5bLLtcxsp4IxvHfYOxB/KriMjyRLBJLJPgGJsZG7HIb6dvyob0ATT2gkjuYDJKr27eZGpBBYEj5XPbHrU6rEXEqSmPdOyRhsN5GOcYHUHkCoLdmW4F3CyrMHJ85sMNx+7kehwfpUdwv2m33vGFkGTJEoOX5JJYdVI7dsVIE26G6kDtC8cILE7ASsX+0M9ietWb8z7IHuI1QLGI5mTG1k4G4L24OM01ZG+zRXMDhnIVh8vyxkcbT22nr9aZcBrGOa2ALRufJlDHmPJ5BHcZ6Dp3p2GK5ubCSO2AkjhkUyQIwVv3Lc4bHJOOlE88wigSSQDyUMtqHOR5fUqvoM4wD1qnHJdrK9zahEmtseUp5bZnBI+v/wCqrkQe7nS2s444yzNJG0x2fNjJTHQqOaq2hPUbKVaI3VtLtjyoaPkFyQQSF9VOSabcSwRlTJHmIgK0MfJBx8rg+/cUuj3RjugbZSF27ZWZv9WejY9Rjrj8KmSP7NI1qkywiU5JRdxDj7gHfaePcUrWKM77LPZ2UDWQNy/nFDHgZP8AEW2/3R7kmrV7d2rIYZA7WIZ1twhw6Jnk8jnLHqe3FJAzR2vm7JPKGPKZm8vymPLLkc5PYH0PrWPdLsk2yNlgQAx4BX6dQR6VaehDRDKi71iu5N4ydjKCW/65+3rmt6SztL0y2UzuSCsMN2gw+8evr6cVl39kvlnM3mRbd6EfeX0B/DOPWjz2ge1k2uBa5Rg2CGU88c9ec/Wt4u5hJa3J9QuLtyqzoi3VsAj8YDsMqoweuR1/CmWICW0VxcKGsJJXUYj3uWUYEYPYHOeKsXd2bm9hmnuY2mVwfMXJVAAArMQOcDgnuaqzI9u8ayK6DI8zK/dyeSg9SMcms29TaK0JYJiqyxI0fmpG5zIMllOM7QejY4/wqITwWwa0t4vPVZN8ThMOfl5Q9+OMY780qHbeNcxzGO5jDCKTtIo+9uz7HB9agm3x3jT27B7gBX8t0wR/eH+99OtANWNA29vcXvkRuJJnhWSKWV9oVupDnvkdT61UW5ggnuvJgZo2TbAJJMeScAlmI6/TvxT74wf2gsaMrWgQSMScKrEA89+v61G8vlwSSBj9okBypjG1Tn72D1yOo+lCQrkb4dGEsgLD5yrDDN7YHc9cVYRJd8Nw0qS284Dsw6RgH7v4cZqH7VFBFLbrtcyMhWcjlG4Jz68ECrPmsjwhCqllPmfNuDSHPPsD/KncViC7lzNHbp5Z+Ziu3O1eeXHoD6U+BRDhpy8jqGLbz8vqACKpeWsRZldRNHnco5Uc4BHrjrU5juIr2S4BSWxjJKYzsdjwHH45osFxfsqzyQQLIFQA/vCoGM84I9+1TSZvminu40Jt0EJxHjaq8K2OlRSwFlReSjseF+Y7gOgPem3Edw7COZ/IuFXGAe3cketCFYmtEa5uvkEbTbC3kA/Jg9SffvimCFoIHNufMjd+UY5BPfcPT0FJIkFvvmUlSCuM98fz+lWry9azaZIrYlp0B3SdFHU+1Mdir5ghcoyNsZdsZOcKT3p00GDEjP8AvIssUHQj1FX7a5tHWTBmR2jKqHAIZu2fQVjxxkTktIvmo3ykHOPUGpZSYyWJ0G9FVeo3Z557YpsbrMHLFd2MgFsEn1/+tVi8ZjPsmRjISCT2P0pk9hF8vlAKQCTuH3j7VmWQG3FzgxFmP8XbJ9RUc0Jt3VbgZbpnoT9auXMZmiJjGzyhsOD90+tRXKeTGrYEpI2srcn6g0EspxKPJ23CHr8pznH0pixiHDShevHoakic3CsYUAQcfN2NJPvcKkinb/CTRYEVpYUkkk29Qcna3T3FNMUSYGDv6knvT/K8qYSKfu/katSMZIGdokHpim1ckz54/MDEAZHIPpTIWDAxSja/arnlKwLyBhn72D2om8qTBZd4ReMcGk4gQlFVlDYPOQR2qu9ttIdQRubg9quiFHjTDYB5JPY+lQxSPCXjkTep7f1o5QK5z5w+0Kdg6kDpRU1zmfy4oyYmA6H+KinYD0tEYRwT5jeINuhkBG5SBynt14z1qMMj3BnigjkjVCJo3diw3cEnPI/Crzw5lEs82+1mj8wPHhflU439Oo6ZqtORazM1vuivIiHR1ALSIeN2eh/lWe2huU4WcXLJKJLZo3EQLEgYxxGzfTofzqxci4tPItYG89Yv3u3aF3Ic52nrn17Uk8jXqpbR2zXWEBmYfIZFJ4JGcZHTIqIK0bBZCY/3Z8sHoMN8uccFhz7HvVITC5EaW9rLG0TWqYZHTho2xzkHkKCeT0ovI7iC68u5ZFgwTuiO8opHIB7qSaS7uEuklJiDKPll/dncOeHA/u9sCoJI1Ft5MRV3CbkYsR5iDqg7bh6VXQRVimmsrpmZXNq+4ssbb1Qjq2R9M0txHIr24M0MlvMxNtcRvgnPUE9h6irKS2VrcG5WMzWUi4KyZDRsRgFcdx6d6zo4oNNW5tbqZXik2yKV+ZcHuuP4hnpVx2M5E1osjSfaIYFW7j58twAGx19m7ZU9O1adtqNxHtWxlENxOcuC24JgE7h/dGcj8cVjW4jafyw5G5f3Dqp3Ejpkn6/41JwBK1vI0U0aZMIOFcZ+dfXnrj1quaxDV9Chq8KTwR6hbI0UhbeBnt3AHpnOOxFFkrLLC9vlFcK5KHBjP8LD68/qKuX1tbXEcTQmTdIQ/lDjbnqAP1HuKgvAbaP7RbyGNISTFuOWbpnpSnK44podCs0qqyBBMWeYgcK4z1Xtn1FSalN5wdpBJJO4jW3lztO0jgNnuOn0FJBNGbCBbcurI2+TKkFAej59RyPeluB9qZftUTyTQ4/dxnAeM87gfXrke/FZGgkJncEzBiqSYkXZgIP749s9altrkGZrctEZwnyPnCkqDt/HHFSzmciUFgZ4gVX5sCUY7+rAcH1H0qnJAshWaIRqshO1wc+UQOh/EdT1qeoy0HONzrE0AwZEXAww6OP8KZeDbb+Tdyb9zfuivAVN3KsOoPpSRyPcOLhNsTgrG8Z/jJ7n0DdPakMEflyJIG+zsA5bv15bPqp496dr6gOfMZKBPJZeJMciQDoT/dyMde4pLmEOk0zysbaZQSxXLJ23k9NwJAPoDTopPO/czg75FEULjlXz/fJ/DH/1qdMUgBgnZoYPlWcEc7s4yR7Dr/eGKQADcW7PDNCPNZQY5F6qwHTj1/WktAihUutsNu8ihMPt2vjgk+meuKliBytq7ptRv3M20jcnQY9xwQT2qujSGXeURy7b3jYkeYOeeOmcGm2GpLDJJDdmJFQB2+zyZ+5uyfmIHYnGKvSyiH9+vmKN4hvIcElHAPzMc859u3FZqrEZYsSSCRCrQ5XluclW9xV1HaWRbuAxIsjDdIHwquQcgjuD+hpJICNp4prmeO1kFsszfcZ8omMdT6Z6ehxVmdWkijjiUtqR3R3MC8tJF97LN2JOBj0qO5CJEkb26lIJNxVm+cpjlAR1PP8AKo7uUWr7JlZ5S6pJLC/HljpE2OPfd609AEnvTK7LbiedtiRrlOWU4woYdcN074qLcReGB/OiYAuhkT5gScErj7vTnPbmtXWHtYUgOnlVSUrMoIIaGUcEAnqDxxVOyhOokyW90nm7mlWIkoPMA/eZY+qjgc5piGLOzx+aqqbiCQbAjAeX1JwnBI4yD6fWpmuRcwFeI1TDSKsYJTOPnBHOSeMe9T3Edm32W7s3Jmw6SWpwWjjwMgEjJxzzVGOK6328kE6IscTmFxgAH7xXdySR2zng0mA+4nmgTyLm1bptnRwQN38Mhx0Kg5//AFVPNBI8NvBcyQuI2BEpHyyP02ueo4Ax6ipdOvUu988SBrq3jSG4gZQBKpznJzz049aoyiCGG7RQkgkbak24sh7bSOpC5zng8UkMidXfy7OKI3HmEukZGWHOdufYjp7VVgtyDCysqSpJtRPvOSTlhjHf3qxI2wC2NwLh8+ZFdO21nAPJx15OAM9BVy+cmCe4tdkMcjKZVSPOwj7rZP8AT8a1i7EtJmUqNFO6o0ithkUNhf3YOTG2ehzUsV2kpQPC3mZJV8/fjxwD/tA8k9cUsEBcxvMsj3BG5UGGMjjuO2Md6YsAMzeY0atMu6MMx3QMDwu0dWOMY9OaHqhbEccgiVpFYo4c5cElkOfvAfhnHvT4WJkMk4a4gTEk0e7aXAPy89yM06OF4jcR3LRQvC376BFLEjd1X2Geo7UpgEaNEqu86TeY753Db/C6/hwc0noG5En2a4j1gXUe212F4XUEBXz0AHY9CeRmobq5dVt0lXZPCnlSHr5mTlc+mRgD6VaniM8DMXXzAx2RLyCCc7VxwV781Acx3X2i0cLwyxtKo5G3hfTPU5qou5LQ13j054JVSOZZI2di65MRPG0/56UtkRcqSxcxONirxuGeAfYelEsa3GBGjeQSD8y4KHGOcetV7BUtr24DZVdwDK4LKB246inuLVFl7V1mkRmZJ4nY+ZH0XAGAT2GOM1HLKQIwWba7Kfl9R0+mKf5UskYMDu0w3NNuPJQEY+uTUJmKSysqI29f3gyDxnPT9KY7aiLGhVfJJIVmDbnyQe9WRqMYYFhG0oQIsY4LDuT/AI025R7WNoV+WOcLIUYjv1wRUUtsv29y5QxWsIwF5DZ/hppXE3YvyMLeRJWMLJIhYIDv8kehPqe1SCZXt3Qsyw5whI3eWSed2PaslZHdikcEnmhTuA6Ip9fWrUgkFkkMO/axBGCDubPpSswuX7oWqBDHE+Ymysj5xL/gKs2yJfgm3WOOSQ5wicADoKg0tpr62liljeaOJThn48od2IpkVr9g2TpI4ikySQcAEcEfTHemgvYr30YuL4TDBl25G3kZHY+lRxH/AElFmjWZGyFAboTU3nW7Rq1uXXzMjjoMHin39uroXicRMoC4A5x65qHuVdlOXfbK5AI+ba5PQ0k5Rx5iAhT1Ldqt2salwl0TNFG27p1PvTbiIvcNJD8/OdoHBFK3UZmyxKYiwGVH3uKmjtLm4MP2cb22kmPuKseW0kUkiAmFPv4HQ06ESDfOsuHC8jpmmhGXMfL3eam+JvvAjkGoocMhKhvKJ71olSY5JhECqH5hn7tVkPmsSyiKMnOB3pWArlG+VgQQDjApskIkuQNm1+nHp61YO21Z22bkf5gT0FLnzI1PTed2V/hNFgKT7SvIKv0Of50PE8i79ykgY+tWLorJGqydRwCO9RSDyY0hlHPXNADTJvh/eR7WXhWoqJo5S5MbZiOePeikB6IkvlQ2+2eFbdWLRMMkxg9VPop/IGodWhuLRPI8xLhGVWjVI8hcn7qsO47jpU6hbu0uTaq6yMoSVEw4RfT1H9aSRSsCLLcqkChWjlEu0nP8PuDjr2NS9NDVFKGVJtPidIxCiMwLbvmBxhsDHIPHH1p0TWMflPtuZY1O2aNByARyyd/r7VE7lJppLeF0g5WWEtjzFznGe3GDxUciLJL5dukikZA7MvqhPv2qlqDZavbeKC7Mtk8sW05gZ3Jyh6hvaqDOgldvniiySmzlFYH+eR170rskFr89zKqk7Q4HzxnPCsfSoLiee2EsM0YjhfHnbeh/uvj+915FMm5pPLa3U63SIElaMtcRqTtlOeqfUfkaoYN4v+jBFZnwiOowirng+pHtxzThDsaI286gnLQzIpIxj7o9D39+abIVluYZrS3WO4QAuNx2lhySM84Pp25oRLYsUIceQ02YJOcdGQn+If7PY0twgMESTkC8tzsLpycDvj+L0/Km3jzXE4VoYrYplglv9xexx9e/vTfJeTYY3EdzAVLIe6jkP7gdKT2GhbtvPQ3NlbpE0JBmRXzl/VSf4T1x2NQy3MhWaGHzDbMAxVxna+ck9M7e31q6ly7TI1rhXdmCA4ILfxKf9kj1qCOS3lYSpHNHC0oVoGbJ9c57rmldFIi86NLiMQjIB+WQnAZTx5bnuM1F85lkInMNyg3xLzhzngDsO5FPgEs+lziSPyxA3HzgAg8n65xmknaHckbArGFDQr0ETkYwfapYErBZBGkbhZ2KgBht2MBjcD65P61Es7gnap2svlyqVwjBv4h7cde3PrTLkpcW6mQyfa8ZdQo2bF4DJ/WpzNiKNUaR54o9sbfezjqjdunT60gIdyyLK0qb5WPlSKByynPI9iO/bFXLfaCsUjyTMw+QseN2MDB6dsYPpVSJmWJtjAAbmjR+oPBKkeg9KltJtgunCKsbAFo3bLL6EDvjqD+FO1tQI40NxM8Us24O42qx24YnnIP8PBHtVmaJ54QZCGaMsQNw3Eg8nJ7jH+FVXhMhZplDb8Yl6fOG4b6E8Grc80Txb7aOYXafJPGTuAcN/rAewOeg9KQDubyYGRwsIfMUki/6stzkd+3HvxSW0tyt2l+nkq7Eja3y7zyTx6N/OoWeSbDT/wCs8v8AehjncTjBHpxSMY4rjzCGubYgqWYFcjs2PzJ9KAJHWL7KGBEyuqyKdp+9k8j0Yd89aI7mEwwqoBdJlVlcblY4OXPoD6ClEbLOyqYw8S+cqkhdzYz8ntg55+lNthHAimJPPQnznjHyl156ntg8/jQDLEIlubKO2kQ+ZJzG0gxlcfdz2zkc981JFc4ZoZGEUaDZcj7/APsgD1IHNLp0sW9orjm0mtxH56g/Kc9u/tinpDJcNDtYrJDDviRyoLRP0P8AvH05OaAM94pFYlHjcowGW5Mi54cKOnAwcdM1PqMTyxpdWC7Jy6hkA5PHIA74Yc/4U+OQQy+VbAwyBWmtNvysOPmRm6gHniq0K/MZIQ6xKpkkkP3lfGCTz0OcYHWqE0dBdz2oSLUba1D3AjxcqX3LIcYPOAS4J5UDFYiKY4Uj3qYm/eQYwQrFgSH/ALp4yR9BUsMST2TnDwvLwpQHEMo7Ensw645qzE0d+iR6iILeN2+d8HCEA4RgOSxOCD1NJghNZ3SzteIXtr4Z82bcAsswOGC44wwwQvt71mQ3kzRrIiEW0JMjqCAEZht3Mf4c8jB9c1fEjXMiQ3LeVMSMSHqT0DDPf+EimyC3fUHSCI2VjO6xSoZCwDLx857hiOnoaQFgQW8ujPaSwgTKjSQXK7Rk5AyzewGB61QiaVo7cMGZIyYPtGSQ7AfdPYnuKa9sYvJRppktHJeHahY5H8Koeoz3PpSLK5EyF5ZIZCHZ0+SPcf43PqDxx0rRbC2ESF0mubdUV0WMSZOG2gep9BnBA61FA8McEk6EljtyRgMjjo3sPf2qLz/PWOd5x5kchZyFwqHPBIPUH8qk3q00ZmMm4hknjIC4J6MMdj6UCI7wvDe3NwVRpRGFXy5DtXI4Yd/f05qxbxTGLzIGM1tZ7UllKlU+bJAYd1Pr71WTyzGiHKLGeFYbTIucsrHPXNNtoGS5MkkjQwl/LZiNxAHO4L3x09qe4JmlNIZIpZoCkchYOyLEBjOSQo7AY7djWZIWn2qLcG3kbcyRk4j9/YH07VanlFzdSNA6F1YujKu0P/wHt74pyCOCJrhWbLuI1UHCrjOQx/UYpRVht3KEzu7FSZFaQDDKclx2/L1qyGjdQBKArjZMEboO5J9aqvvSWNZlYSg8nGNo7D6HrVm6MM/lGzikF2XwCOjYP8XrxgVSJaGlQ8uNrSoFATBx8n+NQyTR243KpOX3jKjlR6f4U9GaO8+zTBVjyZd2eCcdDSNG0rmFypQSDjoFBHAp3AF2/aV2ATK7fuypxt9RVa5EtvN9hjiIM8oIcr0I7Z9KkluI44GiLqfJy684DY6lapy3DCS2lKSNDkgOz5Yg9B7GriZydybUJJYil5O0nlOfLxH8u8Lxwe9SwXUTuEicEFN4BbA3dh9awNe1G51C5t7WOYtHASqRDgRjOfxNOTTb22LEld5G8561RlzWO0vbw3S20b3cyz+QY5UAAVUHQZHX8auxif7I630C+QibWkz1yOMGuL028lFywukM64C784KqD0+tdVNeEwxKoKKfuofnODSeiNIyuUoxEkJVi4dTx6D1YfWrjQpCSt0WjlUBwCOWB9qpzRRAx7WL5UnDfwgVPayi6X9/D5kkm2NWY/d54NZ21NNStcloJSYlmJkO1Nvce9LPI7PEbUtG47jrzW+sbaZPIu+JjF8yFxxk9RWTJcLdX5kk2xlhldo2j2p2srBfUhEkqLJgld+A4HRjUxiSOSIQSK5dfmQ84NTBT+82bNpIRuM496q3cQW72xgqYznevOamwxIoX3Trv8tvRuA9UhvkiEBwYsknPY1euJEMBDnLdQfU96pQxnZ5sj7YzyhHPPvQ0LUWSVpIdpUYQ4BxzQg+YGPAJXLrVu2KiB3mwHA3KPUVWuCjIHjP7wndnHb0poTKqxiWf5j+6zxnsaZJBLNNsKMyscIRySfTFbVhbjVNRt4YQqiVgp7AHuaSC0tD4kNpDqUsMYcC1uvLODJn5c+gz3ot1FcyXhijleJyyOByCMcjt7UVJqaTwalP9rQtOrMspzklgeTRSsB1k9y1vN9pskDvGqr5TqQZl7hvfp/SkvsCQXcChQ65MTLnyz/ErA9verFvtZYiQqTYKODJhZh12jP3W9D3qrdWWLlJYpfMRG8uQO3BzyNx9e1ZrY3GA7rvyZ7fy4XRZUncnCDthvTPGe1U4LG6S4gVHWG5ucyKm4FSM/ePuMVPPGrWPmW8zvaxtkxFvmiJPTHp6/nTL61ELSCR4ZJozwEbJiJHt1U1SYMzoIpLi4lUcs2NsPH7w57n09+1XTvggl3E/ZzuRoyBuhPQoxOc884pbqC4ieVTaxE/K8kSEEhdvJVvQ/zrPEiov2kltspLYBwVHbk9WpkXJ4WlgTyCftCSYIiVuJQORn09sU5TE7K8rF2k+UQjKtC3Y+/vTZWn+wGW3Z0jmwSvVQR6n1PXjoaobhIjPKwFyPmZBnDgHk57H1rRQI5jQhuZS7KsW27jJ8xf72ejAeh7j3qvIhUC9gwCWG1Q2TE2cFM9h3FZlzqH2SVWy0bwAG1mABYqeQHxwy9vWr6X8QthfWMayRTYSeJuQrkYIB7eoqGuhS1L0gW7w75DhGaQBQM+rL646EdqerieNTJJvIYiSKM4BXbgOPeqL28boFMrtExLIzDBjcjgYqe6lfyoJUOLzbgxhcFyOCMfTn6VNkaBmL7KwYG7Jw3mKf4AeQy9M46Ght8tsk0Pzpu8zY4BLrnGW/2hxn86iVYIo1+yzFtq4aHGOepQjuvcNRGypbow8xg6lx32cHcD7/zpNBchuZHjlRrZzIQwOWGdoz9319vcU66aO4UOsX2dHGQkQJVGH8vxpSoRWwMIygAM2RKvByPQj9KWIywW9xaQkSQ43MV4Midyp9RnrU36CHrOrrEl0sK3CODI5PHQ7WIHfJpht5BdusiMkiId3yn52PQD0B7Uj2wCLCjeZbuhjRiv3G9D3GcdauJcYWSJkJcou4MSSke4ckDqQeKLhcjH2d4IreRHhE3+ryDs3Drg9ge47Go5nCuhIMUoRkkIbI9Fz65707C3cqRyBmOWZcctIvX5fejd553Af6SvJQr8zJ91TjsRnn86QxtzNA0DSqGQRgRNC2WYxkcfN6Z4H4U+wfb5J8wrHEmVONwYEY2kdj71NezmTT7ZLmOJX2+WjKOGwcEN6kY6VELeNoZvImZoY0w/y8g56r7dDnuOlNpdAV+oQ22GWCQGNjPiNeGaM4Bxz2J6dqdGTFC582T93IyyhTwobhlJ7gnB9qqXMofKzM6xlTvcg4mU85B/rVi3k3xbDCrXcTjernIkQdOB1zSswuWIy9vavFOxa3bdlVP8XUSDuoJAz+dI6FjA9tPH9s80xsifLH04Ibtn1ppt5ZbpLfzPkxshVyB152H0HpmmqHijlldQ8iKgcL83yAevYgjk0ANLiV9ymRTKQWkYZMb54weeMd6dKrxOly4P77MTxliDnA+bpj/9XNa1tGl5pkwt0hjmkBllLPgkD5uF6Af41k27l1eIbBFtYJKykkZwSo9SegPaqWrBliORZF8+5iZllLRzoWOZsEZwRxuA5qeNYi87F4pF2rhHG4OPr/C6jr7VBE8elRS2iMklrM/nRTTRnfGx4HXnBHHvRZRPdpHHCqLOSzRBhgeZnkegBHQUONwTJjFHPlLto3m2CRJXYoJM4I5P1OT9Kz4DC891DcTPtfLj5SCzEdcd2BG304zUqzEgXCqY2t5iybY87WA+ZSO+fXseaktY4dQaNoZ0gGJBMqglx0O/J79PyNCiDsRTC5iSZZ8i5jwmMj90wwSxPJA6Yx9KkuYGRnnlifzo/lnG4bZWJyWGOBkYwMYpkjM7SPFtGweXL5OcSJ/eP44/GqscrwwwyW23z4yAVccSH8eM9BVrQlhqkcE6vPtMiBiwSU7jsGOCe59qzZC72kklpJ5ZjcJJuYjzA3TGegWpbh2knHlfPD/rCzJxBn7xC+xOM0+e1trm1umsLSWOC3fMcs78N2b2LHtz2q0rmTZPPPHDFlLaJk2BJHRjnIxzz0PbPvUFtPJdRoHMkaRgu4wSNuRkKO/9aj1Fyt2syAC3ICbtoXkD07Hvmr1neeXcedC5ilTlVY4ycYdR7H0okEW2RwCUwvmNvKRgA+ceV1wD7GromjuoUZUjt42XYWHzqXUdfUHHpVS3eGVyZZHBwQwHCgdiD6c0jrHDbQxqxIVt5j3Y2kjrn0PGaixadhVkM063EYDSIxkxKcoo7Dnk5p8s6QytNHG6GVc4B6H+9+ByahvGighMz3G+8jj2SnjDMT2PQjFFtdTzRXNzGkhOw+aXwF291x78Hj0pgXfOtrrP2sPB5dsf3iJ5nmyZ+Tj+EEcZrJiuRcXhUl1tQpyoGWGB39T71oPdBAs+fLLbUmRP49vJKn39Ko2xgtpLswOogn+URPy4BOfwPvQTfUrpE8eQg2vneDt3Ecdvb1FZ58+FHSaTeobcu3o1bJRJzOsUTJKhQxnzMYHcfU1CWU4tLtI7dSSI5OcI3ofWri9CZI5fUbb7DcxTJ5u2UeYjt/FzzXUaNr2mGNZNSgeaRAQFz970rImsjMwhupXSSNSsSv8Awd8gelQWVvDHclJiz+bgZxyD3xVxMZI2ore40+CS6RVuI523yqD/AKsE/LitZrdvs0VyZgJS3+rU9OOtU5pJbPSgG8q4tw48sAfPnP8AEO9V7iK4upmdkdFkYBEJx5fvinKzQ4GsiRXUUiRkCYJn5j1PfFQWLSiWKVCVw+VZl4BFTwq2n6jbTqFuECkyAdvwp6SOLd2cD7M5wmOCpzk1m1Y3uJfT3Nzdwfavk3sX+XuD3qhe2c2owXfkSAtAABg4OKtXLSXcqP5bbCPmI4x70sFrchLh7Rtyx4+71+hpCK+hyiPT1gaRjdB8Lnvnrmtm2hkwViRy8efODdMVj2pjhuBM+F+b5mA556itWaSSIM1tKxDfeDNyVoKRR1Qh4yYF4T+EdjSQny7VU8naWwS3rWjbtDIioAqsx3H6VVuSUuYgP3sIb7g/lQK4klqi3KkuBE/AYHOB7inRxi78yGJFAX7pH8ZqWKzjmXCPh2faIs5K1DMs+mymGdGikiOQV9KbAbYLPpV/G1u7PdJKCke3OT6Y75rq4tOcXXmx+FZku93mIr3AMSP/ALvXr2rI0G9gi1W2kuHjUo4kWWQ449zTrnTLaWSWRfEFi7s5Ikd3yRnvxQS0c1fecl5cm8Dec0jeYW/vZ5/Win3iMsvEomjRiC45Dc9aKV0PU34YvOskWeSRbf7pwMmI5+Xj0ohaS2uH2GOURkrLE3AcDnI+lETpCyZBZXykfmL8rr6nHQ+hp1tJIiMMlFGRHIRnaewPovvWSNxl4saXUl1atILWVQfn+YOO496r3Vx50tvbgxhAHCBe6k5Cse49PSp3W4jt7hJBHsY8KVxtJP3lH9006Ozd4JYTbFli/fFAuG6fNtPXHencCoGCKj24aePOP3hx25U+h9BVW3gEchuY4/MDAuqnIyvcDtketSyyvA5lh8uTK4bA4lHQDH94dzTZZCtoq20knyy7xEw4iY9Qe5Bq0yJRIrRJbf7PKrq2n3BOFbseg3D1q/BFFda+mnSN5cWCsrucBWAyGJHXHHA61Vmkdd58tZbOQKLhABuDZ549R6ipopm0+4ea2kDzW8RS03wg+Yp6B1PVwD0/GrTM3EpfEDSk05Ehkt4472KQrKFbiTuDjtkHpXO2cgFxJKNrwoA0iAldyjsPRh61pz3rbY/N85p7edpGeT5x0wBz36CqsC+TaWtyQVt5GYKynqP4k9jSkhJ2Nm3aLb9ohh2xyJho5OitjOD68d6I7uJYWEaEQy4PmSD5opAeM+vHHHaqS+e8rWojGWyVhLY3gDoT9ORTo9ry+akYkgKjhxy2Byv1rNmqZYSNmlDed5UwJjlyOx6AegohmltArRsXikba/HJA469mHT6VJGm3csbguctEAP8AXJ3U+hGahjcylL1XBuA3lSo2NpUjCtjH4E+tGwbjXZLS2SFfusxZW6bV4xg9weQQas58vcmCyHDwZPTPVc+9V7jb5IRVGwYAyPuEjnI9+mamjG6xKxhVEA8wOefNUkDAB/iBx+FQykFvJHC0vnxbbKZgdgOWjOTjvng/nUkTllZdQU+ZvDK6NgEHgq47Edcd6gzGt00sRZTtMcu/kk9j9T3FTmEXd0ETfldpRlO0Oo9Ae+c4z6VIA1tLbmSJmXEMhjbacmPnIYEfn+NPYETmSQPlSNhVwHdmz1PpwOlKkUk+VEZe7RCHiUH94ozkn6Y6VBGzeX+8VJMKGUA8hB159uuKVrOxRN8wnhExWKO4+UluQGQYBI9e35UjlIjtQnz4gHY9M46pjuR2NSfLIzzzlJJsKu2QYEkWDlx7gfnUMsVySFDebIq7rfLfex0Iz2wePWnfoAyQpANjgJH5e3k7ijE7gAfQ/pSWzRLAuGdJQAp2HG0AnDZPUjP86ddxqbVpCf3rOqypgqsWOvHp05p2nzRxszsNpRNknyhh14fnjOO/+NGoiRAs6O9wG89xg/MAASRtceuDTHuma2RmiWP7PkSA5USEjvjnkAY7d6iFtJJdIiMISWMts7t5aFf84OPwptnfA6q/9pbjLIpQShtwODx1/hJ4I9DRYCa2guLTzIoGEkoh3sij7qkZODn5sDt70+K8tx9nZGMqhTHMrDeCG6OVzxtODjjNF/gwRRrJwiGaJVPJBONpI9OR9MVXsbNb1oPLVLdVl8okD5WJ6gjPOAetbxSMZNjZLq4hae2LCc26tbTblDMy7uNn0HPtWrO8dpaNDIha3lVXt8HbgnAzx1I7A1nPGsMot2jYSwzGOeZvlSH5uBgdSavQKo82O4MZttzrB8uFG4/eH4jIJ9DSkOLH2981nefaPtEituEM0Sx4baRgsAeCcAZ9qja3eC5nkiVAkjOyw8YZRw3ft1APtUFtIvnQySl5GOURUkC+Y5+6zE9RzyD2qxKLqGxNlJHHuibfAFPzNkn5lPRgCMEE8Co1NLlK9cQzLJp7uwkjxcK7AGVS3AHHB9ccUyAiNjbsJXMrAMCuXjb0B6enI61clCxYnjhDQzx+RK82DtfgkDuOnNLqLtI9vI/lk25Kx3GeWHYfT09RVXE1c5zWPMeORITsJZjIAPmC5GMnuT6Vv+CZ8WFxFJbJNEwMUUk6eakTbSSApOAxGeTVbZEhkkbzJJSrrNEy8xZ7+mPTPIrENo8cLO1w0Q+/sDHYWHI4Hf3rSJjOJoTj7CUsl3TyxIsmGKlFRhliCT949APxqVAqhoARJHKB5cj/ACHcOevOPT3qt4euJlla1eBHd5S25sKH7kMTz9BVqcsWmtWMewuJQVTOxz2BPvTk7jRKJZCsETKrhWwYu0int9M1FM4jkDQqUhVWAb1UEcDucE02IN9nVXMcU5cKFwQ4J5DA9AKkieKONpZ/MJZTFsBGd46j6HPUVFkNMi1iFIGkdA4jHyhZEwR3zj0P1o0iCbVXnVD+/wCZR8wVeO2P51YhLLJEkjeZHDvZEYZQgg7gPU+lZ2jaodOnZ7cMg2EA4xlT1B96aQMtOwSS4Z23hGCsCcEc5LCoI40SaaZIlaKUlM8nDZyASehA5qXUIYorOCYyKtw4yEiXaU9SxPXNRQpNfQXGxJJLpSrEqwCoOeWHcmm0K5LDDMgjclIwUJB253p3x64qneW7TJDcrcGVASFJ79yP/r1LBcyymMSLJm3AQurZVeecDsPWnzSwx3VwpD+TIo8uQD5R64HamkFynqklxqgVpEAkiT75GGdT/e9cVXe1mEMcu+Rc84AxnHHHvVq42RSXJEqgrjad2cg1JZmN0eeFpVKnDEjIyemP60yWVtLskurn5JXiUAhpHOSx9q0bZ5UmaFpWlycrIw5x71WZXe6URneh+ZgD0PtVuKVYiyPCPMRS27P3waQlEku78xG2QxjnK5A6r3zS2csd2rOjqHjJwD0b8PWqG9Y1hZ3Co5yVJycE9Kvara2r65byaPvW0IDFW4+YdcUtSyyWYwtFEfMkONjDjr2NFus1vaTbXkjiYg7TwWx15qCWdFmeaRD5ZycD+EjpUwcTxBfMZoWG4M44X2o0AlsfIm0+XAdJGkwS3TFMM4RlR23Ko+/jpiooWIjittuHZjyTwRUtzH5UkqQRZfG3B6H3pMY60jiuP37SnjllXjj6VJPHvkAQ5hJAJHaqcLLEwjEZEoHJ7U7zXDiJcqpbg54o2GWpIljUJHl5FbOVODj61BqUMs2ZRMZhnBYnkVagVxcyQxyRsVG4O3A+lQ6a4l1ZllXZbsdrAdN1O+grWLOh6l5GlsosbG6cMctPHub6fSrQ13e6Rx6LpQxyxMJwKy72A2jzfZvuo33h0xTkTfdRLNOAj/fkC52jucd6i9tA5UyAT7JbrzrdArsWXZ0Gewop2ohUkUWUxnhTPzNHsP8Ak0VVgSZrxS3C211mNEjiYM0THjnrx1wevFQwXVkkqRXKSPC6lSykEpn+Ee316VI8kkv7tWbIbKv/ABSD0z6/pU1rsvGllZoolBAaPA3hvUfj3rE2GtbmB0ZPMWRUYBSMiX0Df/WoeIm3guLeZoOQu/8A55OB0J9DUJuZt7eZlyj5ZR0B/vCi1uPKvTJNG0iSD9+icqR2cD2/pS6jKzyRR28cbbknyHDEDIbJzg+hqrbOTMfJAWcg5R8nI9Md81uJILYm1lVbmzkjfydw+7n+L6+lZzwKqLIYwiK+wMG+ZW9D/MGtGuxJnwqEmRwxUygFEHfsUY9qsSPCs/nqrJcwkbYeSVQevuOue4purxyrdQW0sW2VlP76M8THswHrjrVMg/M87OlxztIJ3MRwDn19aaZLRd1Rba40KVXiiiu7ZWkaIsR9pLHhl7Zwelc5ahoogWjd4om3OkjZyrHGQOnHetO7lEttAhLfadhUqB1UH7wb+lVraGQSrbk/ORmKQnhlPUH8au5lYdCZFiWNMtCC0kMgP3cfxDPb2qwzSJIxVlDSKpaNWypbqGB7ZoS4wUSLYqlTgFfljI6n6GnWsaIkjSbvJRvmx8zICOWA789qgpEy2xk27Imiy2QucncOuT29f0qaa+MirvCq4ZhKUXAlUnofX1qKSW7skiZMMFJPJy0i8HB/n+NNnKGQi2MbbG3BcYAY849+OM0mrlpj8RyXG23GYWyHJGC5A4JH904pro7Qm6tVchWyVDZKH+Jcd89jQ0bPdWj28jxxM+1gRhoyeCjA9hUtlPmMWoieO5jk27o/mMmeq0rFLUigZEmnKOWWdAw/4F1Q+h4p8bRsgAOYy5KlycoxP3s9eentTOZbWTCJAFUkKg435+6Dnn1FLZD9yHEWcptxnG49T9COuKze47jx5jrw4S5DfO5bAIxwQe/P50yArcRwNIgV8YaPkA5PLH8M/jipYHiigVSpeVkBjfIYE45A9Pb8qjSRQrsDH5jqroFyTGw6g9sEdaa8xDsRFEjGC0o+RgDwM8HI6EHA/Go7PKReRIGjkgkY7Om5/wC4P51Ku8wMsaCKCVX2445OMgnsCcUSKrxhi4llWNTK+OFOOD65B4NIZE+51LpFGRlpPLYE5wPmVv5e9S2RUrbpKyicIyAbuAeMAg9iOPrULOYpXO52BHzhRgqcfKxqYLHDeRJIu6R4wWkUByoPcH1FNMRY8n7SYjEG8yFCuxsYEh+7gdcGkmEM4GIk2wqF+bgIwPzA56kn06cVWmhcFZ9+64yXkVf4lx2/lj1p8McEc0LzD/RpnABbkqccE+mehprQdrhOYp5GuEcqI5MFdoA+YYC8cqD6+tSXHlRSI8LfZ7d1EcjEZ5HB3e/Tp2NVJmltLli8kMw3GHzgu9ArDowPRhg4Na1zBGiTSQzxeRIVRgeWIIzu55Hpx0qidNimkawyvJKSWkkZZomGWOV+VvYY5HoKSaR4bJ4Ztu6P9zIiHKgfwlfoT1zzUjzC2lcMUg8pJA8qqSZQw+XcfpkZHNVfuRQzzKWEZ2yIMggfwg8e2aVwSsT6p5itZ27LH5ohRV2gHjOASw4y2cY61bkju7mKC18oPcxOyFWbc+/jhR/d74HpWbA5W5hjZYyIztIl+VHVj3x2B71b1Gd2dp2mZruP93PIDg7cYUj0PbjryaOZBYSMrezXSJIYyf3pWRx14/i785475qCQm4CI6PDA5MYO/nzB0HPOAOpI46VeicNeyJHHZ2qYVA24lDtXp6kN6+pqLzlkmc73dLltrBvvRtxjB7jPB/Ci4yiwcIF2L5kHE3HGBxnH8XXOaRxEkcVtLGNrgmNweXBHAPuDVie2beZIFMWxWLxlsgYOCAe59qpSDyw4YAt/yxYdCOpxnrnpVpkSVxY5XW1k87YPKkLAY6NgDIb19qkFwHMiyBHabBLngk8/MAKIikdv58cbCJztlXy87R/sn1H50xhCYljRneV2/cyl8DZg5+XrnincViMu81wqRN+9C4J9FHfPbAqbTLQz3P2aWfdkHGX2L6iQt9OvFNuFhngdYztMEW7OAMpnk57k+/NM+VLtROTHOG3oVGduQNoH+yRRuLYnmV2G22KpIsjZEXIUAcsG7qRUBjaa7a8k8xYymJDCQcnHDc8Z9RUlzO0reYQGkRfKfdgKOc4GP0+tT24WUSNDIkayKccfKGAztx+lF7DsZb2t3bwzTxXEJh2bVSQYZkJ+ZV/wNV9Kuy8V0sDLby7wSspw+B0Hv+FaUUaTgts2TMd6ktkpj+Ej9ar3CmF1Sa13mRtjMTtYMRn/ADine4noWJTsBmtQpMjjKr91WzyuD19avG1XyWhhQLbSqdrMOp7jHbmsGePU4jsS3EiNEBGrt8yrntjrUmnXF3eCZbq6KKuIjEBt3NnjHp0oWgrXG3OmRh5RPtMluRkHue2PXiqv9tiNI7K3lZop5Azoozj8atJHHEwmfzDIh4AO4sM9TU8elKzfa1ZQsmFkVV4RqtMmUbkEc6xT/ZrtXRlG0HHGPcippZDIwhtXUxqQXkB6A9hRfL9mlIXa9wSQjgYz6VA0cUUe63jZbhPmfAyAalgmyxZWyx3KvHGCkj7VaTnj/GtB0aSNxGzLLEcjaRjHrWFbyXqRmeND8jgNjnGfar1xcQwSkGZU83DKmCCW9DQiropajDJcoV8wpIRlnHr71Pp97NbIbG6Q7lAOQc59KsOVnYEBFkfhh/UU6a0ub29wpiO1cls4wBSC2o22lk80uMq6kkKw5zVmyZjfj7Wz7CCRgd/eqkZUqUmmkEvUNjIzWyt5E99EZ4CsLIFkK9d3Y0JDEv4UXD+WfNccEVmyqYtixsXYnkN+oqWed49YJjlEiqflJORiluD5l6JYlBJ5w3Qn2pFAdrW/mKfkJw+P4TVnT5E8osiq6odrAnBI9qW8NrM8bwYt1f78ee471Tu4kjmC24ZEI3GhgaelrHcavBZ3BItp5grITjI9M+/Sui0q1ksYoh/ZUT3WpXTB7V0J8m3BwcZ5A6nNcfp9s+qX9tbrIAZZAm8/wjua6RP7OkOly202pLHeSS2sk8ku6RsYUH2GT0qlqZS3M2/sEtbmdLeTzbQs4QZ6DJ70VQ1JrnSb+5s7mRSsbFNy9PSiquXcvCyWdt32lwYiSsaHDLjqVz3HpTmR08uWFkMjLtEiDIcD73/6qWBWmuUil4cgyJt6ufX6+1QTTTWjz/eK9WVl5XHcelYGxa+0tH9nlscKsOQyAAgA8Hr1znilkhtld/s5CBRugkOQGHo36/jU0CQyqslsF3jLqrchlxypPt2qpKFk86II0SSLgbwCdx6YpjIIn+yIBdJIYpQyxsRyhz0/+vUqRsLkuzRq64Sbuo7B/f3pkcsjTLFNBvjMgCGQ8Yx0+tTgqAtvJ+6khbaG479m9vekxFOVkuF8qdyVt08vfIxyB2KEfmKqyW07yx+cSs2wSROT/rVxj8P61acs5VYY/On+5NEoz8g9Pb+VMD7tkkiNcJEMoS/Plk9PwpktXMue2KwrImU2Plj3jk9D7Gln8uTdD5uxCT82OI3HofQ1avF884kzK752yIOo7Bh3PvTdirburqxjZgmzGCG9h6U7kWK7sI7rds3DyzHKvQEeqipomba0bspCjMLY+Vs8YP1p5j5ljYB7gqoWRcHpzz7gfnUSL57vEwQtjf5YG0BcclaQ0hsO1IpVkzthkKRtGclSfUf3anh8y0lSMDbLbgmMcNuQ9j/OmxeU0jBxtXHlhgOWzzz+HekhG2GPeY12kHzAT8hz0980FJEoaFoHikceROSdoP3ZAONx9KbqNtcQRgMXNycRllPGVH3hj2wKbGVQvckBAhBkjA53ZxuHtznFHklZGgmkcA4kDE42g/xD2zQF7E0d0iRhigRWhZXO37jemP1Bp27y5zbOSrSAOzHgZAG1wffgH2qHa6XeXDIhZWZewIONwPp/Q0sLxo7q5WVkJCeYDghsggew68VLBDLhHkgy58varqR0JB6so7AEVFbiSa1im+8sQYZ2jdj398/zp4JEKY/eOqjzFB4kVj1z3/xFNtY3gSWYcxuxkU54de+Pf/CpshlmcEgH5vK2fOgPzIRjn6e9Q3NzMssV1k/aVbE+zHzIw4z27Y+tSW673Z/MDLg4Jzk8cIR1OccGldnSfzlSM27KfLUngHHKMfUZP6U+ULk21Le2+0cne26F3xzgjjPc7eMH0qC4cKxY+YEUgw7Pm3sf4W/DNQylQZETzJbdxhWYZBYjt6cUQXCwmNzvxkBQAMo64osK5p2gjWGBwoiMUhRpOrA8nb9KS6KFGlKbpSW8yLHMZP8AEfwOP5VSjkWzuLtx5u0lW2SDLDPOc9MjP5GpGdUcRWyySM7bdmCd2eQCR1NA7lebzceTK4RggBRsDcoOQffv71NJcrBbP5bechTkqvDZHAyem09xR5CTyQRoWCkMkrcNJFjsPQHgc9jVS6tLi0khd5WxGCFiIGNvcKPbrVpNolySJBJK13C0s0k6iPajDJMigZ+X/dPrWqcx3SBlMgjVVmkMhdpA4yrYH91TzisKxledLpdqCVNxZQcFl4IK+pGOR71oaNdmB1hDeVHOgaMqeI3xkA46gg4x74pNdBXZLbgJqFmsSEFlDKUbcccgr9Przirkp3yzSebBMtjGyMrOSCg6EMcZPzcd+KS3hiunmgjEuFdhaJbrnM7FSyeoPU+2KqXSylrSSOWGOTzRGIcHYi7ush/iw2SaS8ymNuIjPFm0lIECb0j5P7vjBB656nBq9C/266dSEknkjjgYl8fNkYdegJ9c9KW3WxtdXeHWhN9mkl+QxKVCP0yB/dOeh9elWrLTLOfT72OG3mkmVjtmUl/LA+8GxwQME57g1VkJMzmllt3lWVEysgSXcoYDHQhR1PHJqvc+SbmSESoYwhkglLHaG9iRzj0xUhk33EctuzSLMnkziJV3Y4HHqDxz1POahXyyLiORfJIACJnIRgeh9KQ2yKDy2Uxom0rmaKRyWC4HzZX3Pc0iwgTeXbO8e8eYjOchVx1PpnkYrQAdrWNhJGhlBT5FG4Ff4SfQ9aznlO1ZpE82HnKkgDI6ggduciqJsRQqsryQhZJDGu8RDjA6tn1wOlW7p1lSISAboVCohQAPGSNqsR1Y5PNMu0iWTAjljTyxIhK/O2eMD26VE0j+eIr4qt3E43KRjPQAcdAvWhK4rdwAYW63EasNvVcZ2j19ueKs2wIs1W4MfkzscyMcKjdzVyNW0aee3mLtazqDlmHBzkZHf61mIFmhd5NxjiUq4Xg898dAAcU+gyWG1iubJZZpmhud+ADnaF7A+/Smzu0rPcsis6kKwPQ9gAD361cjSZba4jSWMuBGvlkj96vqD3xWdE0JlUMdxBxIAcZGOv8An0pIC1DqASRvLkaOVfkRicmMY4H5HFRWaqbadp1Mb7WAbAwfTJPNOZdxhSUqSY8RyIABIvYnPcUkkitLI/lmWPaISGXOT0z7UXCxWt1fEbSsA5wH3HGB0U/Srq+Y9w6SbEhkBDFH4Yj0PrVmeT7TpskN2AoWXMcnl4YADGCR2qsw8qFLaRRuPzb+OnY00wsZepB43jCqM7s7m9qW0nj+07gpkVSMr0Dnvn6GrN9A91ZmONgdj7mXuBS26LHDEFQ7W+ZXcdQOooTuJqxBdP8AZ5kuo9y20p2Sp2Vj0OKlvYluhHE8ZZ4snzQvJpt+sE0UiKp2Op3L/X8Kv6BIZNOn8qXddRKFkjxnjoTRd7CVuplWthO8jy20vmbFY7H4OMdqfa3MKFI32oWwGjY8sO9W51Mjny5njQHk4/iqje2kLopnjZWU4DnjPuDSvcGrFqaON2eOLgDJiDcYqSzgZp44bhiDIu4uDwtV3M1tbpDqKBY2O6GXPJHuasvdo6bVRwpUAn29asCwGtrd0NwivGpKsR/Oq1nH9qnm+cBYvuDOCKgFvNLcGO8uAAFDRoi8tTb6KaNTxuKkblQ4IFMm7LL+XPDtnysuTtKjg/Wq0jNAiDJJHT3pLLUo/LMao5LnALjkVdaOB4XW5l8u5RvkX1FQVcNPS6Oo2b6a6pdNIGjwQAH98120KatDEijw3ZrdQu0sbC4BVHbksEz+OK830zWP7K8SWk9/BvtYnBkCen94DocdfwrprO50y2votQk8RWktukvmbkZjPJznbt9T0NUmRLUr63pl6N0+p/u5myR8wYSc8kEcGiodS1Swn0W2tYLpDcSXUt35Sni3VuiZ9fYUUXGmX7EoYR9oUG5EbYIbr6NnsRQnmTyx+c2BHGR5hPD/AOyfeqrrFHEryjylLbQpGQ3vmrMMKQWbW7y48xjtlz8oYciszoIYCqRLbtIVjkbchxko/ofrViWFXtXldQJkAaRQe394etVhOZkljcIpYfOT1OD1zVm68zbBA0DLMFBQn7z9sH2PakBVnDyYadt8ZTczqcgjsfYj0qSa4iNnBbXg+/uAlQfNIO272zTLvFvaOYCyGeXLW2OAB3z7GluIlm3sp3xjBIbjyzjpRYBstxM0Kyx/LMhUuyryeMbvZexqF5wPLhiUFgd8TY6HHzL7ilkMq+VNbjDPlZUJx19famOmbdER2IjOScAGPjgfnQBJA0Kwt9rcpDIqkRIOQwPQHt61UuWeFtzxt5qKC2OCV7MD61IWD7Zdh3Kp86PONxB7VEhe6DRld7D/AFJP8a5yVHvTJZOzGG0iJAaJVJ/dn76Hrk/3gagSPZPHcqQ5BCsvop6N9PWpiBkhnNvBJJ5m1uQD0Lj2zwRRIJ7TfDhVmTLRnI2suckA0hENxtEShFDTIDvCnKlc9VPcd6YFSKURMquNoIm2n5gOSoHrk9aeQEyIDsJPmRv/AM827ofY1E7pLbwxk+UUYk9shuo/OmAeU7lDJIpkJ27Af4Sev1pkl0XkCO0jTRAxtuBwU9B9M0pVZbeB48Fo0zGB1dQ3Qn1HPNLM6PasSzeYoLRugzvBPKkdqLA9BtsCMfaZGWIkiBQP9b6qcdB3qVJk3L5mXaNSqqvTysdAegI61BJb/aLZ4HO1wgaM5wTnoffHQ0ttK9y0ULMJZ1/dsq8btoxj6kfnRZCvYkEAllKDaJI0WRRGvyuCOhx16Z49aWGHzWZbXMiPl41b/lnJ0Kiq1ncu3mRxhuSFQqMYYdjz25qdWAu5I5WMEM6FWbbnY/QEegJxzUsfMS+S9wsfkyy+fCAjIQM8DceOw6/jTbqXAgEjbYZZA5RB8uezf73PSnK0lteZdS0oBGQ338fwYHfHOaeDlGjnOy3I8yIBc7XHTgelDK6DZwgBjTzCsTFfLC43A9f89qoMZZ0luUnRDGNsiE7t8ecBl/vHPBxzVq5k3XG1XzPuBjVDwG7qT39c984qKCN7h2aOMpJD5axhCMR5J3D8c1UbMynsQWV2r2R+0KPOTlELZDoc/K3rnsfatLSlhtryaC5ecoCnlSIdrMFIyFP8J561kXUMMDw3FxJJNZzMwUJw6qTyQO5GPwqWK02yKskgWWIxlXV929TjAz04HNOQ4M6C6QzXDpbhYrmNSsyq2FmAz37seuPY1bu9Yjn0hLYx72jCsj4yC2MZBPIGMg+9U3kM8UbyyFsSSOHQ48kjnkdhuHc81nuG1MxRzM6dRLHH1Zv4VHpn1px0HIzkXy7xJULK+/EezvzyBnr9a0baO3M8UIURJ5+HaEj5UIz8ue/U5PtSTWbi6VI1hhDv5ZBfJidR3Y889+1BtyLeRnSNJLeTE0DkmWTvk57DqPak0JE2kvJPpty0TI3lTGSNi5B3DnIA+8SME59TTreR7y/jllZv3+Y3KqFGCc7c4wBkiqlvGbS4MrvsR4wScZKgjk++Ks2f+i2FzMkMcnG1Y92QqsfvjvvyBx2FT0KRPruo3M87RO32iHT48CONPlL5w5z3yB94n6VH4bvZ7O8uHtWkn06aLEkTS/J0wCQOwJGcVe03Whp9vbrfWNpfadlpmi8tT8xHJ3E8n2PFWre3WSGymmeB9Khf7OQD5Y2NyFdgM4zxu9sVa2M3uZtzCpv2jhnBeOFEOxMAtjOR2ABqCJvMktJUMb3G4u6N3I6bs8c9qWymja9jJiVYZstHhtwiXJ4Of4gB06c06K5eC/lZI1ido9yMybQU7HHrmpNVJCYa4lkihEkkc/ygEDIc+/Qc1FaRFbt03SSSz/uwygBpO3U8YyCKtXCBYGkkiw6DbdKj4Mg67jg1XGyW4jZlZPLVfJJ/hGMgAD1Pf3oCzGXcI8tY7l3DROCkQbcGjz+gH86YGWaIrtR51beJOckemPw61JczW6xIkzD7ZE7L5cpOChPKgdu/4moLWW3klR1V9yMQw2EgoehY9gOBina5NxJLtzBPCEEhlj/1sx+ZQD92MnoQaltWhmSJLhxDKkZLswILkngE9wahR4XZILuRSmWVFCkoSTk4HX6e9NlkktI3ZGc+T8siEZK9fmHtjt1qidmaPlxiAzpsjlhJiLk8g842j0I79qgFsHRtSO9JmxCVx6D09T1qdYobuON0JjWVIxwpY7vw56cn6Uy9fE20qimJgkhj5yvTf71Nh3FgQTStbP5WZWBt5pW4BA+79Ce9Lc26wQxFFLNkiTEmdzD09DSXEcZSOJMPatkxu648tQeGwOxq1eNBKttsxHOz+VIqr8oA6OD3zQGtyvbyIwQSbngkIJBccv8AWn3ksUlzJM0aCKNlRojzgdOtNCxozIIdozgqR8o9xUiPFYqI5WikjGXGF3K+eze9Iq7GXQiaSRLUFZlGQegaqcayQxqbnLxKTsOefUjFT3MLNDLNbuu1MFQTglfXFLGG8maVkWWQDkjkFcdcdqd9RMrywMNwK7Nxzgjk+1RwJ5Oq/aIowm1drqD19/epLfz49kwJAyXjzzg96bu3kmcNCCQDxnPuKEhStYe77X2FdsRbJY9jVy1ijcJbXTFomBbPfPtVaOP5Z1bGzB2s38Xpj3qR55DCsLrsmj53jqR2pt2YyO58s2a20xEkEZOHfrntWZpE8sb/AGSV9qTHEUhHX2JrXMcEpBlBaNxtZQfutWfFam9tri3DqZLZ8RgDkjsc0tyWXpZCwSONPMvd20SegHpVe5jMcMkl05Rz1ye9P8P3El40ttKojnhOS5OM+4qO8kNxHKoTLgYBPIaqtYVyaW0SaytkSIJIwyHzjJ9azZbcFsTyM7q20qK1buGJ7WyMM7SSBCwUdEPpVOW1uEhW6Do7E/cB5py1FEk8OaNDLr1jFfKkttJKD87cH/ZP1OK6fT9QvyLMTaVZ+cNQe0uoY7RQY1OChHHBH64rD8P2wvb+2tw5jE8gXef4T7e/HFSz6lpOnapLcwaj4hWSf5JnSRAZMcc5pJkyRzGt6RGmp3iSOZZhcSDzBwG+Y8gDpRU11KsskhRpFUMTEX6kZ4yfWinyjOztLlis8bwo6TKAYyvK47g1V81FRYZRtiD5wvVPQ/StLTFMsZuVO+/DBGhBHzg9MCs54U87fFKu8Zb5v+WeP4DWZ0C3LRb9yxFYmIXk9PcH0NRljFOLWU7FLD99kthM8DPt6017wPloQghkbG3rsYc/lTUbyRF9qcGIufNKjLKD1Kj0pAWVgV55LV5YhOu5onZ+HI5wD05HNVmQTNESrJGQV8zGcn0b1pot1Y4KEJCfMEh6quflYVIJygSFgMrJ5kg6Bge4+tMB0IhkJdIyZidrRDkbQM5Bqs6MJ0aN1kYrkbhlXHofcU/aSkMtllSclQe47g/4U9twikLDbGyh0Kj7jeo9RQMrXUR3wmD5XjyJC3f2PpnpVcIGjaSM7GiAJDcbWP8AnFXLmMedHLKzL5rBXZOQDjt71VljkTapg+bcylh0lA9PXt9KQmriKu6Ka5CFYwuGQD7pPUH69ajm2+WoaTaqbQjHrj39sGrVqsjeW0KlreRWDY/i28sCD3A5FJ9mAhhVl84TE+WxPBjGevvTJEvbUgqGf9zNEDmPp14wfwpNm2aJIlJu4R5ikfxDHTH+c09pZF09YGlLYiIVR/Emc/hjqKrJCGECKc+bjyW3dQDzk+tA0RMrJbrM+UhacpwvKMeRkCnlNt5dHAEKth5du5Yzjp9D+maXepkCuvyzkoVB2qr5wGHoO1QPEZ47mIMge2DZUHlxnqPUii5LRXuJdhMcU6q0GAZOeR1C/wBKLplVnjtJ8xtEJnkQcgg8fjk4JFaNjYKwVrm3VrZvlaZmOUYjnK+o6isi+tVhM1oD5glceTIT90huVI7BhzWiVjJuxJJAklpPJH+5YKJHIH3JV6Y9mHOauWlxFdtAzSKJnjXiQYR1/wAQeKzEvJHn+YEkZib+Fin936DpVyCAraRg/MXzLCDnCnP3R+VZlxdyeRbh8/ZnImRvOhk3cFRx/wDW+lX2dUkNwCRFPESNh5V8bTwfc4Pscis6TybW5UEN9jmBWb1ic/dx6rWhIroohjVTmNElOMj1Dn0GODQUQtDEsdt9v+UFQkB2Y2kNgqfz4Y0+7juo7ggxMs6SqkpXrjHHsTwOnekYRPuTbuhO5lYgsS3IAx2B6UqxXEQe0kIZYyoB5GVI5B756c0rBuQOjpeJvAuQ7eZbTSEAHn5h6c98d6VA0JkIULslDRgH5VODlDn9PrUt2BLNt2iMA4dH6Rt/FnHQE4pYE3Wc8dzGxYFWd05ZwuQCv04BNDfQErDnMjTGeQeULhmSXDZHmd8L264z60SxFoUVYzG8RBU4x5g9T6n1pqQn7RDA7RtI8O3eeDJuwVb2P86axYtmQBpowcgnkHsSO/pTTBiS5WZJ4lV/N3EhjuZT/Fx6jsKjMhMlzJC8sqrH5Urc4ZG4yT3PTikT7RJcK0O+LzG+5uGQQOSfT2qby1RGRwy2+8BgpOyIggkEjrmm2CQm5nkQSoJoYiY5cNhnAXnnrjGOnpVvSJY7ZZY7tDNFtZ4wvIbcpAwT3yB+VUrlVZoSI1jSYHYFORHznBx7dB70+KMiCSRH2uSDASRtXaxypHbAyaVgJrvRp44bBozHFvt1LDG7k9GPpmqqwGdIdLlnNta+ZscKwUlc5O7ccdeB9a0oZ5W0OOS2fbHOzxTDqxXAORntx3rCgaeLU0uJrbz1tiCVfglO270x3NEBSLL3Ez6vGpTcYBteNcIofOFwvcnjNXJYnFyInL/aYmEYDNk9yQp6fjS2MqtfaoElE9tJCFeQja3PJ2k9cHBz3AqrFAbu2ku5Jihj2iZd3Lk9HX/ZxwT6mnIS0L0VwWa1unCIIRtLhQS4zg/L3Iz1qtJm5m+zQuEVFVlfo2SflRfQ96bEwtHvLaeEsy7vLTOFd/4c/jyRRBCixGDc32uPcyluFYDuOM7s5BqS+YlS0Edwjxou5iS4lQ/OBySxzkkGpo7mK3gIBQSPG0cqlBuIPOR/PP1qQ7rswQIkKm4IIcygbZCOh9B1/OoIz584mijRGiGxpQM44IOfYjn0xVJ9hETRRPHIH3Bvl8jzMEMc8jPbjmorrYbdrmGNUlJddgOF28EnnnINWLSNYl+yzqjNG+/eOpHfaegBHSomKPJLFhvJnAC8nDOD1OBzgH8adxNXI4pkjnZ7jYF3bXgRyJA2Mgr/ALJ9R9KmiRnt3kXyVEIVkh3ZMinnGB1xmnCKJo5LZgJxuxEykEo44Jz6cZFVLctayRCRt8ZJJwO+cHP/ANbilcEizPIba0RNrhQuYw2OUJ45HTnPFNjWVJTFdHCwpvPlnDlexH5ip5lVJfLLI+1giyk8AdQQO/cGqzeUGddpZog0kG4ZMn+y3t7U0hlnT3nnnRGPmtEm1Q7dQf5mrFu62k8sVzbrckrtKNwDnoc+1VIVW2WK9t0EsKTcrJ1ZscjHXFF5cGGATYIuUO9s8hQTwB+BpDJVNpAjmVhHAq7hk43AfeANUbaZ5VT7MkkazNtSeXoy9hioCk0whmmSOaNnIjgK8qD3NaMsQQJHFICB0XHIb0H0pCKF/HfIwn3Qhjj5AvT3PpVy2k82z2XcLSR7ucH7nHb8aY6NHEZN24ythpCepqo8oimgimWRV+Y59c+nrVrTUlouG8tiphUmZ0AAOME//Xp9uqGFpPMUvuB9/oKzZo98BhkZlYNlCvDfWpLVXs5xHcSB7Zx8km35ge360ctwcraGjvWKZpVBERPzIwz1psiiKUFAiRLyWQdc+tVJblHl3Ox39HA4GPX60+AyOvkcqpJ5XqV9TQtB7kt9sd3K+X8qD5143VWN6uYhCDGApDAjORQyM8JQAMIzgsamX7PaWwYMrPIMBPSjmbYuUclubW9XD4tJE3cnJWpL+WEuPIbepAAz1B70IvmRRtMN7Dkr6CkvIlafbBgDblFUdfahsLWNDQrRJdTszcI5h85WZVB/MY56+lXNVudekuyZvC9m8pcjJsS/GeuQeaq6fJaS2azXGqy6dcQt/qhEW6d8imeTZXd408XjG8UKMFRHIAv60WsZvVnNXX2lLp1ukRFMhLJtwEOegHbFFXp7VrjzJFna4G5gHbjfz1P160UuYvlNmNJIrc3CEsYQDvRuWTPGPemXY+0PbtIEL7CV2cbxzyff1qeK38uOKWyZWDAKwzwtRS7ESQRKGU/MQwx5b+lBoNaAib5E2/uw0sanqD3X1+lQWqbZEgOZLgH/AEdwMhl7g1akW2eFZY5WjiXGBg5jbvg96itCrsGnby2ZSiSKcAN1H0qRorWjOJxBMPMiycNnoD0BPpmpJNgYwxfK5IUN1KMOq/SnSKoi3ICs7HbMm7Gcj/JqMyt9otBdgTJ5IQOowVPbPqRSGSu3+jkNhMjcQBjZJntUkRmeJEjkWGaFXypPBXHO33NVZJN0WXVwpwkgHOTnqaaDOt2Qp/exp8uf4gen6UwuOiXyUWAykjeCrkZKHHy/h2NPnM1vqID/ALxMCUryFjJHLD0qa4fabZDGPMjJR2bgJnoP8DVW3BW8wWZV5WMk5yMZ2HPvQA1HC3FvEcR72Ksd3Gc8N9MHFNt4p42aNiVkQs0WRjDA4OB6EVGy+dEYwfmfMcbY6NnkH6U6yQmIC4bzZo4yEyfmODyDSCxFIrZjUYE+TjcucAnlfoKeZCsOwhAxPk8DGO4b24qVY8zqI3Rd0oX1w+MnNQzAf8th+6cHeq8HJIBz6+tArEM8L3bLvwjocsP72eBgUjBSRMrbnXG7IwBg/qD0psrkKivulaL5WC8bSPut9DU0ZRWjuGbcD8jFuNpHTJHYVRLLlkYBHbTMufLLP5Rc77lc9B7qM4z1rM1YWwtbmKIebHJL5ls7dGHVufYVI8wtLm4RdpEjZR4x94H+Ie3es+8djuWKUlA22Nz/AHSeijtzzmrT0Mmio0iShWEL5iVlaTODLuPX6/4VoWg8lBGykJIBuZv+WbH7pX6/1qlLB5g3REokxVCm7IDqpzz6VdIVNPWCVne6Ubdq87+/J9RxSuhxdie5ge5juvObOAEmJxhXzweOo7fjVyIzQL5QjVkifyp8NyVxxk+nT8aoxoqxR7n3brfccfxDP9MkmrMybrSZJWYlYw2xDkTDPykY6DHOfaoe5oiVF/dxhmRWkJRvQKed34YqRZImt42naRJGfDEc7kxjGOxxzUdytkIAsZkJBw8h4AB7AfUg/nUYUNDhkV5S7LK+clTgBRSYD5maGVlikEoRSikLnKkcgj1xUrS+SjNEsongw0RLZxGQQQ3vjv6VGqsI7gquZIiqqpJ3Bc9Vx1B6HsKS5gDQeVbEpIGCpt4Cr0IJ78/pUlCggrFDIxKowaPHU8ccj07VKgW9lXIEBRecnCrzweO2etMtU/0NH3oNijy3fnIHVR6nP6GpraQOBcR7IiB0b7oZei4PYjP41SBkKwLcXESeaHlmJf5uNpHRGx6nvT5XM8EqTRiN1KpJHGpABzjcx6ceneoDKZ73flj52GYpjzAV5OAOAf8ACrMUQuTPcM26KEBbtN53uWP3gvcHAPPSh7CRBcSskb2xPmNavIFAHBJwN2RQbSRbBru5+WSIDehG3BbgKeMkN2NWhGFiVboZkUOjuOpbg7R26AEVCwnkeJplbfAmJUi4IhYZ3Drz157VSE9y3JdyXesoUAWF4xiMAFlCjGDjgtgfliqGtW/nfapfMjcn5iWY42kDbH7n9BVnTj5V+ssUhijeUJuYBmhGfkyO+e9TwyBLa5aQvIUZlCiLKRqT9/P144/CjYHqZDxSTR2isu15GRgxX5TEoOAfXvxVx44pLRJbiZleSRIobdyciM5Ik9AB0GeOajmQvJKVBkiQb42RSB0ywGewOcmrTSQ3dvZQGKONVhEPQIzSO2OT6Drz0BNK9xWKupr5MEW0MwgnyQ53HDZK/jx16elTSXMkyC3kbcJCJ45X6qSMEZHXjnAp15G0tuLcK+6zymY2AJQNkOwA5A9arWpYBYljeO6UCSI4xk47eo64obuxouWTxT3T24SOKaVNwaU/KjKDjn0bGce9NWGC2+yXW0yRsAZF9uRnjkDPFOie1NlG6qfPwfMA5yPTP1qsqxx3LxYEhlUGPLHbyO9BW45oFSzkki3NIrBoweC+TjjscHt6VLqMkeov5qPIszqrBY3ziUAAkEYwD6DpRp11IqRxxlGkteV3HgrznjvkGo3EN1qHkQq22V/kcAKR16dhmn5iElHnlCwCq5y0akbhJj27Ultt8uNmLNKThiegUelOtZIBDd28t19nR8MQADvbsAaRmWYecGbypCI8ZAyQMDr29aVhXIb5BE6EBRHjy5EkOCc/xKOympbqWH7C0QgKSQkFHP8ACOuCe5qtJqLTxzWdw8RVQsZMah3JX7pzTIo5pFaaSIyRq3SVs498emaadiXcs6dNA00u5wFugV3ty8begHbPFQJCTqEcbBnitR5kyscAkHHXv64qGKwWC4YtG7SOQWA9Ryce9S3cyPcyzj5IdoVVdeduevHU01sF9TTN2IpWjgO6IK3k7xjIPXP+FZ8k9w0e+GJ0gckKOmG74/Ck05Eu4/tUm5gHMcC46Dsx+tTTzSCPNw4W2zhyh5U+v0ouNlWeY214rvBvhIyqxt14/nWd+9nulczOqhSUGPzFaUEf22SQTKWjEbMoztAPZhVeLZC6vuUMy48oDgeppvbQm/cc262i86ZjcSMuxN3YH0qEzXS+WhCTN05bGPepd0TqjcsoO7aP4TVmJHZWnEaKkY+8eflPeqWq0JaKAvCjebNGQ5BD8cCrFveciUAKe2e4oeWNGlJZJUmGAWG0J74qhA5ScMrgy5IJI+XaabQuazsbfmo9vutwX3Dc4Has0SwRz+cyeYpXDIwwAfWr9nKtvNEsHzZ5KjofanxgNJvKLtZ8hey1kaENhcCXEaspdOSV7itC4a2s5lfcHBUPuJxj2qjq4tjcG4iAtpCBuCcA4qunlySkmJ+BuXPOaYGzJoWp69Cl1YQBbRwQXDqpJ/E1YtfCGq28S+XZI5YbWJmTk/nUGlRx6he2dgBKIZiFcg/dHU49607R/DQTTpZ9Pvo7S8uXtFzOTsYYwWA7HI+lWlczk2mc1OstlJKZDsCMVZB83I4NFQ6lMI9SliuR9lSKZ4vLPOAGx17/AFoqR3Ogmh8mKKa0dgjAgpjhX/u/Q1JGWuGdpD5FzGN2zHb+v1pk0ssiTlDmyyhZF7Y4yPenOkfzTxyeaIyAh7svt9Kk2K6zi2uobdvmtpBukU9FNPkgWKOU7R5W7bnPI7Z+nvUzzlv3xVZd0gk2kenB/wD1Uy8AWdg6gRjGxCc8HnZSZSIY4UngaAGITAlBK7cOoHIz61DAh8nLSAyqokUAcFV9felkEclvMoUJExDg91IPTFMvyfOMbhS20eY6D7p7Ee3rSASaOWHzHRsYcfIe4PJBpAsdzM8kbGMxv8xb+Eds0ruZVaQc71O4HnOOA31qCMSxksOBjfJt5z7f1oBIfPcSkGTy1ZpFzIo6Y9SP5UiMnnSO67omIXGck8feqQR4lBGxcp8nO4SHGcH60kluwcL5ew26DCH7xB5/Q0wEtshA7KwDnarDjDjow/rTNq3UwkZlEjNsY44Dgc/nT5pQLYSSl5GmlZmH8PbgehpGRRcS7Jv3UrLtcdic4P8ASkA29PkjzYFJLKHlVuccYyPpTrwL9rWdWWRHVWYleFOO9JK7EucmMpmJ1A4wT2/Go55TarLEhLWzAMV47fd/HNDC4+OyaS5HUs0boDwdwHNMGJoF8onaYwZI+BufdjAH4j3p0lvKrQhHQtGpcMGzhTyc5/lVadUyX3MVm+dlzgqR1+mDg0ITsSTSxtdRRbChj34UHOweh/H9Kqqh3zyshO1vKmAHEan/AOvzVi9T/TJLgwsyywjec9DjG7657VWaZ0idmYqZQEnL8F1/vfUVb2M7EMi7TJC4UySSfeIwoPG1v8RSuXRZhMADMTvbH3HB7e56U6P9w8Ku6yQJkKAeFDDG78D6+tKjGQqbiQFrdlTZjrg9R6nikBatiTdRebH5YfKYA4DYwR9OmaQs5ihKFQbWMxttAAwW+Ucds8c02B5ZZbkTqxiLbgMclfTPY4GfepDgTqzsc4WN9o4YE53e+OKRa2LUkkQ1ES3cLiGebBWMZAxjcFPfmkaUiK4DqgMS5YY5fn+fT8qVozIBCuJGt3JAxwykfoe+ackiNbAKSksYYTHtsPzBxn3AHFICKSX7PKru0ckiKrEFTh0bkg+w6VO4MGyYRebGrl9p/iToTgdOv51FazJIkyOmzyWHlfLncB2z1x8x/P2qaf8AchiwJaVSY3J5Y8bhj8D170WGmOnDhBLcytJZli2doBGPuE449iBVZp4jOMGSSXYVljVerDPK8evSh1M6Os+UZfnbe2Qrj+Lb3XGM1OrSJLCP3aSwAlJD2BIxn19PoaYhhghiktvLL7Jo2kVonBdW7bvTOKfG+/zryOANJHkMgBA24wenXGKqMj3k0wjHlLJJ5jADIjC9ST6ZI6etW7LUg0t1AzKsqE+aQDhux2/UY5pAPhZo5jCHW4E6gAopYliMqPY89qZO8ilmH+viGFjReJIwMNnHcD9aknAMhtoAESF/MjYPuIBxgsw9OgA55qpGzTXkYUgNI4MZcjiQY3Z+vHWmIdbSWz2YSKVjEQY2Ro+euQ3OOc8ZqwkryswuSQUXZIEYAyR8YwBxn3+tRyF3eGaaGPyZt+QnXOcEHuuTUF75q7Yra3Z548szOflwMDDe4yPzoYFxPKiSYASGOBuGQ8GNuGzx1Pb0xUOolY5GjgZniK/LIxwxJx82OwxxzTxaahHpRvWvUSVy0MkUagIjgcBgckkjNVxFJp0sglHnOkW0NIvLKw444IoA0oJTcaZbuAxmZHjmEK42oW5Yt3Ax0PrVWd47i2iXO+4iYjAGQFGec98/pVaHUXsbySx1SFcHHmhwRk4yG9jz+OKedksipDHMzEh4jIowxwMj0xnJPtVWFcW2VY42cRofs378gnGVPBX3OecVHNE0jGJ8EN+8Vl4KDso/Gp9KbzRPZupMjHKNwAMZ6N35qEmSOQm3HmTWx3Zj/hQdTzwR+tSUXdKbz7CZxGN9sMNt4LKe49waolmaKS2aTbbwMZA4Tb5hJ5P4E4q9ctb28EckUj+aVUtHvHzoepz61Sv4kSJbUXSTR2p8wyRjCsrc8Huwz39KfSwiuxzCYbKJfPJIMzjO36D075qnHHcXEpS8WGQqpb5pCASOpUY4z71fmJhn3yxv5ceFkkwTuzzuHvip7hXEXmRvGs7RhkZF5Ceh9TQ0BUhk+y2YEdptn3EMVcYdTgjAxT7iWWdmlSE56siMPmXuMVLPKQiTI58wIEZmPDKff2qZ4ZFYvBgROoKJ13diF9qH5AQG4R7QSTu9vE4YQ7hjJHBOao6he+VmC2kttz2wVm3Ahhnkgnoa05Io3EMfCWk5L7SMBPXiqeqWUNzZedJCHkhyTgcso9vpTT0FKIW93HZq2nRq/wA0fyg/xHtyOoptzFNPFFJcJiPIDCPgYHHSm219DNbphsuVHkIpAORwFqyJmit45jCGUHa0TH5h60xDkh8ndnDMpyGzwyj+VVdWTdNCxMYif5yQckVUMl5ezTpCogCKWXzmwGHoPWnCC7ksU2yQfMuF4Ix7U1YhkkTStE8ShQqjGcfeBp80jW0KRR/NHJjC4yT7ZrOs71o5yk6YliAibac7vQ4q3cysjRiB1WSM52jnn1pxC6ZDZSbtXWO4AU795zzjHQVp3AubWWdZooClw3mBjgce1Ylytza3bXilH3DJA5znvS6zrP8AaMUUIjWOSAYbb3qr6EdS5ZOLiVhvPl5+UjitOORY1MbHY5bgdiPWsqySWC1G8Eyp90r0x6VM0pklUF1MYBye4qJRLUi7KiPA8rhTMo2+xqC1uJJI5AybJo/4+mR6Ckshl4pcALGDndzu96keMMclfnLZD+1TsXYtaZbTf2xavYu4vJHVosH+LNddZzzNrNxAG0l/Ml82IOv7rzwMDy8d/rxXLaTPcW2rQXkULS7JQsfyEhyOqjHfFb89lYWNzFdrYa467/NjtfJ+TcDkAv1xmrWxMrdTlr55Fu7lr2JHm3t5pYc5zzRTdVla7urh5wRNI7Ox6ck8iip52VymxL5pcvACjSrkqFwrnvipA0SfZfLk2xyHKnPMZ7g1M12xWK2nb91B88co+97Y/rVSJC8iMkMcjRljKBwDUmiHO/ktK6xqgcsuB/D7gVTBMUdwzwlkDY3d0OOPwqZY5oHR1In81SUz6Z5FQwZQ+ZjfEwZcdvfIpMYRARW80u4MCq5jPO/PcfSkhlDQLdhMuqkTA9CvTNSu5hiht2ZPNUbonHYHsagmC/YZojlJVkwE9VPWgBLWEgw+buFuWyh6fL60wPtMjDBZWIOeN6dx9absEFtEjuzKR8hP8PPSn3cIgtminb/SGYM5U52qRwfrQK4KNimIgvGp3hgMfKR2+lWraV2dDP8AvFMgAAOPMUDGM1Hbx+WgimwWSJQnPLg9fwqEOxigQFg6Skt6L6c0hCPvUbZMrbtKdobtzwf6UiRmRXR0KxEgnbwEc9KasUskzRMcrIdxDngH0+hp4PyO5L7MLleyc/zFMdx4XN2/mTL5qoffOz/GlIW5nMgKsro0hEhwMd1J9fSmXc0UDfIjuI3IVnXmTjofeoLfdE8i7keJsk9s8Z/MZpAtSeKN7Ywx3TMhU7nkIztQj5XA9B6VWm8sKrNJhXdkLAdCDkH8elPnuNs8MhBdIwOGOd0ZHU+9JeDyoXiXa7H5iw6bTgjB9RQJizFPtV1Hh4oTIoAzu25X17/TtUc/zRRRPFlgSGUDJdD1JPtTxAJo4mClNrqZcc9c8kU+3lMiSh9qXkUedw6yA9Dk9BjimKxRNuNrbRny18tmHOAfu/T0zTkiVZY3K/vUX7p/ukYP1ParGxYEjZVLKdyuAfvxjrn3HbNQShIriUq5aJGLI27LGP696TYWLsXMrRqzFlG5B/z0wBgn8Miomb7gXA8190Z6c45Qe1KMF8AJ5ZVpICBywI4Hv0/nQVBBn8uPyMbdqKR5bY7E96SHcdbyG3iC+YrNBmMgjBwR69+vT2qWOF4oZGlIlkgCKyuOXVh0x6CooXF7ZCQrnziIXjJ24IYHLfypYp4l3SThmkSQwk5/gxx/Tn2pgSW8SSKYg6eedmWkOF4Ukc/TioVu2hhJlVTHI6lWZfnQjnAPYHJyKeEnjtCW3Rtb/vIiON5zjP0Bx+dMmTzgryq+CCzluS0p+99KYE0tr/pJUt5yqcb158xM8kDvj+lLHbrPeLbTymOJcqHPIeMnoAOpHBxUPnGEylcCYLkcYLJ0x+VMCF4zOZGV7cb0DfKpX+pPt6UdQ0LryPG7ScLtX7PNkBTKAccf3eKZdFEuYPKVROYiPNU8jn5PYcDFKJFgVXuEi2lT5kb/ADkEn7x9+QR7VCx84mPMa+e5dHYhVVs9x6YHFIBouJPsULRB90O5dwAVY+7DI6596fDA8vkxx+WDcMCcYAQjOBuPb1NV7meQTrci3WOEgkDORyQB+IPf3pb6SPEtu03EbAxZXOOeVH0piJUkkjiEYdBbXDMWPK4cY43dTjAxVqxkig1APNbyJbOVhm8xyoLd1YjnB64qgbtJsvJJDCSuNhTAiI/i6ewzir0amewa8uJ1MN42yUNnzPMB++f7oz6U0hMVGhY3EDhUY9Ty25c/IVA6kevvTArXaCO6TM8cnlzMSAdvB3MfXI4qKItAu6zMqX0AIyeAVxjKE+o5xUcRgtTC0ZeZ33NIudpI6nJ7mgVzQ1C4N8iJdiNgn7uaUINxbPyjJ9OD9DWXBNK4K3GWlhGY8EBMZxn3zyKkubhpriRVKPHJGIxJIMiNQfvfh0yaluNiWiSwReXNEgiIU58xgcsT6Dbg8U2CGRmJIvJ+dgQJEYkLhv4himSu5kSeZ0iWNTE6quNyg849cdzTJNxilnhwSp8whedgGMNntWg5tJY4JI9zLIuJVlGQrHgH3pWLRBFs3GNhH5YLGKUjg4GcH19hS2SQR3ojkglePyDIFI5JI+8fao7mLyvIRlbYz5jEh25YcDJ7CkAu0u02fvhFuVwh/hJwee60ge4+23+TPG7s4crEytyUXs30xxT7MyeU8cEivLFlkyAMDp178dql1WZpFSaICRMKhAHysByFz7UtzIsIhSIpJKiAq4XDc8sp9xTuIgtkjuH2+R+6lchA/wDAw+8R9cU4X9udMEUQcXdqzI83UGMn07EetVbe4hlmeeSRhZrIVUg4Ide5+opwZRZNJKdkoZpApXAZWOeT60XFa7HRXMbI6v8ANbzJsHbaeoGfrVuWe4RYJIViZYY/KkbaM8+3ce9YE6yXCMdNEi3BcNjHBTHI5/izT7KffEI5o5DG58ssZMFSD1NEU7ibuVLhE04T3VrHvgVg4Y8Mjd9tP0+8h1OaK8mnLh/lOxvun1b2NW9TeDMhkaIwOuyYcFUcdCPrWDNp0E8Motw8Vx8gRojyw9wKtoi7OmvpNxeGIo/kgbW4Py9wKzJLm3VfLilPmg/L6qfTFQWNlZoht7qCSSXkrKzED8RWpDFb27bLYBIZuXGPun2NIpFJ7Dzl+1RBku1G5i3BJ9Kft3LazeUxCDMqYwdvc1qrH5ZYSg4Tlto6jsaZNFDmXYcucFWBwNvcH3qou2jE0ZspRjLHHgJjfGTzk9hVC3hYmYpHunLZLFeDU/kvDdSwS7oiv7xSw+8PSrkQ2h41YhgNykUJ23FoyF55oI0ZkLxkfMo6j8e1ZdpIs6XDRyuLjklO2PrWjBJLKJcNiLIWQnrSahZQWsWSQgzhccEGi9yeW2pNYR3v2VLiVtuwbNnoD3q55kmNs2SMfKR2rPtLiUwGZXEkhUAoTxgVakkmu3wiiNQMj6+lS0aRkXdGe5ur6ysBdXNu5uMxmHkoTxvA9cd66VNQiur9dMXxlqXnbtiP5OFZvQNn1riodUudM1K0vYIs3MbgIhGc9sY756V2FnpwW6F+PDEsN7H++WF71HVG658sfPx6GmvImTRk6ppht1jvYLt7u2eV4pGlj2SRyjqGHv1zRWbq+uGXTbawVGGZnnuLjdkzSN3x2A9KKhrUpS7m5L8xeMYBz8w6Zb1HtVVp5YZkLFmUsfMUe1SZ3O1tNkSRAeU3cn0NSqwkuVNyAGOTIfYdhQaCM6OWf94YkfOB1UH0pq25mkTy3CnJ2Z6OO5+tPl8u31BvsrskLkhCeu0jgGq9q0nlNsA2E/I2f9WaQ9UMCR7QrKCZOVYnlMdqVhJtkVnD3CsGQ456d6kEoaX7UqoYiSOT95sc8dqiLlyBIQMqArf4+9AxLxmluGWVVXzSATj7p9vTNM2yPKUdw0kZOGY8up7GnFvnZ5PmjB2Px6d/rUHzMGDfwNlWA6j0pE6DwxSYLE7O0SYRx0weqmojMu4RwtmM5Jz1x3U1YKMZBEnl/aGAZT0BI5/OqkJhNzHLtIjLncc8K4z396ALdwrTbInkLCSAKrp7crn3FV082ZndifP3BJB65PQ/XFSSqY8BW3CRQVbOdjHsfTpT79yxEgbzJd/JUY3js1AEVwyXMu5RI0cchIC+h6/THrSlVe13D5Sjs0b9nUDoaUysXeNcMS4ZDjh8jDAn6VA0StuVkI/5aKg5yehX+tACwqx2ybiw8ttqEZ3DPIFOhMhjRZWXy0PmBTzlTwQaEaRDIqDJ3FkKjlc9Vx2xUluyRo4j3YCnGSOwOQfY9hTAZLutp2YSF3XMbY4DLjKn8ulPcRNcpOp/d7VCknk8YIPvxUc7N5ojchnkURrtHGM5U/XtSSRtbTGK4wh8xdwHzBXxn8KTAfKPNg8wF/s4+bHQheM/jVeyllFtFbvAru8oKk9WByOv9KmtwI4YEEZIn3OUc8EqTx+IolZfJjcOVVSqiQD5lGCQceoNCAmU+XCnIZmV1jZh90deP89eKI5hMYz5exHYeap4Ac/d+nvUDxzfaJY5FG50+VmPCk4JP6VOEdlmk3iNrmIDD5w7DGenf0oAbHKsbrbtEWjZtkir0Zgcj/DNDMfN8kwDzo5XEkbckkr3I6/0xSBvLR96qu8iORmznkYGPboaegZrgyRqxEZYSKmTwOCxPr3pbDYltI0VmkUjs5gUg78nfGey/jnP0qKFVMLFs5SMsBuJCvxtJ9cg9B3pHeSeQEKxKxEIG6Fc52e5I7VZh+/F5khiknKwM7J9xgMjaOoOcCqEF9Gz+TJOPKfYZQxG4nBwFA7DGRUbfLEpkOI5CEZjxweRjPUe9GrXRLR+aB/rJFdw25mJ4IY+uQfwNPF6Ly323LoxjtzFHIxPQdvr2zRa4rkVqjvdMnnCPCODJKwwyY7E9+mKZbrGLNCD5jqShwc8D7rD15PNRW7GRGkYnMYVCpHzMnOM+ufXtirKRJbyACI+TC+2QjnIIBHT0/WnawEbR8qzD5mwJI/u7cdQc+ppbaNNRgWMhY5YMq2Dglv7xJ+8e1ST7WtJbiKSVySI2DgnzT/eHoR1p0amJI36R48iUoQzFcA7/wBetIVypdqFMavsBLBZEI+8w7k9MH+lONxBAxjjCSwuzeXvYg59u45598Usik30NrkqAf3ajGQG7Fu/rVABbdLhck3yFIoGThTyctv64HariQ3YnuNRdJlFx81ww8p0ZiA/oR3x3qcLGqW727k3EkeER+fmH3h+Pas+PSzLE/l3e+4BzLuyWz2x3NV7LUJvJ+wmFPtG7LSyDJCg5znseo/GqaM1LU6HTmD2byIyO0ZEoBOFI/u47ntTZfNmu3uIQz/Lvkwm0AA8hfqKqWrRBEa3+5Kf3anPBzyMfyqS1nKyASxb0tSWCscD8ajyNU0XrUtEskkUQbBwFU8eVzg49snmo1GyVYWZQkrY3KdxwPakw8Fk8SOXhHzJJ/C6twQO/XNEUDz2+PMxJnaqBRuLKOpPpjvS8ixzI4hkSeN5Sn3+gbafukdahildUheQFUVtkrYxv5yAcU8yF/KdiWSLHmkNzjOMCp3tfMgnYbYlEZcgnJYDtjsR2NKwETtIkUsKkGB5AOGwEc9CajuGmadriNBEqBXCoen8NRS2SSlp55JdyACVVbBPGF//AF1JaWQSXfIf31u25i75yvoB3PfPtTAo6Bcpdw6nbGRobUsWBMYJkO7jPoAa1hELuNHCBntvlMKrkD3J7561nQyJE6ApvjXc7AZG+NmyM46Y4NaFtdeQbncXNs4Gxo/kJI5Bb2609iWZVxqBsEEsaFgj5VfXPXpVeezkls47pmkUMCWwuEYseAPUjNPtJidWtWeRY0dmYo4yoIHce9Wb1dpbc84gR2UBE+7nvjoM04kyKmiaZb6hG0EcSfbEUrKJD8rn1HbpTZVuNPn2W0SRS24KsUxhx6VpWttA0Nu5kSOVlYtxwhXoD65qrq10966XssMNmgl8uSFE2tgj72PTjrVWsiUyqkcssSXWnXHmGIklWGQoPtVu+WS2tbfUGSJoGbMhib5o+eSVpixPbzE2EbwRXHDRtyGx6Go5FYR3cHlF0KjaQOMd6luxVjXiugSs0TCViMggcMnofpS3qiGIQxne02GhIXG5vasNpH0oQ3lq2bUgK2P4QepxW46x+YixTrcwld8LochCf61JRhakLjUJUNw5+0qdrD0AqO+tpYrTz7EyAqpyxPHvmte6t22vxiVeWB6k1TjBRpPPhlaJ1/hGQD6U1oK1ytZ3MEduDASEnT96M5z71NqFxDPbiMsxJxtzxxVezWK2f91FIyscgFcfhUk1jLq106xRlGUfLk9Kq6Ia0G6b5UErSM5Ebn5Wz19am1C+hiIa1wEY/OBzgfWq1tp7WbtbX8irIj/Ieo20XliTICmBDIDwnei40zR0a5t9P8SWF9ds0sKSK5IGSi+oHt1rdsNJjt9XTUX1nT2topvPF3HPmVwDnGz72T0xXGwaHdyX8cttbX0tkfkLrGzgH04Fb/hrSL+LWrEPp94ipcISxt22kbu/FBJHdTW13ql5JEgEFzIzKhHKZOeKKd4ltov7WvJbeQhTcyArjG07zRSKRqXMKHa8beYGO6NycdOxoWQzSLMoCuVwU7fhTZI3D7wcw4yWHKgmmA7REckPG23PYr71JsSgbYdhwyyrjOeVI6CpWY/YoRMu14eqrxuT196r2sfnB3kXacMAF7fWpfNaaNEOC8CsvmeopBcgniFvFA8RASQb1bscdsVEk0c0kyBAysNy542sP89KkTDhCwPluh2ktgI/rVZQygxSt1w3AyQT3z70ABkZJ4vMIfcCDxxnrUsbN5EcAj+bzA8Tk4z60kifeYghw/zAjgr7UkUqT74RlPKUMD1b8PakOxYbcLC8nQrlJgr47HB6VS+yyLczPJgpIinGOjY4J+tTQxs5KuA8pfcwPAYY5FDyDidh+7UHagPUDtQIW4kLROi8RORyBjy3Pb86ert9oiYIAysYpwndFX+H3zVcqOCCZY5eXGP1FN3CNyyH54ZCrYz82R1FADxGMYVilp54YOegJHH5090dbRDGNsqkzbT2P+e1JFDmGNJ5AFlUp/u55/8A1U15i8a4dRLDlvVQv9c4oY7WFzIbfzplYJct5iOCPv46flUDgXIM0IZXZS7Lnoe/04pQIDPNGhkSBmWTHXGRkjPvUrlkuAy4Eip90LgEDocfT+VAiG9i81JPJdkYBZIQABvAwSPY5qW4nEsLy/x3ILfKoA2nA3D3zQUCKZNjtFKSyP2cjkqB74pQy+d5LxgQ795iY9GAz27c/hQAqQbbxIZZBFCy8NjcFcDoP8aR94cl/lEnUsNpx04+vrSxBjHtlkCYiLZY/eUj+H6YoG6WEGRstDCuUIySmcgAe9A0xhTCLEzFWI8rBH8PUEY/LNJbTtDbmO4bcu13R+eB6/UHFOcPcII22iUgYIboo5Az2xSEo4WVtiyINyqc4bHWMf7R65prUNmT3cMiq37tYJbdF8zfydxOQc/rQo+yalLh2W2nX5kQkF+OcfUVVfBlVXlZoQSjlfmwh5GCfr+lS5mZNm3fcqvBY7vlU5/DA/SluDHCTEtt5bNmJmePHRcA8H9KfDG9xYy3MoKxTlhLKACUfGVx3Hoao3CMFRpDiKQeeqjj5gcMAO39abbeam+OWYqrnzASmSw5JAHuDTRDZPrEMY8NLCy4nG2Q88hwckYHrxWPEj20zm73nIDLGTgFOvT8K1Lf/Sd8cwDStsKJHwEU8lmP+yKqXUclxKTdSbGtkECOOdxDcc+mDVJEs1blfLnmlSCRLh0VoYF5zGRxz2I61XsrlDGrvvPlKEmUscKc/fI9MkU5oVRMRyPAIwCpdyWkPQ49z79KqagVFs0qKkGyNYxGn3pjnGT6j+tO1ybsulisxhjIlBIfBXAL/wCFSWkpiu2tkMktnc9Djbu45H4HNUEvAxsjGd05YnnuAMZx6/8A66nSI3Nq7CUJaRSEqx67u2B6nilyspMQpHcCVWb94QUjMZwFZB1Yn2otzI4fUUC+ZDshiDAbB8pyMd+/NQRB2keBgI+AeSFCOOpYd8g4p1lcQw6oRL5G7kxq+QIyRt3kd19B61aWpMtjT8HNbR219daqVjhlxEJHxncBkDPUVzc/l3Gqm4gk4M+Y328P7Y9Ku2EBiuil7bm7hWXyfsq/K1wTyhz/AAqM5qa1ZLfUNQtdQhhN9tEUGz5ijqMLtI4J9e1W9jIbdh2jnMkTwyxyeYkanAiXOSPU8nj60yecQxwOshXcodXYYw2e/rU19PczzyT3iQwzxAJIuOmB/Cvcn1qnHa75Ve4DOijcBIeSvr+FRJWNImpHJvVwrlYpBlxkZLdTz25weKbHcJJLCsaebK5KuqttwQedx9x2FVVUQOMyBdiNgg9CemKk06zSWwmkd2HlYaOIfw5POfTNQ0apjZHufJXzpRGjSMSQmcFfun39Kmthd21ukMrrNIx3KAuNwPUU6YfbZwkxMcbJuV1XgleAqj0NV9Qc3bxBJDGE2oVYlipzyVPvSC3UmYCcwmNSzoC+F583BzjHtToLxbfUoLl1aS3lG35hyeeuO2OlTwywvNIYA8MW0rCuAW68rn0qPTSiQPbSqgXezFypJUE44+nWhC3KySSidHeKU2rF1YMcHaW4J74qSS4k3EFkuYoR5QHqn09KpRGT+0TYhvNBYqhDcOp6frVu3Z4oJZFjjYxho5gOu0nHT2oe4iOaFLkpvTcyJu8wNjcP4T+FTiUtcFZyZIvLKSIp5wF4Y9uKreekbGISgqoGC3LNGfSmBjdJLEgI2PwzDB2dh9KpaAyrb3DQmIyE+eVDZwG47N9atXSCdmeUyGFzjI+bPHPP9KwtWRrW8IiLOzt/rWztYdlxUumalfgYjlcKMsFcgoWHBAHrTW9iLm9bzyQQQxnMksOCsh7L/u02/mDWzSRtkK3mEsduMnoKda6lDPIk/mMzYCshGSQOo+lV9R2PDPJANscjYMYOdp9qlopMuyHdEUWNGhYiQKRxgdRUPNuyHIQg/LgY2fhVlFzaLMjMGiI4YcH2poIZmWaNCwXaWY5IyetGxRbtbhpLcTxGN3XKvuHOPWmREoJV25juMYwfuGs9Fl0zWlSUqVYhgzN8uPWrgnDTGH5FEkm5SW4znt7UgTF2LJFJA67mj6OO3uKLeMfOVZY541+UseGHekLvaSmVdhblXAOQPenQxwSwv5rr5i/MnzfeFCDQiv7GISgXChty4ypPOe+az5JZLONIJk8xcjy5R2A7GtWGcXkLxStiZPuDt+dVbob4lVVBZTuJPYjtVCsWoL69Fpssb64hjcl2jhcrtPrVWLXdYj3BtWvi6txmY9K29G0Wx1W1uLr+0DZzRoXkjSIsdo7jB596yJtB0hUM0Pidt2ejWLNgfnT1IdkROWluX35kMvzHJ6nuTRSQ7RA6qxkKE7ZMY3DPXHbPpRSKSNKLdbBo1LNGRuCnvUMmS26NyY1Ifd6Z7GpLUuqTJu+QMDESOenT6VNLIkitujGGA80AYwc9qk1FWQmQMp/fDO8dmWqc7ER/6Od3zbx6+4NPWVYZ43wAjkrnsMdvekw7MTGM+cTgL13duKQCrOYpIhICsbjJwM4qFgpEm3jaRjuWUVKznZvR8sow4I79wKjuirk3FmjJKQMR44JHU00Ap+WREJLpjeDn7ue5owqw+bEP9IXIYj+6TToys0c0aFVPlhsv8v1X3qOKRmG6NSYyv7wHoR2NLYCeFpNxKkrJ/wAsPfsc1ULGGR02kwkHr0Bz1FNvFlW6j8hwFWTaEB3ZX69qslUNtHMsWAVYPubIGTjIFFtAW4rRLZTAMBI7Krp8+0Ddy2fw7UxnMShEbMSOR5hH3gc0plCxTJJGZCNqxyN0IHb60tzAjqwlciQYkKHuxIAxSAjhA8ny2ZjwFUeh9/enQwyBo1kBDRZG1Rzg8hj7U63YmVvPVdgJDANyXApsMxXbJnzSMFs8bsjFOwXuNkQJGXQR5woUeo6hjU82+7d7kbxOv3kAG3G319+eKSSLylAblthLZGCUIxj6ZFRXCeZL5tqX2MgK/LtwV6AjoD70kA0h2jfLfuoTvTr8vsPc01Ejne227fMmZsfNgIc8s1OlJMayBtscnDBuT6lh7U9t6TTZYSRqnlu8a4I3AFdtMbI1YK+9mDyBhksOBjO7A9DRcy3Nl5c0y4ECBFII3bHOV+uQfwqYOQA8UhygCSR46nq4Hr2/OmvBGpkklDtbo6BhkFgrdMfjxj0pLUTJMKImcL5UcRGxF5yp689T/wDXp08TyecP3aJlUfAyYz6+wIqCeOSAM0wLQlyBzldmc8Huc4pJC0bSuQpVcRORzk9dw/SmtBD7lpLldxVRtUW77xjocbjjpxUJi2Wsu4srxFgG9S3TP4DGKkluUeW4eM7Y5JSHVuhBGQc+tR+U3kSsC27bgtnkr/Dj3z3pdRvYszRrcQsIAhYshZWUbvNHX/gJH51XvJW8mSWP5YpB5qsR8+9ONq+nB5pxnE87zwxmHdjdCG4ZQMHn1zUKXKpGHUbY5AYsdcAnr/Q1RIQXCxXLXKAJHIM8E8Anr+GBRptxb/a54bxJHcRs0KBcfvsEgk+3FEEwW5LAyeRGSjrgZ2dB+HNNcRtYCMEGRFbc3Jyh5DD06YNCJehYg1DzFLmIHzPkDMeEfHOPXms0W7XCxzsJIoLMkTTuchWZjtCj6062MjSwTsI0i3HKnhU49O2aI7i5YRWVtvl3SKQvQE7c7/qMd6qO5MndDLOzluDbwAvGz5kUyrjJwefXkfzq94S2CV9PuUi2zJ5kbzE7UdQeDj1H610euqIdKm1rUI4JZ7y0G0wqAsDdBj07g981z0UcF4rxK4juIkAIAKkEdGz7jrVPTUmPYqXV2ba7gu40YbFw2GDM3PQ574zx9KjmW7ubaa63LiQlliWIE5zgEt1HXp0p96Gg0rTSqLsSRu2QZO6n3waXS4YWu3t5rs2tleI0kbe6n7jZ6A+1VYlvUfFBfvLFcJIIPKQqJYwPujIOAe/603+wFsfLuWmlaRsOZN2dq5x+ffFW7FZIbi/ihVnt4JGyWz8q4B/xq5EqXWnvZzSNlGBVhk7ucgemOaRVkV4rOJZGvYZg75PmeY+Xcev/ANamTxJCLqUNwiBRHgksp9/TkVDa3T2+onySFKFVGcFVbHc+lV7mZ7mW9Y5Me8rlDw7L2Ht1oaKuSyxtFbpG4SQMckFv9nuew/rVzTQ8Vw7iWMKp8sOxO3gcE1QykTz24k81mCBCpyDz0J7gVpxQN5X2OUqsuXWTauDwc7ie/tWepcSte3BH2dLfJmiPHPzAHr/Wo/s6fa40hmQ25ZQXZSfmIzk1WmyLgSyAlw4Rsfd28Ac+verM0KmTyLUPMjNuGPvH0H1BpBcuXKxTT/uG8rygFbtkgVWeU3ELPCRHsd3UscFv9nHv0qFmeNoXyN2CzKerEcEmnyeWuqJ9n2zxMoMYAwA3f8atIluxBNGt26bE23P312cYIHK0mmzm3jFw8rPO0rK6t2XoM1avUigf7RDkR43rk8hweQcc1HaeXFdysUH2KbO7ByeeRjPShoSFvECJK8rAJCquo2cMCensKat2t9H9pEi4bIK9vTb9abdSFVngYNIAuGQNnKHoPqKz44ltJlMW6PeS4BOcKe5FIbubF3FBrVzFa5aJUhVYxGePMUcE/WuXgWSLVL/T508vawkHdVzwSK6HTIZHs3WM7XgkLnJ68cc+4rI8ZQFjaXsQ2W0vGAec9+aaJsLYrJaA3SiLapMW0c59x7VrWxVBG8a7oh8/yjJcnrxT9NkhXTY4bgq8kgA3BRkjsPaobu1eC68mKVkYYYAjAIND01GkXoEWS6igL7I3PDMflJPQNVJfPNzNaps2gFWkBzxntT5VLxSKm4An5d7cE+1V9NmmgQQzIiqhzvA5JPUUh6k8VptiLyRtOEOG3HnbTJoIhbiRAqmPhQO9WpWWJg8zkh8gsvQ+lQWriSRU3JFEDt3MeCaljI7JGnuX+0gCHZkqDjIqzZ6daxzMJc7lI+X/AGTVaSaCC9aIuhiOM5bvUsszBkkkRiEbDOO49qEtQJZo4hIrQbmZOPlHDVNcz27TRjasZcKpGf1oluI45fNjwsLYIBPLVi6zLFFcLLkNHL78rTE9jpbTTNVWV30u3umKkiOWBSQSeoyPao5dC1iSTeNKvkdhgqIDin+HNZurXFvbGW7ieMq0UZO5vRhjoQe9O1WLWLO3LXJ1KJQNyyMXAz7mgNTMiV4/N3KY7lDseIjp2Ofeimi9PlwztsLHhyeS3uaKpDNCJmF35UoBRhgHONrVLbxu08Q3gSNlC7Hg+1QPG0sUsJOS3zF/UD+tRBJFtFUvjLcHHX2rM0JwAqRqcmPzG3IOdvbiktn3TJscxspwpPAC9jSswjgj8v5gGO1h/wCg1Xnt2XDAsUIIRwON3dTQA+NsOZWX905IOP7/AGNK8mWYshOxgzJ0Hv8AhTN8ErRJCz+SSA+7qCPT60x5pFeZthMkYKHjOF9/U0DXYeXhYPIQTESRgdV9D701wI1O3OYxlu29RTkmEyRFjEgKeWOMAjsfrUVqHuJTC8oUxHO5hww9c0+gh+5S8TAhNrGQZHIPYNSeY0c0eUCK5bCdVLZ9KbPIv2jzXyYZFwwB5BHQk0y4kR5JCB5fmL8jAcrg9aQFrYY440DHcVEgDdAwP3aSZzeYdRljgYzjJJ6U23ljuLQb0YXayLgs3BBHBx7nOabFMPtLZz5bv8yjtjv+BosFwnw08Z3Eea21mUYwR0/wqVCY4HkICgsUZQMnOOPwzUEyBIVkBBjdsOF67hzux6c0nmL98hjnO9QccY65oAsWkyRTmOcCRiRtU4OSOoPt1qCQGMXayIACxwVPA4HI+vepJ7diEuGaMypGu0AY3jHJ/wAaFjTc0e9Qvlht7nGUHUY9QTSAkhZZBG0IUSxsQYzypyPuqPzqOMNAUmHzIAFZgPvEHJA9wKmV1S6eKJ1ZpCCsmMFWHQH0yOajRtqtLA+xJCysCQSuTgfn/KmAsuxcmEFIp3d0YfwnOQR7djTpBJM/nSYjO5QQOeeu7HoKqqJIbhreQII9pVCD90jnaD/WrETpFPEUO9HVfNjQ5MYJzjPrnrRYLjIf3jmAymRYmkaFHJCP1J+gqazKPYxuLgbblSJXAHynsF9uMZqtJbpK0y7QmMsij+IE85PsKWUR25nEEW2GUExK3TYf4wPbBo9RDin+gqjzHG3ec9GDEAj224/GpuYLErc5M0bo/wAhw0sZP/1vw4p7SJdRpe3Lq8dwdpUKeGAxn6mmLcyLJHLeSZ8qNbZvkGFTnj+RzTEVpJS12qbCVWR5o0Y4UZPQ/kKS3O2a1h3lbefLMSBweSR9OKs/ZpVDxmLDJmVHI4I6/dPUEdPrUAYTBjFb/uCRMBnogGD+POcCgLj8lLQhgF4Mc6LyQh5Dk98c1FcW5S3CbtkkbYVVwTJkZVj6ZAHFRbkFyRMzPGeDIQfnB/ix6im3DeTC3QSBdqDuI2PBz6ii9g3G2csOFkmH+jEkyxKcEsD8oOeTzUK+dHqQllDB5S0mxD/qyxGAP5VeuxFAbiaaMEp+72hujMBtbB6jrV+2sRc6VqV3fH/SbeAbBGdrJt4UsvcdKtGZT1yNriAWCh4wZ0mi/eYVY2PO73BB57VHeXMUM0eqR3QuZiCl3FsIZeSMg9COAQaS9vzba3b3rQIAyeYq/eUk9fxxk+1R69q8V7rVw8QhW3MbO6wtnzTjqM9u2PWqWu5GzuP8uK/tjIbiNY4CbndjOZFH3Me/HNUdOWUO32gIHRw8LqcqrZyQoPuRRoZ2hXd1iWZSXLAkDacr9CcVow+XHZyO0ciXMbpNEvljBDZ3Ek9O2BSvYrluXLS6+zQ3FxKrPJfSMducFyCBj371iS308bxxxMwEJeOUryEU+/8AEef0rQaBLe7j8yfyh5ZMcobcvzdf+BHnpxUOoQ+Rb+XDbmGG7hCeUvONvfP5k00wd9kUtNd7aIuhLL5mXYkAlORhffFJcqHW4eFXSIpttVbqFY/e9+AeamaKMBUl81kxutgq7fMbsD7VI78TIAzvOFi6YKHqQB2FK4kilHBdLaiNrgedb5XaY+rDqM/Srct5LDGlxPaF7UqVeWJjlQePm7j0qK4YXLqIAEd12sznPK85HuelWtNnVxKk8fko3zSgjJzjlRU7sojVopLpIo5VZA2WEYypIHA/AVJJujkt3jdhIjMxbsPUHHfHNRXLfZSm9tht5QF2rgbSOrHuecVZVoBKEj8xreVd7gDkA/e2+3TmiwEmnGOfzZogZ/IG50PyjbnGPfNUQscXntCiwpKcRrkkq2cgj+VVZ7dYLlzp7SLbswjk67AM5xn8qkngiS5dZndhCP3eMncCf4cenNVewEst7icXHzPMwKydPvY7jtVSd2hma3WQHcdvoAcZqeIQQQTWweRYZSZIwvzEt6E1XDJeTiBZVgikKRTMBlwepYUxXLv2yGEx3r3ECzYA2ryWGMH6GqF1PBFOVadnZMbXxxg84+lXE06HTZpLYN56mUlPlHz8YJ9fwqGa123JjUgykbUL9CvXmp2DdF9GEljHcW7bN67GbB+dh2/KjUBBf20SOpa0aQYVDwhHU+1UY5JIorZslbRm8x0Ukqr5wDVrUbiKzkuVVlk88eZH5IIUP0x+VMaehkWxVZp7ZtxZQzRnHUZ4IrQsZJJ4bhpZcSIM5c8saqagLiNbK68p3jgXllA+53WrVsIppSkUZLSAFCzfxUriWjNBb6SQW8IX5hkDjhR60zUJLfzIEt3aVyMS46A1U1Ayugk2/vbY4lwccd+KVmguJkjti6RSD55ccsalIu4y7S4kt1RwXVs7SOi+1Jpdqr2kizkMjPtwf4T61pXUiyWXlAMkicbR2AHWs90c2sphkVsABnXjOf60waJLHTYF3Xc0Slt3APQqOPzpNTnjtowEMrM5/cxjkc+1S2pmj0+GST542HTurDr+lUsLNM1wjHdD8yEjge2KQPYbYI06E36nevAQdFFM1iFYg1sAvI3Rt3rWaWCbTBIuEuHBGT3NUpLdZLNLmY75V7HqBQyeh1ngaVpvChtNLuYodT80+cgkEbyx4wu1j6HPGamstO8R2GpJNPqElrYRurSvd3IaNo8/MpUk7uMisbQNN0y00capf20t5LPcNFBCkhjVcLksSO/pV240WyuJ9IurFpbnSbm7RJUkPz27k8o/sexqkrkOxzDzxy6nfG3gZLSWVzEGGAqZO39MUVr68tnb3t1hiqtLJCsY/hwxAoosFywpDREBsNGPMbP8Qp6lD5kyKJIwoLxlvu+mKp7UZjHJlcKWTj7/ALU6Z1Sbz4V2IAuUxnI71nY6RrBmCMD+7Y7iR0U/408tMEYb3+Ul15+8fUe9LE6xStsOYnH3Kjd96kI+Xj+YN/sigCH7XsucKg+YHP4VIriWZSSHbaGKr/GO4+tQjAYMhHms2VHr6ilG7zG8thu2bkbGCOf6UbgK5UgvsdRvYxp2+n4VJFDmXEshi3DG8/0FQyufJDMSV3ZJHVT/AIU26eSdrQ22fMhyrlz2JyBSQmTp8yP5wxtOJEP6GmSwHdFHweC0fPGfQ09NziSUAfMF8wkdGzweaMNLLbo3M28gHsSaeg3ews85cT70SRyuVOcYIPzKKgm8xopDbois67sdQH6gZ+lSiN/IaJ8B4zubuS/f8KaoTyYXQrsQFJEBOS3JBP04oEOjd5xbrCD5pZOGGfmA5FSwS+XbYCKRKrbc9FfODx3z0xTFRljSRdwTaqN6qR3z+NOslaSIFShkdwACw+Vwep/KhgN5ibjDJGAgyPujPzZHtUkqpBcTQyNvtyQodly2DzkD39KjBck+fIQGVndhjnnk/nTGVGla1lYrE21i2edwBI596QyWWCZfJRlKsjAHLAjdj5cnpnFRRujNEiqqMUMUzjnDk4/Dj0qXzhJbADJm8xXAHOewP4c80jQFBCY2BE6MOOhfPzMf6UxDwwEBhZQQsyuGIwzLgjH0qbTrYXl7JCmIkZdkMzvsCMeeT34GOaqgEwyvu3MGAJJzuHf+lOch4CjKqidvOQ9dpXt7ZNCBg+SYVwuGfcHz0YdQT6HrTnld2kdEaJ3JjBU9ISOUGfeorXzJ9Me4aMqCAJN3GWLdvw61K5kIiGGzGXkCA7vk7rkfTrQwJbTDxiCUObJpPOUFsFowNpIx0xUtrK8drLIs277Wv2WVFXkx9nOf4TVBnlSWOWJdqxgsFUfKVJzt+gFTeZuSQLnesf72NRkvGT6+vpTAbNOwEX2hlZ4z5chHJcAdcey4FE2YwtrwBHJujf0Q98+gz0qG8eI3DOiqI/KwjMvJI6N9T0/ColjmS5W4jH7mLCzRFs7M9Tk+pPTtRYnQmmhRbswOxJY4JAzhx2H1oQm6uLMOiGdZGDhhgPxxn8sfhTg6FwHZkjjZUbaMMCDwfc5P5UgYxDcUDPbM8chZuG3H/JoewIi1yEebamMjMow5dup69fp0q9qUsU6Rtb7yAVFxMgO0ozAHcPUVW1hS2noNyssXzR5PMgbncPbIqmnltp17GXkVlXzAvquB978elXFrYicddDUu7Rl0uQKqyFZWmikjGS0SHZz/AHQeTn2rLsIrBr6d4zKtqibEDfMS/UKW/u1q6bfI/n3TzeZAgRPKUZGMnC+4BxWdLbGJLyykXyrrertKGB8sAZA44PJp3voKyKvC6Q0s2QqgrnP8W7k4+nFaEygwrIiSDeitMFbcoiP3B+GP1rFaXzLE27qfOkO7IPBYHoPbHUeta1uHtiYjuUn92yNzhsZBqWVEsW0SXKNFcl/MWJowxXO0jlc+g61AsyiyhRnUuuQSwzkHGMfrUz5ulmktmWMMmcbjmR4+p+pqF9he2YNvgaJfMSJjuGcgAk8Ag1NxjJo3SdVmRl8odehZc889uKmuLZo2LANHFJIFXOC+O35imG2izdBnfzol2jDE7zkYz/KnSxvciCJgPMKEBlJXY46EnvjpTBlO6YLK8YWNnhcGPywMdOT7n+VWrmQFLeNdpVE2xFyflb7xHv3qnYzxGRUdvJmiGJzLwSOcgD0P5094mheQA58jEigdDu/ziqRJDcCS6091YbhO3mFyOQw5CgenFS20RW0Wa0leSQICUJ4KHgg+vI6CrEsBWNZ0XK3B2x/LgF8/cB7cdapJDLp9xPvYeTHIfJQHOGzyPTinYm5au4miWGa2QfZ7hN7Qg5BYZGfbFVYX8/coYSXVvkvI2ApQDHH0qSESXVyqWz+bcXeRHbxn5kbrn2BqFZGiiKsqs7SFXhAwWPUBj2FNK4nLsWkVZ4bOxS4hU3G4ZRCzwqOck1lPut7gPCEbcfIkA52sDw340zTRE2oXDzCONJTuVzJtQKOo9c9q0VImlaG8EQiRAqbFxuQ9DkdSPU1VieY0JLQLCtwjs8eMlm42t6jPJGap38skcA3DDxLu3dzu60aaiTOttNI5ihTYpyeBVa8mlnCSKm+YMyMC3zOQemKhlqV0Wp5BGI7ZotkUiLJHCTuycYyf505WmFt5Kum62xIPMxuftgVX0Se2uILnzDKs9uu5eOQQccn9KuNDHJctDZY/egSRk/xHuuaOhSF2+fYPb24DFhvGe/HSqdtERYR+UoEjnpjkkdQKu2YuozNEsKTKjb1AOGX3HrWfp8/mQzJ5jxzQyGRBIMbs1IE7OkshS1jCKoO4HqQetOge3tJlt49+wpmAns3pmrGmvGIXlk2GVTnaT2PYUXCqrSW88atg7gR2z3pD2RLGnmXcE0jbg+RJxgA+lUIo/s2pXcBfAzvRcZyM9BVxrOWCaSC2lE67BJGWbBz3/GsrULxp7VQkLRXMZzHL7g8gmnYLmiXVYpld3jYZZR6GqduwEYaNgRuGQRVea5a6QPdYjXH+rB5PvWdYtdCdQXC2yknPU4oWonI2iXS5lljAeDPyZGAD7UTXccCvGBzKO/UeorJmu4fNli+0SLGMso7k1AjT3KA3LOyZypI7VVieY6/RdXubXQri1hSOSJuWSRd204+8vofeq2kavfaddG7sbhF3kF4mUMjgc4Yf16itrwxDAbCO6jjgMsu9EE/+riSMAySsP4uoAHqafazQ6xaTperatFG6qxjgEMsCsdqyqVADAE8qe1CQM5O9n+1380wG2SV2mI7Bic8fnRTp1SzS5indHvbaUwuB7HGfpRVJEtm9I4m2YX94RtcE9/Qegqi0c0e9XlyjjOR29qfL/wAfa/Si+/1cH+4P51gdI6335WZduwcH/Z96Y8qRyFW6AYUgfe57j0qyv/H1GOxIyPXiobgD7ITjkN1/GkMYX3TLLhQzgr8v8J7cU0h5Ht2QMXQENu49zVf/AJ6fX/GpoSfOfk/cH/oNMCyYwoKsB5JAII7e1RRMvkSL0dmGfp2P4VSjYlOSf9XV5+JI8f3f6UhLce0jW5VGmzFK4QkrnA7HFEGDDKTuzAxKNnBIzyaick2RySf3OeahsCSUySeP6U2O+5LJIqRFw7b5CykHqU6qaevImRVGQRlyf4sc1FJ/q0/65H+tTDjTrcjqWUn34pCJwzS7owCIJJAG46OKqxyeUG2oEZsiRSp6g8N7VcfiOADp5ucf8Bpr8zXWf+eS1QEMbusstqiq5MfAPG4EfNg9h3qO0tpWhLSj5Igu58/6wZ4I9h3qS4JGnQMDhvtZGe+No4qYkj7OBwP7Pk/9CNJANaWR4w5G02ykk9iM8AfUdBUFwzJERkLAWZo3d+ccHb+f61PGT5Eo7G1jOPfBqpcgGxuM9nGPbpSe4lsXGcOI5Y1JdlJdcY8vHVPf1qB0WIx7AxjkbfCx4+Ufez/Knwk4kOTnCH+VNh5Kg9N8n9Ka3B7E0MmwGRhGFYAuFOdoI4/PoadEDFbK5B3BAev8B+8CB3B5qpH964Hbym/lVi84jXHeRv8A0AUMZLBPNGI4mHyRbsALgtE3Gfc5pkMYjS6tpWKTQgeWU5ZmyMJn055qKZj9kLZO4WZwfTkU2fjaRwfPb+lUhMrlFgiuo7iZwykSRBB0IJ4+uc1NZ3CyXM32wJCt1GN4OQiyDjkH2qtrP/MWb+IOuD6cCtHSAJNT1TzAHwbUjdzzmtImZQ3tJKjz7miTCSA5HAOFPt2NWIilzYJKn724R2yGwS5J6AdeOuaryEnUJwTwS+R6/eqOy4ttw4bPUdfuVLGjRidfscvIaPYUBwQWB6AfQ81Q1Pf5cawZVrqLy2A4LEccfl3qe1YmztASSBKODVO5/wCQjce0hA9ualgyaCCG3t0W2OG2DaWIVHIHzfXkcVNJOLhLKQnc+Bkk7cnOPm9AD2/GpdJVWtNU3AHbt25HT516VWtADfzggY39P+AGqYkWLy3jFzPDM3znYytjAicn5gPUkc1BYrcy3c1rIVmllYMrysF3e7e4AqzYkyKhk+YmOUktzk4HNAALvkD/AFH/ALIKQ0RhpriZMRoDO5dedqqR1HsDSQW7zl080JHOSxcDoB2Aqxcf8eMP/X2B+GKvSqBeTgAAC4QAe2aFuUZYl8ho2AQrJ+5Yds9if501ZJGWRlc+XODgcZDA8Y9s5NNueJr0DgZk4FTRgf8ACPA45F0QPypoDN1aJAyXIjjM/MbqDkrgY5/nV6GOFRp78/MoD5AxjPyk+vPepYgPtw4HKPn34FZ1z/x7qO2zH/jxpmYPGwUWoJBXLwnnDH19OMGoIm8/T2fdmOKYSlNvGenXuW9KvX3/ACLkDd/OcZ9toqGEDydQX+EAkD0OwUyZE8Dsl5MDttpoYmk29PLXrjI6ZrLktFe9CTRvDJdRNcIG6sOwGeSDVm5Yx6T5kZKySQfOy8FvmHU96r687G/09yzFwkQDE8gY9ap/CZ9RbEvNpdtHPp8cBtix89ec/wC8KHDyG3uTI7+bmOZj91T/AA8elXrgkNqYBwMr/KsqYkPeqDhfLU4HSmN7F+7eNbiO3uXkt1mcJJIeBtI4b6ZqppyqmoTyLKHni3JC6Dj5TwefWs/xIxa+j3En/Rh1PtVOMkQNgkfKvSlISbOkaSOKKK4QBG2gSBedwz1NS+avnFpWfbC37tYxjAbndn61Tt/m04BuRhuv4VPd8WNjjjdFz781LNolyS+it1aVg8W0lWZW5PGc1zBuhfNJtVi+eNvHy1p3nOgzk8nP+NYln8t1Bt4zCen0qByLtpdiyu44ZHLw9pG5z9a6SGeJSJQgZ4yOd2Qyn1rBjUGMggY8sUzwwSVvATkc0LYEbpuBFNLHJ/rE+dSvaqF/JtRN5JimbcvHT6Ve0kBtQXdz+7br9KxLkny8ZOAxx7U0Ampaa/2tAZSEI3AnkqKjh0+4kkK+Zng7QowcVo3HIbP/ADzFGnE+Yp77TSI3K9tpQliS5hQO6dSTn2xV9YzvZJV2siZAPFV9KJEEuDj5j0+taGtf8ecR75HNUVZI09A1C1XT4xNPbW88RfyfP/1UqyAB4pMcgHAIbsRUtrc21lEy3MVhZwB1keG3vPtc11tO5YweiIWAJJrj4VBnIIH3hUupIqSSlFC8r0GKroRYWO6WTVLue5REmvGaQs3QMTnFFPu1B06IkAnB60U0Sz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small inflammatory papules and pustules are present in this patient with folliculitis. Erythema is difficult to appreciate due to dark skin pigmentation. Postinflammatory hyperpigmentation is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12714=[""].join("\n");
var outline_f12_26_12714=null;
var title_f12_26_12715="Bicarbonate buffered dialysate";
var content_f12_26_12715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bicarbonate buffered dialysate",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Solute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        135 to 150 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium",
"       </td>",
"       <td>",
"        0 to 5 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloride",
"       </td>",
"       <td>",
"        85 to 120 meq/L*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bicarbonate",
"       </td>",
"       <td>",
"        30 to 50 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        2 to 3 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        0.5 to 1.5 meq/L (may be added as MgSO4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        100 to 200 mg/dL (5.6 to 11.1 mmol/L)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Chloride concentration is adjusted such that [Na+] + [K+] + [Ca2+] + [Mg2+] = [Cl-] + [HCO3-] + [SO42-].",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12715=[""].join("\n");
var outline_f12_26_12715=null;
var title_f12_26_12716="Antiseptics umbilical cord";
var content_f12_26_12716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiseptic topical cord care agents and rare associated complications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rare complication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 percent basic fuchsine",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacitracin",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloid silver-benzyl-peroxide",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micronized green clay powder",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorhexidine",
"       </td>",
"       <td>",
"        Slight delay in cord separation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hexachlorophene",
"       </td>",
"       <td>",
"        Spongiform myelinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isopropyl alcohol",
"       </td>",
"       <td>",
"        Percutaneous toxicity, central nervous system depression, skin necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neomycin",
"       </td>",
"       <td>",
"        Neural deafness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Povidone-iodine",
"       </td>",
"       <td>",
"        Transient hypothyroxinemia, hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylic acid",
"       </td>",
"       <td>",
"        Metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silver sulfadiazine",
"       </td>",
"       <td>",
"        Kernicterus (sulfa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triple dye",
"       </td>",
"       <td>",
"        Carcinogenicity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Roberts J. Drug Therapy in Infants. Philadelphia, PA. WB Saunders 1984. p. 341.",
"     <br>",
"      Rosenkranz HS, et al. Br Med J 1971; 3:702.",
"      <br>",
"       Lin CP, et al. Eur J Pediatr 1994; 153:756.",
"       <br>",
"        Pyati SP, et al. J Pediatr 1977; 91:825.",
"        <br>",
"         Payne CM, et al. Lancet 1992; 340:126.",
"         <br>",
"          Pezzati M, et al. Biol Neonate 2002; 81:38.",
"          <br>",
"           Siegfried EC, et al. J Perinatol 1999; 19:31.",
"           <br>",
"            Rutter N. Clin Perinatol 1987; 14:911.",
"            <br>",
"             West DP, et al. J Invest Dermatol 1981; 76:147.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12716=[""].join("\n");
var outline_f12_26_12716=null;
var title_f12_26_12717="Learning disability exam";
var content_f12_26_12717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the examination of a child with learning difficulty*&bull;",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential clinical implication",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        General observations and appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sadness, anxiety, attention span, impulsivity, activity",
"       </td>",
"       <td>",
"        Emotional or behavioral problems may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to communicate and respond to instructions",
"       </td>",
"       <td>",
"        Measure of language skills other than phonologic processing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stigmata of genetic syndromes (eg, Klinefelter, Turner, fragile X)",
"       </td>",
"       <td>",
"        Klinefelter syndrome: tall stature, small testes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turner syndrome: short stature, webbed neck, micrognathia, short metacarpals, nail dysplasia, widely spaced nipples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fragile X syndrome: narrow face; large jaw; long, prominent ears; large testes (after puberty)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Growth parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Head circumference",
"       </td>",
"       <td>",
"        Head circumference &lt;10",
"        <sup>",
"         th",
"        </sup>",
"        percentile may suggest fetal alcohol syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children with fragile X syndrome usually have head circumference &gt;50",
"        <sup>",
"         th",
"        </sup>",
"        percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Height and weight",
"       </td>",
"       <td>",
"        Height and weight &lt;10",
"        <sup>",
"         th",
"        </sup>",
"        percentile may suggest fetal alcohol syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short stature is a feature of Turner syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tall stature is a feature of Klinefelter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caf&eacute;-au-lait spots, ash leaf spots, adenoma sebaceum",
"       </td>",
"       <td>",
"        Neurocutaneous disorders (eg, neurofibromatosis, tuberous sclerosis) are associated with learning problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed sexual maturation",
"       </td>",
"       <td>",
"        May be associated with Turner syndrome, Klinefelter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small testes",
"       </td>",
"       <td>",
"        Suggestive of Klinefelter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large testes (after puberty)",
"       </td>",
"       <td>",
"        Suggestive of fragile X syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Sensory screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hearing assessment",
"       </td>",
"       <td>",
"        Hearing impairment may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vision assessment",
"       </td>",
"       <td>",
"        Vision impairment may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neurologic examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetry, increased or decreased muscle tone",
"       </td>",
"       <td>",
"        Cerebral palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coordination problems",
"       </td>",
"       <td>",
"        Developmental coordination disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weakness",
"       </td>",
"       <td>",
"        Muscular dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tics",
"       </td>",
"       <td>",
"        Tourette syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staring episodes",
"       </td>",
"       <td>",
"        Seizure disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In this table, \"learning disability\" refers to a heterogeneous group of disorders characterized by the unexpected failure of an individual to acquire, retrieve, and use information competently, rather than intellectual disability (mental retardation).",
"     <br>",
"      &bull; Most children with learning disability have a normal physical examination.",
"      <br>",
"       &Delta; Learning disability is rarely the first manifestation of these disorders.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12717=[""].join("\n");
var outline_f12_26_12717=null;
var title_f12_26_12718="Bogalusa threshold girls";
var content_f12_26_12718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Thresholds for defining cardiovascular risk in girls, Bogalusa Heart Study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 183px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smoothed body mass index (BMI) and waist circumference thresholds for predicting risk factor clustering among female children and adolescents in the Bogalusa Heart Study (1992-1994). Each curve defines the optimal&nbsp;BMI or waist circumference which predicts having three or more cardiovascular risk factors (high blood pressure; low high-density lipoprotein cholesterol concentration; or high low-density lipoprotein cholesterol, triglyceride, glucose, or insulin concentration, adjusted for age) at a given age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004; 114:e198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12718=[""].join("\n");
var outline_f12_26_12718=null;
var title_f12_26_12719="Abduction adduction exercise for frozen shoulder";
var content_f12_26_12719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1120px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/83382/Abd_add_froz_shoulder_video.mp4?title=Abduction+adduction+exercise+for+frozen+shoulder\" style=\"width:512px;height:304px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Abduction adduction exercise for frozen shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise to improve shoulder mobility and strength is performed by patients with frozen shoulder after their motion has begun to improve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tore Prestgaard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_26_12719=[""].join("\n");
var outline_f12_26_12719=null;
